Oligomerization of glycoproteins and uses thereof

A recombinant protein system with viral fusogenic membrane glycoproteins and targeting domains forms dimers, trimers, or tetramers to create membraned vesicles for targeted cell delivery, addressing the need for specific cell targeting and enhancing viral vector delivery efficacy.

WO2026236565A1PCT designated stage Publication Date: 2026-11-12VYRIAD INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027198
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-27
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for components and viruses or enveloped delivery vehicles that can specifically target particular cells, and for viruses and delivery vehicles that incorporate such components.

Method used

A recombinant protein system comprising a viral fusogenic membrane glycoprotein (FMG) with a targeting domain and an oligomerization domain, capable of forming dimers, trimers, or tetramers to create membraned vesicles and enveloped delivery vehicles for targeted cell delivery.

Benefits of technology

The recombinant protein system enables efficient targeting and delivery of payloads to specific cells, enhancing the specificity and efficacy of viral vector systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027198_12112026_PF_FP_ABST
    Figure US2026027198_12112026_PF_FP_ABST
Patent Text Reader

Abstract

In aspects, the present disclosure provides a recombinant protein system comprising: (I) a first recombinant protein comprising a viral fusogenic membrane glycoprotein (FMG) or a functional fragment or derivative thereof, (II) a second recombinant protein comprising (a) a targeting domain and (b) an oligomerization domain. Additional aspects are as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Leydig 775437Vyriad P-64-0041OLIGOMERIZATION OF GLYCOPROTEINS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This patent application claims the priority benefit of U. S. Provisional Patent Application No. 63 / 801,718, filed May 7, 2025; U. S. Provisional Patent Application No. 63 / 805,244, filed May 13, 2025; U. S. Provisional Patent Application No. 63 / 846,680, filed July 18, 2025; U. S. Provisional Patent Application No. 63 / 882,873, filed September 16, 2025; U. S. Provisional Patent Application No. 63 / 904,457 filed October 23, 2025; U. S.Provisional Patent Application No. 63 / 904,491, filed October 23, 2025; U. S. Provisional Patent Application No. 63 / 979,558, filed February 10, 2026; U. S. Provisional Patent Application No. 64 / 008,025. filed March 17, 2026; International Patent Application No. PCT / US2026 / 017725, filed March 4, 2026; and International Patent Application No.PCT / US2026 / 021378, filed March 27, 2026; the disclosures of which are incorporated herein by reference in their entireties for all purposes.INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: One 730,427 Byte XML (Extensible Markup Language) file named "775437_SequenceListing.xml," created on May 7, 2026.BACKGROUND

[0003] There is an ongoing need in the art for components that can be used in a virus or enveloped delivery vehicle to target the virus or enveloped delivery vehicle to particular cells. There is also an ongoing need in the art for viruses and enveloped delivery vehicles that incorporate such components.BRIEF SUMMARY

[0004] In aspects, the present disclosure provides a recombinant protein system comprising: I) a first recombinant protein comprising a viral fusogenic membraneLeydig 775437Vyriad P-64-0042glycoprotein (FMG) or a functional fragment or derivative thereof, II) a second recombinant protein comprising (a) a targeting domain and (b) an oligomerization domain.

[0005] In aspects, the present disclosure provides a dimer comprising two recombinant protein systems as described herein, wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other second recombinant protein, wherein the viral FMG of each first recombinant protein is bound to the viral FMG of the other first recombinant protein, and wherein the second recombinant proteins comprise a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0006] In aspects, the present disclosure provides a trimer comprising three recombinant protein systems as described herein, wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other two second recombinant proteins, wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other two first recombinant proteins, and wherein the second recombinant proteins comprise a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0007] In aspects, the present disclosure provides a tetramer comprising four recombinant protein systems as described herein, wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other three second recombinant proteins, wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other three first recombinant proteins, and wherein the second recombinant proteins comprise a binding domain of a receptor protein, wherein the bindingLeydig 775437Vyriad P-64-0043domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0008] In aspects, the present disclosure provides a membraned vesicle comprising a recombinant protein system as described herein.

[0009] In aspects, the present disclosure provides a membraned vesicle comprising a dimer as described herein, atrimer as described herein, or a tetramer as described herein.

[0010] In aspects, the present disclosure provides an enveloped delivery vehicle comprising a recombinant protein system as described herein.

[0011] In aspects, the present disclosure provides an enveloped delivery vehicle comprising a dimer as described herein, a trimer as described herein, or a tetramer as described herein.

[0012] In aspects, the present disclosure provides a recombinant viral vector comprising a nucleotide encapsulated by a membraned vesicle as described herein or the enveloped viral particle as described herein.

[0013] In aspects, the present disclosure provides a composition comprising a pharmaceutically acceptable carrier and a membraned vesicle as described herein, an enveloped viral particle as described herein, or a recombinant viral vector as described herein.

[0014] In aspects, the present disclosure provides a method of delivering a payload to a target cell, the method comprising contacting the target cell with a membraned vesicle as described herein, an enveloped viral particle as described herein, a recombinant viral vector as described herein, or a composition as described herein.

[0015] In aspects, the present disclosure provides a retroviral vector expression system comprising one or more nucleotide sequences encoding a recombinant protein system as described herein.

[0016] In aspects, the present disclosure provides a rhabdoviral vector expression system comprising one or more nucleotide sequences encoding a recombinant protein system as described herein.Leydig 775437Vyriad P-64-0044

[0017] In aspects, the present disclosure provides a rhabdoviral vector expression system comprising one or more plasmids encoding: (a) a nucleoprotein (N), a phosphoprotein (P), a matrix protein (M), a glycoprotein (G), and a large polymerase protein (L), each of Vesiculovirus Indiana (VSIV); and (b) a recombinant protein system as described herein.

[0018] In aspects, the present disclosure provides a method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising: (a) transfecting or transducing a packaging host cell with a retroviral vector expression system as described herein or a rhabdoviral vector expression system as described herein; and (b) recovering the membraned vesicle, enveloped viral particle, or recombinant viral vector produced by the transfected or transduced packaging host cell.

[0019] In aspects, the present disclosure provides a method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with a retroviral vector expression system as described herein or a rhabdoviral vector expression system as described herein, wherein the host cell is ex vivo.

[0020] In aspects, the present disclosure provides a method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with a retroviral vector expression system as described herein or a rhabdoviral vector expression system as described herein, wherein the host cell is within a subject.

[0021] In aspects, the present disclosure provides a plasmid comprising one or more nucleotide sequences encoding a recombinant protein system as described herein.

[0022] In aspects, the present disclosure provides a composition as described herein, a retroviral vector expression system as described herein, or a rhabdoviral vector expression system as described herein for use in treating a disease in a mammal.

[0023] In aspects, the present disclosure provides a method of making a viral FMG dimer, trimer, or tetramer, the method comprising: (i) transfecting or transducing a packaging host cell with a retroviral vector expression system as described herein or a rhabdoviral vector expression system as described herein; and (ii) recovering the viral FMG dimer, trimer, or tetramer.

[0024] In aspects, the present disclosure provides a method of stabilizing a recombinant protein system as described herein, the method comprising maintaining the system at pH 7.4 with 0.1 to 2 mM of Ca2+.

[0025] Additional aspects are as described herein.Leydig 775437Vyriad P-64-0045BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 A is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a FLAG tag (SEQ ID NO: 66) fused N-terminal to a mutant form of epidermal growth factor (EGFml23) (SEQ ID NO: 36) fused N-terminal to a oligomerization domain with valine and alanine substitutions to form a coiled coil structure (helical-peptide-VL) (SEQ ID NO: 26) or with aspartic acid substitution to prevent oligomerization (helical-peptide-AA) (SEQ ID NO: 35) fused N-terminal to the three cysteine rich (CR) domains of the low density lipoprotein receptor (LDLR) (CR1+2+3) (SEQ ID NOs: 1, 2, and 3) fused N-terminal to the IgGk signal peptide (SP) (SEQ ID NO: 5) connected with no linkers, a long linker ((G4S)3) (SEQ ID NO: 8), a long linker ((G4S)3) (SEQ ID NO: 8) and short linker (GGGGS) (SEQ ID NO: 6), or two long linkers ((G4S)3) (SEQ ID NO: 8) and a GSGGSG linker (SEQ ID NO: 10).

[0027] Figure IB is an image of a western blot showing binding of a VSIV-G antibody (anti-VSV-G), EGF antibody (Anti-EGF), FLAG antibody (Anti -FLAG), and a GAPDH antibody (Anti-GAPDH) in the cell lysate of cells transfected with plasmids encoding recombinant proteins with combinations of wild type Vesiculovirus Indiana G glycoprotein (VSIV-G) (labeled G-WT in figure), mutant VSIV-G with K47Q+Y209Q+R3 4Q substitutions (G-QQQ), EGFml23 ligand (EGF), the helical peptide-AA (AA PEP), the helical peptide-VL (VL PEP), the CR1, CR2, and CR3 regions of LDLR (CR123), the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled.

[0028] Figures 2A-2D show the targeting specificity of lentiviruses pseudotyped with a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to either a VL substituted oligomerization domain (+PEP(VL)) (SEQ ID NO: 26) or an AA substituted oligomerization domain (+PEP(AA)) (SEQ ID NO: 35) fused to three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) with no linkers or various combinations of linkers. Figures 2A-2D and are a set of micrographs showing K-562 cells and K-562 cells expressing the EGF receptor (K-562(EGFR+)) 3 days post transduction with a lentivirus containing a GFP expression cassette (SEQ ID NO: 67) and pseudotyped with wild type Vesiculovirus Indiana G glycoprotein (VSIV-G) (SEQ ID NO: 57) (G-WT), a LDLR blinded VSIV-G with K47Q, R354Q, and Y209Q substitutions (VSIV-G-QQQ) (SEQ ID NO: 68) (G-QQQ), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2. and 3) (EGF-VL PEP-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to a VL substituted peptide (SEQLeydig 775437Vyriad P-64-0046ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2. and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-VL PEP-(G4S)3-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a G4S linker (SEQ ID NO: 6) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: L 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-G4S-VL PEP-(G4S)3-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a (G4S)3 linker (SEQ ID NO: 8) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-VL PEP-(G4S)3-CR123), or a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1. 2, and 3) (EGF-AA PEP-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-AA PEP-(G4S)3-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a G4S linker (SEQ ID NO: 6) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1. 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-G4S-AA PEP-(G4S)3-CR123), or a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a (G4S)3 linker (SEQ ID NO: 8) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-(G4S)3-AA PEP-(G4S)3-CR123) wherein viral transductions were performed without centrifugation (FIGS. 2A-2B, “No Spin”) or with centrifugation of the plate after viral vector addition (FIGS. 2C-2D, “Spin”)..

[0029] Figures 3A-3D show the targeting specificity of lentiviruses pseudotyped with a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to either a VL substituted oligomerization domain (SEQ ID NO: 26) or an AA substituted oligomerization domain (SEQ ID NO: 35) fused to three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) with no linkers or various combinations of linkers. Figures 3A-3D are a set of cytometer images showing GFP positive K-562 cells and K-562 cells expressing the EGF receptor (K-562(EGFR+)) 3 days post transduction with a lenti virus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) (G-WT), VSIV-G-QQQ (SEQ ID NO: 68) (G-QQQ), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) (EGF-VL PEP-CR123). a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: I. 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-VL PEP-(G4S)3-CR123), a recombinant protein ofLeydig 775437Vyriad P-64-0047EGFml23 (SEQ ID NO: 36) fused via a G4S linker (SEQ ID NO: 6) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-G4S-VL PEP-(G4S)3-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a (G4S)3 linker (SEQ ID NO: 8) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1. 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-VL PEP-(G4S)3-CR123), or a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) (EGF-AA PEP-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1. 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-AA PEP-(G4S)3-CR123), a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a G4S linker (SEQ ID NO: 6) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-G4S-AA PEP-(G4S)3-CR123), or a recombinant protein of EGFml23 (SEQ ID NO: 36) fused via a (G4S)3 linker (SEQ ID NO: 8) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-(G4S)3-AA PEP-(G4S)3-CR123) wherein the plate was not spun (FIGS. 3A-3B) or was spun (FIGS. 3C-3D).

[0030] Figure 3E is a bar graph showing the fold increase of GFP positive (GFP+) cell number in K-562 cells expressing the EGF receptor (EGFR+) compared to K-562 cells that were transduced by lentivirus pseudotyped with WT VSIV-G and combinations of the recombinant protein containing the EGFml23 ligand (EGFml23), helical peptide- AA (AA PEP), the helical peptide-VL (VL PEP), the CR1, CR2, and CR3 regions of LDLR (CR123). the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled and that had either undergone centrifugation (Spin) or had not (No spin).

[0031] Figure 4A is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a FLAG tag (SEQ ID NO: 66) fused N-terminal to an anti-CD3 scFv (UCHT1) (SEQ ID NOs: 41 and 42) fused N-terminal to a oligomerization domain with valine and alanine substitutions to form a coiled coil structure (helical-peptide-VL) (SEQ ID NO: 26) or with aspartic acid substitution to prevent oligomerization (helical-peptide-AA) (SEQ ID NO: 35) fused N-terminal to a the three cysteine rich (CR) domains of the low density lipoprotein receptor (LDLR) (CR1+2+3) (SEQ ID NOs: 1, 2, and 3) fused N-terminal to the IgGk signal peptide (SP) (SEQ ID NO: 5) connected with no linkers, along linker ((G4S)3) (SEQ ID NO: 8), a long linker ((G4S)3) (SEQ ID NO: 8) and short linker (GGGGS)Leydig 775437Vyriad P-64-0048(SEQ ID NO: 6). or two long linkers ((G4S)3) (SEQ ID NO: 8) and a GSGGSG linker (SEQ ID NO: 10).

[0032] Figure 4B is an image of a western blot showing binding of a VSIV-G antibody (anti-VSV-G), FLAG antibody (Anti-FLAG), and a GAPDH antibody (Anti-GAPDH) in the cell lysate of cells transfected with plasmids encoding recombinant proteins with combinations of wild type VSIV-G (G-WT), mutant VSIV-G with K47Q+Y209Q+R354Q substitutions (G-QQQ), the CD3 binding scFv UCHT1 (UCHT1), the helical peptide AA (AA PEP), the helical peptide-VL (VL PEP), the CR1, CR2, and CR3 regions of LDLR (CR123). the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled.

[0033] Figures 5A-5D show the targeting specificity of lentiviruses pseudotyped with a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to either a VL substituted oligomerization domain (+PEP(VL)) (SEQ ID NO: 26) or an AA substituted oligomerization domain (+PEP(AA)) (SEQ ID NO: 35) fused to three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) with no linkers or various combinations of linkers. Figures 5A-5D and are a set of micrographs showing Jurkat cells and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudoty ped with VSIV-G (SEQ ID NO: 57) (G-WT), VSIV-G-QQQ (SEQ ID NO: 68) (G-QQQ). a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) (UCHT1-VL PEP-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-VL PEP-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a G4S linker (SEQ ID NO: 6) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-G4S-VL PEP-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a (G4S)3 linker (SEQ ID NO: 8) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-VL PEP-(G4S)3-CR123), or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) (UCHT1-AA PEP-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (EGF-AA PEP-(G4S)3-CR123), a recombinantLeydig 775437Vyriad P-64-0049protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a G4S linker (SEQ ID NO: 6) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-G4S-AA PEP-(G4S)3-CR123), or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a (G4S)3 linker (SEQ ID NO: 8) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-(G4S)3-AA PEP-(G4S)3-CR123) wherein the plate was not spun (FIGS. 5A-5B) or was spun (FIGS. 5C-5D).

[0034] Figures 6A-6D show the targeting specificity' of lentiviruses pseudotyped with a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to either a VL substituted oligomerization domain (SEQ ID NO: 26) or an AA substituted oligomerization domain (SEQ ID NO: 35) fused to three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) with no linkers or various combinations of linkers. Figures 6A-6D are a set of cytometer images showing GFP positive Jurkat cells and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) (G-WT), VSIV-G-QQQ (SEQ ID NO: 68) (G-QQQ), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) (UCHT1-VL PEP-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1. 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-VL PEP-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a G4S linker (SEQ ID NO: 6) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-G4S-VL PEP-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a (G4S)3 linker (SEQ ID NO: 8) to a VL substituted peptide (SEQ ID NO: 26) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-VL PEP-(G4S)3-CR123), or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) (UCHT1-AA PEP-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-AA PEP-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a G4S linker (SEQ ID NO: 6) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: L 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-G4S-AA PEP-(G4S)3-CR123), or aLeydig 775437Vyriad P-64-00410recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused via a (G4S)3 linker (SEQ ID NO: 8) to an AA substituted peptide (SEQ ID NO: 35) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)3 linker (SEQ ID NO: 8) (UCHT1-(G4S)3-AA PEP-(G4S)3-CR123) wherein the plate was not spun (FIGS. 6A-6B) or was spun (FIGS. 6C-6D).

[0035] Figure 6E is a bar graph showing the fold increase of GFP positive (GFP+) cell number in Jurkat cells (CD3+) compared to Nalm-6 cells (CD3-) that were transduced by lenti virus pseudotyped with WT VSIV-G and combinations of the recombinant protein containing the anti-CD3 scFv UCHT1 (UCHT1), helical peptide- AA (AA PEP), the helical peptide-VL (VL PEP), the CR1, CR2, and CR3 regions of LDLR (CR123), the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled and that had either undergone centrifugation (Spin) or had not (No spin).

[0036] Figure 7A is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a FLAG tag (SEQ ID NO: 66) fused N-terminal to an anti-CD3 scFv (UCHT1) (SEQ ID NOs: 41 and 42) fused to a oligomerization domain of the C-terminal Foldon domain from T4 fibritin (Foldon) (SEQ ID NO: 28) fused to CR123 (SEQ ID NOs: 1, 2, and 3) fused to the IgGk signal peptide (SP) (SEQ ID NO: 5) connected with no linkers, a long linker ((G4S)3) (SEQ ID NO: 8), a long linker ((G4S)3) (SEQ ID NO: 8) and short linker (GGGGS) (SEQ ID NO: 6). or two long linkers ((G4S)3) (SEQ ID NO: 8) and a GSGGSG linker (SEQ ID NO: 10).

[0037] Figure 7B is an image of a western blot showing binding of a VSIV-G antibody (anti-VSV-G), FLAG antibody (Anti-FLAG), and a GAPDH antibody (Anti-GAPDH) in the cell lysate of cells transfected with plasmids encoding recombinant proteins with combinations of wild type VSIV-G (G-WT), mutant VSIV-G with K47Q+Y209Q+R354Q substitutions (G-QQQ), the CD3 binding scFv UCHT1 (UCHT1), the C-terminal Foldon domain from T4 fibritin (Foldon), the CR1, CR2, and CR3 regions of LDLR (CR123), the CR3 region of LDLR (CR3), the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled.

[0038] Figures 8A-8D show the targeting specificity of lentiviruses pseudotyped with a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to either three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) or one CR domain of LDLR (CR3) (SEQ ID NO: 3) via the (G4S)x3 linker (SEQ ID NO: 8) or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) and either three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) or one CR domain of LDLRLeydig 775437Vyriad P-64-00411(CR3) (SEQ ID NO: 3) with various combinations of (G4S)x3 (SEQ ID NO: 8) and (G4S) (SEQ ID NO: 6) linkers. Figures 8A-8D and are a set of micrographs showing Jurkat cells and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) (G-WT), VSIV-G-QQQ (SEQ ID NO: 68) (G-QQQ), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)3-CR3), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused directly to a Foldon trimenzation peptide (SEQ ID NO: 28) fused to CR123 (SEQ ID NOs: 1. 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-Foldon-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S) linker (SEQ ID NO: 6) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)-Foldon-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S)x3 linker (SEQ ID NO: 8) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHTl-(G4S)x3-Foldon-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused directly to a Foldon trimerization peptide (SEQ ID NO: 28) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-Foldon-(G4S)3-CR3), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S) linker (SEQ ID NO: 6) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)-Foldon-(G4S)3-CR3), or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S)x3 linker (SEQ ID NO: 8) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHTl-(G4S)x3-Foldon-(G4S)3-CR3), wherein the plate was not spun (FIGS. 8A-8B) or was spun (FIGS. 8C-8D).

[0039] Figures 9A-9D show the targeting specificity of lentiviruses pseudotyped with a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to either three CR domains of LDLR (CR123) (SEQ ID NOs: 1, 2, and 3) or one CR domain of LDLR (CR3) (SEQ ID NO: 3) via the (G4S)x3 linker (SEQ ID NO: 8) or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) and either three CR domains of LDLR (CR123) (SEQ ID NOs: 1. 2, and 3) or one CR domain of LDLR (CR3) (SEQ ID NO: 3) with various combinations of (G4S)x3 (SEQ ID NO: 8) and (G4S)Leydig 775437Vyriad P-64-00412(SEQ ID NO: 6) linkers. Figures 9A-9D are a set of cytometer images showing GFP positive Jurkat cells and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) (G-WT), VSIV-G-QQQ (SEQ ID NO: 68) (G-QQQ), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)3-CR3), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused directly to a Foldon trimerization peptide (SEQ ID NO: 28) fused to CR123 (SEQ ID NOs: 1. 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-Foldon-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S) linker (SEQ ID NO: 6) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)-Foldon-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S)x3 linker (SEQ ID NO: 8) fused to CR123 (SEQ ID NOs: 1, 2, and 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHTl-(G4S)x3-Foldon-(G4S)3-CR123), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused directly to a Foldon trimerization peptide (SEQ ID NO: 28) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-Foldon-(G4S)3-CR3), a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S) linker (SEQ ID NO: 6) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHT1-(G4S)-Foldon-(G4S)3-CR3), or a recombinant protein of UCHT1 (SEQ ID NOs: 41 and 42) fused to a Foldon trimerization peptide (SEQ ID NO: 28) via a (G4S)x3 linker (SEQ ID NO: 8) fused to CR3 (SEQ ID NO: 3) via a (G4S)x3 linker (SEQ ID NO: 8) (UCHTl-(G4S)x3-Foldon-(G4S)3-CR3), wherein the plate was not spun (FIGS. 9A-9B) or was spun (FIGS. 9C-9D).

[0040] Figure 9E is a bar graph showing the fold increase of GFP positive (GFP+) cell number in Jurkat cells (CD3+) compared to Nalm-6 cells (CD3-) that were transduced by lentivirus pseudotyped with WT VSIV-G and combinations of the recombinant protein containing the anti-CD3 scFv UCHT1 (UCHT1), the C-terminal Foldon domain from T4 fibritin (Foldon), the CR1, CR2, and CR3 regions of LDLR (CR123), the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled and that had either undergone centrifugation (Spin) or had not (No spin).Leydig 775437Vyriad P-64-00413

[0041] Figures 10A-10B are bar graphs showing the results of fluorescent nanoparticle tracking analysis (fNTA) for lentiviral particles as measured by light scatter (Scatter), or by immunolabeled FLAG (FLAG) or VSIV-G (VSV-G) for lentiviral particles pseudotyped with wild type VSIV-G (VSV-G WT), mutant VSIV-G with K47Q+Y209Q+R354Q substitutions (G-QQQ), or wild type VSIV-G and combinations of recombinant protein containing the EGFml23 ligand (EGFml23), the CD3 binding scFv UCHT1 (UCHT1), the helical peptide-AA (AA PEP), the helical peptide-VL (VL PEP), the C-terminal Foldon domain from T4 fibritin (Foldon), the CR1, CR2, and CR3 regions of LDLR (CR123), the CR3 region of LDLR (CR3), the GGGGS linker (G4S) (SEQ ID NO: 6). and the G4Sx3 linker ((G4S)3) as labeled. Figure I0A shows the particle concentration of the pseudotyped lentiviral particles as particles per rnL (Particles / mL) as determined by INTA. Figure 10B shows the fNTA determined particle size at peak of the pseudotyped lentiviral particles as the particle diameter as measured in nanometer (Particle Diameter (nm)).

[0042] Figure 11 A is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) (SEQ ID NO: 59) fused N-terminal to a FLAG tag (SEQ ID NO: 66) fused via the GSGGSG linker (SEQ ID NO: 10) N-terminal to a mutant form of epidermal growth factor (EGFml23) (SEQ ID NO: 36) or the anti-CD3 scFv UCHT1 (UCHT1) fused either directly or via the GSGGSG linker (SEQ ID NO: 10) N-terminal to the GCN4 leucine / isoleucine zipper peptide derived oligomerization domain with valine and alanine substitutions to form a coiled coil structure (helical-peptide-VL) (SEQ ID NO: 26) fused via the (G4S)x3 linker ((G4S)3) N-terminal to the three cysteine rich (CR) domains of the low density lipoprotein receptor (LDLR) (CR1+2+3) (SEQ ID NOs: 1, 2, and 3) fused via the (G4S)x3 linker ((G4S)3) alone or with the Furin cleavable RRKR linker (Fr) (SEQ ID NO: 69) N-terminal to a VSIV-G (VSV-G) as shown.

[0043] Figure 11B is a bar graph showing the results of an ELISA assay detecting FLAG levels, as measured by OD values, showing the presence of the recombinant proteins of FIG.11A with the WT VSIV-G pseudotyped lentivirus particles.

[0044] Figure 11C is a bar graph showing the results of fluorescent nanoparticle tracking analysis (fNTA) for lentiviral particles measured as the particle concentration of the pseudotyped lentiviral particles as particles per mL (Particles / mL) as determined by immunolabeled FLAG (FLAG) or VSIV-G (VSV-G) for lentiviral particles pseudotyped with wild type VSIV-G (VSV-G WT), mutant VSIV-G with K47Q+Y209Q+R354Q substitutions (G-QQQ), or wild type VSIV-G and combinations of recombinant protein containing theLeydig 775437Vyriad P-64-00414CD3 binding scFv UCHT1 (UCHT1). the helical peptide-VL (VL PEP), the C-terminal Foldon domain from T4 fibritin (Foldon), the CR1, CR2, and CR3 regions of LDLR (CR123), the CR3 region of LDLR (CR3), the GGGGS linker (G4S) (SEQ ID NO: 6), and the G4Sx3 linker ((G4S)3) as labeled.

[0045] Figures 12A-12D are a set of micrographs showing GFP fluorescence in Jurkat cells, Jurkat cells with low density lipoprotein receptor knocked out (LDLR-KO), Jurkat cells with T cell receptor knocked out (TCR-KO), and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), VSIV-G-QQQ (SEQ ID NO: 68). a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had undergone centrifugation (Spin).

[0046] Figures 13A-13D are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), VSIV-G-QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had not undergone centrifugation (No spin).

[0047] Figures 14A-14D are a set of cytometer images showing GFP+ Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), VSIV-G-QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFvLeydig 775437Vyriad P-64-00415UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had undergone centrifugation (Spin).

[0048] Figures 15A-15D are a set of cytometer images showing GFP+ Jurkat cells.LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), VSIV-G-QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had not undergone centrifugation (No spin).

[0049] Figures 16A-16C are bar graphs showing the number of GFP+ Jurkat and Nalm-6 cells transduced by a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57). VSIV-G-QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had undergone centrifugation (FIG. 16A) or had not undergone centrifugation (FIG. 16B), or showing the fold increase of GFP+ cell number inLeydig 775437Vyriad P-64-00416Jurkat cells compared to Nalm-6 cells that were transduced and had undergone centrifugation (FIG. 16C).

[0050] Figures 17A-17H are a set of micrographs showing GFP fluorescence in Jurkat cells and Nalm-6 cells 3 days post transduction with 100, 50, 25, 12.5, 6.25, or 3.1 lentiviral particles (LP) per cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), or 1000, 500, 250, 125, 62.5, or 31 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or 1000, 500, 250. 125, 62.5, or 31 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had centrifugation (Spin).

[0051] Figures 18A-18H are a set of cytometer images showing GFP+ Jurkat cells and Nalm-6 cells 3 days post transduction with 100, 50, 25, 12.5, 6.25, or 3.1 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), or 1000, 500, 250, 125, 62.5, or 31 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or 1000, 500, 250, 125, 62.5, or 31 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled that had centrifugation (Spin).

[0052] Figure 19 is a bar graph showing transduction efficiency of Jurkat cells transduced by 100, 50, 25, 12.5, 6.25, or 3.1 LP / cell containing an EGFP expression cassette (SEQ IDLeydig 775437Vyriad P-64-00417NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), or 1000, 500. 250, 125. 62.5. or 31 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or 1000, 500, 250. 125, 62.5, or 31 LP / cell containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with WT VSIV-G and recombinant proteins containing the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization domain of the C -terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled

[0053] Figure 20 is a bar graph showing the percent of GFP+ K-562 cells, Jurkat cells, Nalm-6 cells, Skov-3 cells, A-549 cells. HT1080 cells, HEK293 cells, and PC3 cells transduced by a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57), VSIV-G-QQQ (SEQ ID NO: 68), a 1: 3 ratio of anti-CD3 scFv UCHT1 fused to VSIV-G-dK47 to VSIV-G-dK47 (SEQ ID NO: 104), or pseudotyped with WT VSIV-G and recombinant proteins containing the CR1, CR2, and CR3 (SEQ ID NOs: 1. 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, fused to an oligomerization domain of the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and containing G4S or (G4S)x3 linkers as labeled.

[0054] Figure 21 A is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a FLAG tag (SEQ ID NO: 66) fused via the GSGGSG linker (SEQ ID NO: 10) N-terminal to an anti-CD3 epsilon VHH antibody (VHH 3-aCD3s) fused directly or via the GGGGS linker (G4S) (SEQ ID NO: 6) or (G4S)x3 linker ((G4S)3) to either the GCN4 leucine / isoleucine zipper peptide derived oligomerization domain with valine and alanine substitutions to form a coiled coil structure (helical-peptide-VL) (SEQ ID NO: 26) or the C-terminal Foldon domain from T4 fibritin (Foldon) fused either directly or via the (G4S)x3 linker ((G4S)3) N-terminal to the CR1, CR2, and CR3 regions of LDLR (CR1+2+3) or the CR3 region of LDLR (CR3) fused N-terminal to the IgGk signal peptide (SP) (SEQ ID NO: 5) as shown.Leydig 775437Vyriad P-64-00418

[0055] Figure 21B is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a FLAG tag (SEQ ID NO: 66) fused via the GSGGSG linker (SEQ ID NO: 10) N-terminal to an anti-T cell receptor protein VHH antibody (VHH 9-aTCR) fused directly or via the GGGGS linker (G4S) (SEQ ID NO: 6) or (G4S)x3 linker ((G4S)3) to either the GCN4 leucine / isoleucine zipper peptide derived oligomerization domain with valine and alanine substitutions to form a coiled coil structure (helical-peptide-VL) (SEQ ID NO: 26) or the C-terminal Foldon domain from T4 fibritin (Foldon) fused either directly or via the (G4S)x3 linker ((G4S)3) N-terminal to the CR1, CR2, and CR3 regions of LDLR (CR1+2+3) or the CR3 region of LDLR (CR3) fused N-terminal to the IgGk signal peptide (SP) (SEQ ID NO: 5) as shown.

[0056] Figures 22A-22B are images of a western blot show ing binding of a VSIV-G antibody (anti-VSV-G), FLAG antibody (FLAG-tag), and either a GAPDH antibody (GAPDH) or p24 antibody in either the cell lysate (FIG. 22A) or virion pellet (FIG. 22B) of cells transfected with plasmids encoding WT VSIV-G alone or with plasmids encoding recombinant proteins containing the targeting domain UCHT1, VHH 3-aCD3s, or VHH 9-aTCR, helical VL peptide, CR123 of LDLR, with the G4S and (G4S)3 linker as labeled.

[0057] Figures 23A-23D are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) or pseudotyped with WT VSIV-G and recombinant proteins containing the targeting domain UCHT1, VHH 3-aCD3s, or VHH 9-aTCR, helical VL peptide, CR123 of LDLR, with the G4S and (G4S)3 linker as labeled that had undergone centrifugation (Spin).

[0058] Figures 24A-24D are a set of cytometer images showing GFP+ Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) or pseudotyped with WT VSIV-G and recombinant proteins containing the targeting domain UCHT1, VHH 3-aCD3e, or VHH 9-aTCR, helical VL peptide, CR123 of LDLR, with the G4S and (G4S)3 linker as labeled that had undergone centrifugation (Spin).

[0059] Figure 25A is a bar graph showing the number of GFP+ Jurkat, LDLR-KO Jurkat, TCR-KO Jurkat, and Nalm-6 cells transduced by a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) or pseudotypedLeydig 775437Vyriad P-64-00419with WT VSIV-G and recombinant proteins containing the targeting domain UCHT1, VHH 3-aCD3s, or VHH 9-aTCR, helical VL peptide, CR123 of LDLR, with the G4S and (G4S)3 linker as labeled that had undergone centrifugation (Spin).

[0060] Figure 25B is a bar graph showing the results of an ELISA assay detecting FLAG levels, as measured by OD values, showing the presence of the recombinant proteins of FIG.21A or 21B with the WT VSIV-G pseudotyped lentivirus particles, at different dilution rates.

[0061] Figures 26A-26B are schematic diagrams of the plasmids encoding recombinant CAP proteins encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1 and two copies of the CR3 (SEQ ID NOs: 1 and 3) of LDLR, fused to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL), hCollagen XIX NC2, hCollagen XV NCI, or hCollagen XVIII NCI, fused to the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42 fused to a Flag tag (SEQ ID NO: 66), with PEP-VL variants with 0-8 heptad repeats (FIG. 26A) and with a "‘trimmed’' variant of PEP-VL with the first three amnio acid residues at the N-terminal and the last five amino acids of the C-terminal of the 4 heptad repeat removed, and an untargeted control with a 4 heptad repeat and no UCHT1 scFv (FIG. 26B) as labeled.

[0062] Figures 26C-26F are images of a western blot showing binding of a VSIV-G antibody (aVSV-G), FLAG antibody (aFLAG), and either a GAPDH antibody (aGAPDH) or p24 antibody (anti-p24) in either the cell lysate (FIGS. 26C-26D) or virion pellet (FIGS. 26E-26f) of cells transfected with plasmids encoding WT VSIV-G alone or in combination with a plasmid encoding the recombinant CAP proteins shown in FIGS. 26A-26B.

[0063] Figure 26G is a bar graph showing the number of GFP+ Jurkat, LDLR-KO Jurkat, TCR-KO Jurkat. and Nalm-6 cells transduced by lentivirus pseudotyped with VSIV-G alone or bound to the recombinant CAP proteins of FIGS. 26A-26B as labeled.

[0064] Figure 27A is a depiction of the ratios and amount of DNA plasmid used in the experimental protocol for testing the role of the ratio of WT VSIV-G to the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 in transduction efficiency varying both the amount of WT VSIV-G and recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123.

[0065] Figures 27B-27C are images of a western blot showing binding of a VSIV-G antibody (top panel), FLAG antibody (FLAG-tag), and either a GAPDH antibody (GAPDH) or p24 antibody (p24) in either the cell lysate (FIG. 26B) or virion pellet (FIG. 26C) of cells transfected with plasmids encoding WT VSIV-G or VSIV-G-dK47 alone or in combinationLeydig 775437Vyriad P-64-00420with a plasmid encoding recombinant protein UCHTl-G-dK47 or recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.

[0066] Figure 27D is a bar graph showing the results of a sandwich ELISA assay using a capture antibody specific to WT VSIV-G and a detection antibody recognizing FLAG tag on the bound protein, as measured by OD values, for lentiviral particles (LVPs) as labeled at dilutions of 1:30 and 1:90, showing the presence of the recombinant protein of UCHT1-G4S-VL-PEP-(G4S)3-CR123 with the WT VSIV-G pseudotyped lentivirus particles.

[0067] Figures 28A-28D are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with PEG 8000 concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G or VSIV-G-dK47 or pseudotyped with WT VSIV-G and the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, no spinfection.

[0068] Figures 29A-29F are a set of cytometer images showing GFP+ Jurkat cells. LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with PEG 8000 concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G only or VSIV-G-dK47 only or pseudotyped with WT VSIV-G masked with the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, or UCHT1-G4S-VL-PEP-(G4S)3-CR123 only (no G-WT) as a negative control.

[0069] Figure 30 is a bar graph showing the number of GFP+ Jurkat, LDLR-KO Jurkat, TCR-KO Jurkat, and Nalm-6 cells transduced by a PEG 8000 concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G only or VSIV-G-dK47 only or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47, or pseudotyped with WT VSIV-G masked with the recombinant protein UCHT1 -G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, or UCHT1-G4S-VL-PEP-(G4S)3-CR123 only (no G-WT) as a negative control.

[0070] Figures 31A-31D are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with ultra-centrifugated concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G only or VSIV-G-dK47 only or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47, or pseudotyped with WT VSIV-G masked with the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, or UCHT1-G4S-VL-PEP-(G4S)3-CR123 only (No G-WT) as a negative control.Leydig 775437Vyriad P-64-00421

[0071] Figures 32A-32F are a set of cytometer images showing GFP+ Jurkat cells.LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with ultra-centrifugated concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G only or VSIV-G-dK47 only or 1:3 mixed UCHT1-VSIV-G-dK47 with VSIV-G-dK47. or pseudotyped with WT VSIV-G masked with the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, or UCHT1-G4S-VL-PEP-(G4S)3-CR123 only (No G-WT) as a negative control.

[0072] Figure 33A is a bar graph showing the number of GFP+ Jurkat, LDLR-KO Jurkat, TCR-KO Jurkat, and Nalm-6 cells transduced by an ultra-centrifugated concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G only or VSIV-G-dK47 only or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47, or pseudotyped with WT VSIV-G masked with the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, or UCHT1-G4S-VL-PEP-(G4S)3-CR123 only (No G-WT) as a negative control.

[0073] Figure 33B is a bar graph showing the number of GFP+ Jurkat, LDLR-KO Jurkat, TCR-KO Jurkat, and Nalm-6 cells transduced by PEG 8000 concentrated (left) or ultracentrifugated concentrated (right) lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G only or VSIV-G-dK47 only or 1:3 mixed UCHT1-VSIV-G-dK47 with VSIV-G-dK47, or pseudotyped with WT VSIV-G masked with the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled, or UCHT1-G4S-VL-PEP-(G4S)3-CRI23 only (No G-WT) as a negative control.

[0074] Figure 34 is a depiction of the ratios and amount of DNA plasmid used in the experimental protocol for testing the role of the ratio of WT VSIV-G to the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 in transduction efficiency varying the amount recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 while keeping the amount of WT VSIV-G constant at L5pg or 2.25pg.

[0075] Figures 35A-35B are images of western blots showing binding of a VSIV-G antibody, a FLAG antibody (FLAG-tag), and either a GAPDH antibody (GAPDH) or p24 antibody (p24) in either the cell lysate (FIG. 35 A) or virion pellet (FIG. 35B) concentrated by PEG 8000 or ultra-centrifugation of cells transfected with plasmids encoding WT VSIV-G or VSIV-G-dK47 alone or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47, or WT VSIV-G in combination with a plasmid encoding recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.Leydig 775437Vyriad P-64-00422

[0076] Figures 36A-36F are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with PEG 8000 concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G or VSIV-G-dK47 or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47, or pseudotyped with WT VSIV-G and the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.

[0077] Figures 37A-37F are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with ultra-centrifugated concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G or VSIV-G-dK47 or 1:3 mixed UCHT1-VSIV-G-dK47 with VSIV-G-dK47 or pseudotyped with WT VSIV-G and the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.

[0078] Figures 38A-38F are a set of cytometer images showing GFP+ Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with PEG 8000 concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G or VSIV-G-dK47 or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47 or pseudotyped with WT VSIV-G and the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.

[0079] Figures 39A-39F are a set of cytometer images showing GFP+ Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with ultra-centrifugated concentrated lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G or VSIV-G-dK47 or 1:3 mixed UCHTl-VSIV-G-dK47 with VSIV-G-dK47 or pseudotvped with WT VSIV-G and the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.

[0080] Figures 40A-40B are bar graphs showing the number of GFP+ Jurkat, LDLR-KO Jurkat, TCR-KO Jurkat, and Nalm-6 cells transduced by PEG 8000 concentrated (FIG. 40 A) or an ultra-centrifugated concentrated (FIG. 40B) lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G or VSIV-G-dK47 or 1:3 mixed UCHT1-VSIV-G-dK47 with VSIV-G-dK47 or pseudotyped with WT VSIV-G and the recombinant protein UCHT1-G4S-VL-PEP-(G4S)3-CR123 at different ratios as labeled.

[0081] Figure 41A is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) fused N-terminal to CR1, CR2, CR3 or combinations thereof fused via the (G4S)x3 linker to helical peptide VL fused toLeydig 775437Vyriad P-64-00423UCHT1 via the G4S linker fused to FLAG tag (SEQ ID NO: 66) via the GSGGSG linker (SEQ ID NO: 10) as labeled.

[0082] Figure 41 B is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) (SEQ ID NO: 59) fused N-terminal to a FLAG tag (SEQ ID NO: 66) fused via the GSGGSG linker (SEQ ID NO: 10) N-terminal to the anti-CD3 scFv UCHT1 (UCHT1) or a mutant EGF ligand (EGFml23) fused N-terminal to the helical VL peptide fused via the (G4S)x3 linker ((G4S)3) N-terminal to either the CR1, CR2, and CR3 regions of LDLR (CR1+2+3) fused via the (G4S)x3 linker ((G4S)3) alone or with the Furin cleavable RRKR linker (Fr) (SEQ ID NO: 69) N-terminal to a VSIV-G (VSV-G) as shown.

[0083] Figure 41 C is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) (SEQ ID NO: 59) fused N-terminal to a FLAG tag (SEQ ID NO: 66) fused via the GSGGSG linker (SEQ ID NO: 10) N-terminal to the anti-CD3 scFv UCHT1 (UCHT1) fused N-terminal to the C-terminal Foldon domain from T4 fibritin (Foldon) fused via the (G4S)x3 linker ((G4S)3) N-terminal to either the CR1, CR2, and CR3 regions of LDLR (CR1+2+3) or the CR3 region of LDLR (CR3) fused via the (G4S)x3 linker ((G4S)3) alone or with the Furin cleavable RRKR linker (Fr) (SEQ ID NO: 69) N-terminal to a VSIV-G (VSV-G) as shown.

[0084] Figure 41D is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) (SEQ ID NO: 59) fused N-terminal to the anti-CD3 scFv UCHT1 (UCHT1) fused N-terminal to CR3 alone, CR1, CR3 and CR3 (CR1+3+3), CR1, CR2 and CR2 (CR1+2+2), or CR3 and CR3 (CR3+3) by the (G4S)3 linker fused via the (G4S)3 linker N-terminal to wild type VSIV-G (VSV-G WT) as shown.

[0085] Figure 41E is a schematic diagram of the construct design of the plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) (SEQ ID NO: 59), the anti-CD3 scFv UCHT1, CR3 of LDLR alone or CR1, CR2 and CR3 (CR1+2+3) of LDLR, Flag tag, and VSIV-G- WT, fused directly to one another or via the (G4S)3 linker, GGGGS linker (SEQ ID NO: 6), GSGGSG linker (SEQ ID NO: 10), and / or Furin linker RRKR (SEQ ID NO: 69) as shown.

[0086] Figure 42A shows a summary of the experimental design for testing the transduction efficacy of lentiviruses pseudotyped with WT VSIV-G and combined withLeydig 775437Vyriad P-64-00424different amounts of purified recombinant proteins containing UCHT1. CR123, and a helical peptide in vitro as labeled.

[0087] Figures 42B-42E are a set of micrographs showing GFP fluorescence in Jurkat cells and Nalm-6 cells 3 days post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or with different amounts of the purified recombinant protein UCHT1-(G4S)3- AA PEP-(G4S)3-CR123 or UCHT1-G4S)3-VL-PEP-(G4S)3-CR123 as labeled.

[0088] Figures 43A-43D are a set of cytometer images showing GFP+ Jurkat cells and Nalm-6 cells 3 days post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or with different amounts of the purified recombinant protein UCHT1-(G4S)3- AA PEP-(G4S)3-CR123 or UCHT1-G4S)3-VL-PEP-(G4S)3-CR123 as labeled.

[0089] Figures 44A-44C are bar graphs showing the number of GFP+ Jurkat and Nalm-6 cells transduced by a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with VSIV-G (SEQ ID NO: 57) and mixed with different amounts of purified recombinant protein UCHT1-VL PEP-CR123 (FIG. 44A) or UCHT1-L-AA PEP-L-CR123 (FIG. 44B) as labeled, or showing the fold increase of GFP+ cell number in Jurkat cells compared to Nalm-6 cells that were transduced (FIG. 44C).

[0090] Figure 44D shows a summary of the experimental design for testing the transduction efficacy of lentiviruses pseudotyped with WT VSIV-G and combined with different amounts of purified recombinant CAP proteins containing the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42 fused to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide, either helical peptide VL (PEP-VL) (SEQ ID NO: 26) or helical peptide AA (PEP-AA) (SEQ ID NO: 35) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or the CR1 and two copies of CR3 (SEQ ID NOs: 1 and 3) of LDLRUCHT1, CR123, and a helical peptide VL or AA in Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells as labeled.

[0091] Figures 44E-44F are bar graphs showing the percent of GFP+ Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells treated with lentivirus pseudotyped with VSIV-G that was combined with different concentrations of the CR123-VL-UCHT1 and CR123-AA-UCHT1 (FIG. 44E) and CR133-VL-UCHT1 and CR133-AA-UCHT1 (FIG. 44F) CAP proteins as labeled.Leydig 775437Vyriad P-64-00425

[0092] Figure 44G shows a summary of the experimental design for testing the transduction efficacy of lentiviruses pseudotyped with WT VSIV-G and combined with purified recombinant CAP protein CR133-VL-UCHT1 for 1, 5, 10, 20, 40, or 60 minutes before transduction of Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells.

[0093] Figure 44H is a set of bar graphs showing the percentage of GFP+ Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells treated with lentivirus pseudotyped with VSIV-G and combined with no CAP protein or 20 nM of CR133-VL-UCHT1 CAP protein for 1, 5, 10, 20, 40, or 60 minutes before transduction as labeled.

[0094] Figure 44I shows a summary of the experimental design for testing the transduction efficacy of lentiviruses pseudotyped with WT VSIV-G and combined with 7 different concentrations of purified recombinant CAP protein CR133-VL-UCHT1 for 1 minute before transduction of Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells.

[0095] Figure 44J is a bar graph showing percentage of GFP+ Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells treated with lentivirus pseudotyped with VSIV-G and combined with no CAP protein or CR133-VL-UCHT1 CAP protein at different concentrations for 1 minute before transduction as labeled.

[0096] Figure 45A shows a summary7of the experimental design for testing the stability of lentiviruses pseudotyped with VSIV-G and recombinant protein CR123-(G4S)3-VL PEP-G4S-UCHT1-FLAG at room temperature (RT), 4°C, -80°C, or a combination thereof for 1 hour, 4 hours, 8 hours, 24 hours, 32 hours, or 48 hours.

[0097] Figures 45B-45J are a set of micrographs showing GFP fluorescence in Jurkat cells and Nalm-6 cells at 5 days post transduction (FIGS. 45B-45D), 4 days post transduction (FIGS. 45E-45G), or 3 days post transduction (FIGS. 45H-45J), with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or combined with purified or co-expressed recombinant protein UCHT1-(G4S)3-VL-PEP-(G4S)3-CR123 at different temperatures as labeled and a bar graph of the percent GFP+ cells quantified by flow cytometry.

[0098] Figure 45K is a bar graph showing the results of a sandwich ELISA assay using a capture antibody^ specific to WT VSIV-G and a detection antibody recognizing FLAG tag on the bound protein, as measured by OD values, for LVPs as labeled at dilutions of 1:30 and 1:90, showing the presence of the purified (G + purified cap)or co-expressed recombinant proteins UCHT1-(G4S)3-VL-PEP-(G4S)3-CR123 with the WT VSIV-G pseudotypedLeydig 775437Vvriad P-64-00426lentivirus particles (co-expressed: G + cap) at different temperatures, or WT VSIV-G pseudotyped lentivirus particles alone (G-only) as negative control.

[0099] Figure 45L shows a summary of the experimental design for testing the stability of lentiviruses pseudotyped with VSIV-G and recombinant protein CR123-(G4S)3-VL PEP-G4S-UCHT1-FLAG at RT for 1 hour, or 37°C for 1 hour, 4 hours, 24 hours, 32 hours, or 48 hours.

[0100] Figures 45M-45P are a set of micrographs showing GFP fluorescence in Jurkat cells and Nalm-6 cells at 5 days post transduction (FIGS. 45M and 450), 4 days post transduction (FIGS. 45N and 45P), or 3 days post transduction (FIGS. 45N and 45P), with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or combined with purified recombinant protein UCHT1-(G4S)3-VL-PEP-(G4S)3-CR123 at different temperatures as labeled.

[0101] Figures 45Q-45R are bar graphs showing the percent of GFP+ Jurkat (FIG. 45Q) and Nalm-6 (FIG. 45R) cells transduced by a lentivirus containing an EGFP expression cassette (SEQ ID NO: 67) and pseudotyped with WT VSIV-G (SEQ ID NO: 57) alone or combined with purified recombinant protein UCHT1-(G4S)3-VL-PEP-(G4S)3-CR123 at different temperatures as labeled.

[0102] Figure 46A shows a summary of the experimental design for testing stability of lentiviruses pseudotyped with a viral FMG alone or with a viral FMG mixed outside of the cellular environment with a recombinant CAP protein when incubated for no additional time (TO), 4 hour (Tl), 8 hours (T2), and 24 hours (T3) at room temperature, with or without human serum albumin (HSA).

[0103] Figures 46B-46E are bar graphs showing the percent of GFP+ Jurkat cells, TCR-KO Jurkat cells, LDLR-KO Jurkat cells, and Nalm-6 cells transduced by a lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone (FIGS.46B-46C) and combined with purified recombinant protein UCHT1-(G4S)3-VL-PEP-(G4S)3-CR123 (FIGS. 46D-46E) with no additional incubation at room temperature (TO) as labeled.

[0104] Figures 46F-46I are bar graphs showing are bar graphs showing the percent of GFP+ Jurkat cells, TCR-KO Jurkat cells, LDLR-KO Jurkat cells, and Nalm-6 cells transduced by a lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone (FIGS. 46F-46G) and combined with purified recombinant protein UCHT1-Leydig 775437Vyriad P-64-00427(G4S)3-VL-PEP-(G4S)3-CR123 (FIGS. 46H-46I) with an additional incubation of 24 hours at room temperature (T3) as labeled.

[0105] Figures 46J-46K are bar graphs showing the percentage of GFP+ Jurkat cells (FIG. 46J) and Jurkat-LDLR KO cells (FIG. 46K) from all the different incubation treatments (T0-T3) normalized to TO data both with and without HSA. as labeled.

[0106] Figures 46L-46O are bar graphs showing all the cells treated with uncapped virus (FIGS. 46L-46M) and capped virus (FIGS. 46N-46O) for each incubation period (T0-T3) without HSA (FIGS. 46L and 46N) and with HSA (FIGS. 46M and 460) as labeled.

[0107] Figures 46P-46Q are bar graphs showing the mean difference of GFP positive cell counts, Jurkat cells or Jurkat-LDLR KO cells in HSA 1% conditions (HSA+) versus no HSA conditions (HSA-) as labeled. Transduction was performed by “G-WT virus only” (FIG. 46P) or “G-WT virus + Cap” (FIG. 46Q).

[0108] Figure 47A shows a summary of the experimental design for testing the transduction efficacy of lentiviruses pseudotyped with WT VSIV-G and recombinant proteins containing UCHTL helical VL peptide or Foldon peptide and CD123 or CR3 with the G4S and (G4S)3 linkers in human peripheral blood mononuclear cells (PBMCs).

[0109] Figure 47B shows the flow cytometry7gating strategy for analysis of PBMCs while testing the transduction efficacy of lentiviruses pseudotyped with WT VSIV-G and recombinant proteins containing UCHTL helical VL peptide or Foldon peptide and CD123 or CR3 with the G4S and (G4S)3 linkers.

[0110] Figures 47C-47F are bright field (FIGS. 47A-47B) and fluorescent (FIGS. 45C-45D) images 3 days post transduction of PBMCs with lentivirus containing an EGFP expression cassette and pseudoty ped with WT VSIV-G. VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHTL helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0111] Figures 48A-48B are flow cytometry dot plots showing intensity of side scatter (SSC) vs. GFP in PBMCs gated on Live / CD45 at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudoty ped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3. and the linkers G4S and (G4S)3 as labeled.Leydig 775437Vyriad P-64-00428

[0112] Figure 48C is a bar graph showing the number of GFP+ PBMCs per le5 PBMCs at 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0113] Figures 49A-49B are flow cytometry dot plots showing intensity of CD3 vs. GFP in PBMCs gated on Live / CD45 at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G. VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0114] Figures 50A-50B are bar graphs showing the number of CD8+ (FIG. 50A) and CD4+ (FIG. 50B) PBMCs at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0115] Figures 51A-51B are flow cytometry dot plots showing intensity of CD8 vs. CD4 in PBMCs gated on Live / CD45 / GFP / CD3 at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide. CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0116] Figures 52A-52B are flow cytometry dot plots showing intensity of CD8 vs. GFP in PBMCs gated on Live / CD45 / CD3 / CD8 at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0117] Figures 53A-53B are flow cytometry dot plots showing intensity of CD4 vs. GFP in PBMCs gated on Live / CD45 / CD3 / CD4 at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ,Leydig 775437Vyriad P-64-00429a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0118] Figures 54A-54B are a set of flow cytometry histograms showing intensity of CD69 in PBMCs gated on Live / CD45 / CD3 at 6 and 72 hours post transduction with lenti virus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0119] Figures 55A-55B are bar graphs showing the log (FIG. 55 A) and linear (FIG. 55B) mean fluorescent intensity (MFI) of CD69+ PBMCs at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0120] Figures 56A-56B are a set of flow cytometry histograms showing intensity of CD25 in PBMCs gated on Live / CD45 / CD3 at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G.VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0121] Figure 56C is a bar graph showing the log MFI of CD25+ PBMCs at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1 - VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0122] Figure 57A is a bar graph showing percent viability of PBMCs at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.Leydig 775437Vyriad P-64-00430

[0123] Figures 57B-57C are flow cytometry dot plots showing intensity of side scatter (SSC) vs. Live / Dead, as measured by EF780 labeling, in PBMCs at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudotyped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0124] Figures 58A-58B are bar graphs showing the results of an ELISA assay quantifying levels of the cytokines human interferon gamma (hlFNy) (FIG. 58 A) and human interleukin 2 (hIL-2) (FIG. 58B) in the supernatant of the PBMCs at 6 and 72 hours post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, VSIV-G-QQQ, a 1:3 ratio of UCHT1- VSIV-G-dK47 to VSIV-G-dK47 or pseudoty ped with WT VSIV-G and a recombinant protein containing UCHT1, helical VL peptide or Foldon peptide, CR123 or CR3, and the linkers G4S and (G4S)3 as labeled.

[0125] Figures 59A-59C show a summary of the protein purification protocol for recombinant proteins containing a targeting domain, oligomerizing peptide, and receptor binding domain.

[0126] Figures 60A-60B show a summary of the workflow from vector design to purified protein with quality control analysis for the protein purification protocol for recombinant proteins containing a targeting domain, oligomerizing peptide, and receptor binding domain.

[0127] Figure 61 A-61B are images of a western blot showing binding of a VSIV-G antibody (anti-VSV-G), FLAG antibody (FLAG-tag), and either a GAPDH antibody (GAPDH) or p24 antibody in either the cell lysate (FIG. 61A) or virion pellet (FIG. 61B) of cells transfected with plasmids encoding WT VSIV-G alone, plasmids encoding the recombinant protein UCHTl-VSIV-G-dK47 and VSIV-G-dK47, or with plasmids encoding recombinant proteins containing the targeting domain UCHT1, helical VL peptide, different combinations of the CR1, CR2, and CR3 domains of LDLR, with the G4S and (G4S)3 linker as labeled.

[0128] Figure 61 C is a bar graph showing the results of a sandwich ELISA assay using a capture antibody specific to WT VSIV-G and a detection antibody recognizing FLAG tag on the bound protein as measured by OD values, for LVPs at dilutions of 1:30, 1:90, and 1:270 that were produced using the constructs from FIG. 41 A.

[0129] Figures 62A-62D are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, CD3 E-KO Jurkat cells, and Nalm-6 cellsLeydig 775437Vyriad P-64-004313 days post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G, with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47, or pseudotyped with WT VSIV-G and a recombinant protein containing the targeting domain UCHT1, helical VL peptide, different combinations of the CR1, CR2, and CR3 domains of LDLR, with the G4S and (G4S)3 linker as labeled that had undergone centrifugation.

[0130] Figure 62E is a bar graph showing the percentage of GFP+ Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, CD3 E-KO Jurkat cells, and Nalm-6 cells 3 days post transduction with lentivirus containing an EGFP expression cassette and pseudoty ped with WT VSIV-G, with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47. or pseudotyped with WT VSIV-G and a recombinant protein containing the targeting domain UCHT1, helical VL peptide, different combinations of the CR1, CR2, and CR3 domains of LDLR, with the G4S and (G4S)3 linker as labeled that had undergone centrifugation.

[0131] Figure 62F is a schematic diagram of the plasmids encoding recombinant CAP proteins of the IgGk signal peptide (SP) (SEQ ID NO: 5). different combinations of CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3), helical peptide VL (PEP-VL) (SEQ ID NO: 26), the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42, and a Flag tag (SEQ ID NO: 66) all fused directly to one another or via (G4S)x3 linker, GSGGSG linker (SEQ ID NO: 10), or GGGGS linker (SEQ ID NO: 6) as labeled.

[0132] Figures 62G-62H are images of a western blot showing binding of a VSIV-G antibody (anti-VSV-G), FLAG antibody (anti-FLAG-tag), and either a GAPDH antibody (anti-GAPDH) or p24 antibody in either the cell lysate (FIG. 62G) or virion pellet (FIG. 62H) of cells transfected with plasmids encoding WT VSIV-G alone and with plasmids encoding the recombinant CAP proteins shown in FIG. 62F as labeled.

[0133] Figure 621 is a bar graph showing the results of a sandwich ELISA assay using a capture antibody specific to WT VSIV-G and a detection antibody recognizing FLAG tag on the bound protein as measured by OD values, for LVPs at dilutions of 1:30, 1:90, and 1:270 that were produced using the constructs from FIG. 62F.

[0134] Figures 62J-62K are a set of schematic diagrams of the plasmids encoding recombinant CAP proteins of the IgGk signal peptide (SP) (SEQ ID NO: 5), different combinations of CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3), helical peptide VL (PEP-VL) (SEQ ID NO: 26), and a FLAG tag (SEQ ID NO: 66) all fused directly to one another or via (G4S)x3 linker, GSGGSG linker (SEQ ID NO: 10). or GGGGS linker (SEQ ID NO: 6) and with a targeting domain of the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO:Leydig 775437Vyriad P-64-0043241 and a VL of SEQ ID NO: 42 (FIG. 62J) or without a targeting domain (FIG. 62K) as labeled.

[0135] Figures 62L-62M are images of a western blot showing binding of a VSIV-G antibody (anti-VSV-G), FLAG antibody (Anti-FLAG-tag), and either a GAPDH antibody (Anti-GAPDH) or p24 antibody in either the cell lysate (FIG. 62L) or virion pellet (FIG. 62M) of cells transfected with plasmids encoding WT VSIV-G alone and with plasmids encoding the targeted and untargeted recombinant CAP proteins shown in FIGS. 62J-62K as labeled

[0136] Figures 62N-62O are bar graphs showing the percentage of GFP+ Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 4 days post transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G and an untargeted recombinant CAP protein (FIG. 62N) or a recombinant CAP protein containing the targeting domain UCHT1 (FIG. 620) from FIGS. 62J-62K as labeled.

[0137] Figure 62P is a diagram showing the structure of the recombinant CAP proteins containing different combinations of the CR1, CR2, CR3 domains of LDLR bound to a VSIV-G trimer from a side and top view, with moderately to highly functional CAP proteins bolded.

[0138] Figure 63A is a set of schematic diagrams of the construct design of the plasmids encoding recombinant proteins of an IgGk signal peptide (SP) (SEQ ID NO: 5) fused N-terminal to CR1, CR2, CR3 or combinations thereof fused via the (G4S)x3 linker to helical peptide VL fused to UCHT1 (oriented VH (SEQ ID NO: 41) N-terminal to VL (SEQ ID NO: 42), unless labeled otherwise) via the G4S linker fused to FLAG tag (SEQ ID NO: 66) via the GSGGSG linker (SEQ ID NO: 10) as labeled.

[0139] Figure 63B is a schematic diagram of the control construct designs for the constructs of FIG. 63 A, showing plasmids encoding recombinant proteins of an IgGk signal peptide (SP) (SEQ ID NO: 5) fused N-terminal to CR1, CR2, CR3 or combinations thereof fused either to FLAG tag (SEQ ID NO: 66) via the GSGGSG linker (SEQ ID NO: 10) or fused to helical peptide VL via the (G4S)x3 linker and fused to FLAG tag (SEQ ID NO: 66) via the GSGGSG linker (SEQ ID NO: 10) as labeled.

[0140] Figure 63C is a schematic diagram of the construct design of the plasmids encoding recombinant CAP proteins fused to VSIV-G WT protein, with the CAP protein containing an IgGk signal peptide (SP) (SEQ ID NO: 5), CR3 domain of LDLR alone or in combination with CR1 and CR2 domains of LDLR, the helical peptide VL (PEP-VL), theLeydig 775437Vvriad P-64-00433anti-CD3 scFv. and FLAG tag, fused directly to one another or via different combinations of the GGGGS linker (SEQ ID NO: 6), GSGGSG linker (SEQ ID NO: 10), the (G4S)3 linker, the Furin linker, and / or P2A linker as labeled.

[0141] Figures 63D-63E are images of a western blot showing binding of a VSIV-G antibody (top panel, anti-VSV-G). FLAG antibody (FLAG-tag), and either a GAPDH antibody (GAPDH) or p24 antibody in either the cell lysate (FIG. 63D) or virion pellet (FIG.63E) of cells transduced with plasmids encoding WT VSIV-G alone or in combination with a plasmid encoding a recombinant CAP protein of FIG. 63C as labeled.

[0142] Figure 63F is a bar graph showing the results of a sandwich ELISA assay using a capture antibody specific to WT VSIV-G and a detection antibody recognizing FLAG tag on the bound protein as measured by OD values, for LVPs at dilutions of 1:30, 1:90, and 1:270 that were produced using the constructs from FIG. 63C.

[0143] Figures 63G-63H are bar graphs showing the number of GFP+ cells as measured by the number of cells (FIG. 63G) or sum area of GFP fluorescence (FIG. 63H) in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells after transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or with the recombinant CAP proteins of FIG. 63C.

[0144] Figure 64A shows the experimental study design for in vivo studies using LVPs pseudotyped with VSIV-G- WT and the UCHT1-VL PEP-CR123 recombinant protein and containing a BCMA-CAR gene to generate BCMA expressing CAR T cells in an OPM-2 tumor containing humanized mouse model.

[0145] Figures 64B-64C are a set of bioluminescence images of NSG-MHC I / II DKO mice implanted with OPM-2, a multiple myeloma, cells expressing firefly luciferase (Flue) and human peripheral blood mononuclear cells (hPBMCs) 2 days before (Day -2) being injected with either saline (Group 1), 1E7 TU lentivirus pseudotyped with VSIV-G- WT containing a BCMA-CAR transgene (Group 3), or 1E7 TU lentivirus pseudotyped with VSIV-G- WT containing a BCMA-CAR transgene that were capped with the UCHT1-VL PEP-CR123 recombinant protein (Group 2), and at 7, 12, 21, 28, and 35 days after injection.

[0146] Figure 65A is a set of flow cytometry dot plots showing intensity of murine CD45 (mCD45) vs. human CD45 (hCD45) in blood samples of OPM-2 Flue mice taken 21 days after injection either saline (Group 1), 1E7 TU lentivirus pseudotyped with VSIV-G- WT containing a BCMA-CAR transgene(Group 3), or 1E7 TU lentivirus pseudotyped with VSIV-Leydig 775437Vyriad P-64-00434G-WT containing aBCMA-CAR transgene that where capped with the UCHT1-VL PEP-CR123 recombinant protein (Group 2).

[0147] Figure 65B is a set of flow cytometry dot plots showing intensity of hCD45 vs. human BCMA (hBCMA) in blood samples of OPM-2 Flue mice taken 21 days after injection either saline (Group 1), 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing a BCMA-CAR (Group 3), or 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing a BCMA-CAR that where capped with the UCHT1-VL PEP-CR123 recombinant protein (Group 2).

[0148] Figures 66A-66B are graphs showing the percentage of body weight changes in OPM-2 Flue mice over the course of the experimental study shown in FIG. 64A.

[0149] Figure 67A shows the experimental study design for in vivo studies using LVPs pseudotyped with VSIV-G-WT and the UCHT1-VL PEP-CR123 recombinant protein and containing a BCMA-CAR gene driven by a RSV promoter to generate BCMA expressing CAR T cells in an OPM-2 tumor containing humanized mouse model.

[0150] Figure 67B is a set of bioluminescence images of NSG-MHC I / II DKO mice implanted with OPM-2, a multiple myeloma, cells expressing firefly luciferase (Flue) and human peripheral blood mononuclear cells (hPBMCs) 2 days before (Day -2) being injected with either saline (Group 1), 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing a BCMA-CAR transgene (Group 3), or 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing a BCMA-CAR transgene that were capped with the UCHT1-VL PEP-CR123 recombinant protein (Group 2), and at 7, 12, 21, 28, and 35 days after injection.

[0151] Figure 67C is a set of flow cy tometry' dot plots showing intensity of mCD45 vs. hCD45 in blood samples of OPM-2 Flue mice taken 28 days after injection either saline (Group 1), 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing aBCMA-CAR trans gene(Group 3), or 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing aBCMA-CAR transgene that where capped with the UCHT1-VL PEP-CR123 recombinant protein (Group 2).

[0152] Figure 67D is a set of flow cytometry dot plots showing intensity of hCD45 vs. human BCMA (hBCMA) in blood samples of OPM-2 Flue mice taken 21 days after injection either saline (Group 1), 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing a BCMA-CAR (Group 3), or 1E7 TU lentivirus pseudotyped with VSIV-G-WT containing a BCMA-CAR that where capped with the UCHT1-VL PEP-CR123 recombinant protein (Group 2).Leydig 775437Vyriad P-64-00435

[0153] Figures 68A-68B are a set of line graphs showing body weight measurements of NSG MHC I / II DKO mice implanted with an OPM2-Fluc cells and humanized with human PBMCs and administered lentivirus pseudotyped with VSIV-G-WT, w / o CD3 targeted CAP protein, or a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 as shown in Table 25.

[0154] Figures 68C-68D are a set of bioluminescence images of humanized OPM2-Fluc mice 1 day before (D -1) being injected with either saline (Group 1), or lentivirus of Groups 2-8 as described in Table 25, and at 7, 15, 23, 29, 36, and 51 days after injection.

[0155] Figure 68E is a graph showing the probability of survival of humanized OPM2-Fluc mice of Groups 1-8 of Table 25 over time after treatment.

[0156] Figure 68F is an abbreviated illustration of the gating strategy for cells collected from humanized OPM2-Fluc mice to determine BCM A CAR expression and T cell activation.

[0157] Figure 68G is a bar graph showing the number of CD45+ cells in humanized OPM2-Fluc mice from Groups 1-8 at 24 hours after treatment.

[0158] Figures 68H-68K are flow cytometry dot plots showing BCMA CAR expression vs. CD3 expression in CD45+ gated cells in T cells of humanized OPM2-Fluc mice from Groups 1-8 at 24 hours after treatment.

[0159] Figures 68L-68O are flow cytometry dot plots showing cell count vs. CD25 expression in T cells of humanized OPM2-Fluc mice from Groups 1-8 at 24 hours after treatment.

[0160] Figures 68P-68S are flow cytometry dot plots showing cell count vs. CD69 expression in T cells of humanized OPM2-Fluc mice from Groups 1-8 at 24 hours after treatment.

[0161] Figures 68T-68W are flow cytometry dot plots showing BCMA CAR expression vs. CD3 expression in CD45+ gated cells in splenocytes (FIG. 68T), liver cells (FIG. 68U), blood (FIG. 68 V), and bone marrow (FIG. 68W) of humanized OPM2-Fluc mice from Groups 1-8 at 16 days after treatment.

[0162] Figures 68X-68Y are bar graphs showing the number of CD45+ cells (FIG. 68X) and BCMA CAR+ and CD3+ cells (FIG. 68Y) in humanized OPM2-Fluc mice from Groups 1 -8 at 23 days after treatment.

[0163] Figures 68Z-68ZA are bar graphs showing the number of CD45+ cells (FIG. 68Z) and BCMA CAR+ and CD3+ cells (FIG. 68ZA) in humanized OPM2-Fluc mice from Groups 1-8 at 44 days after treatment.Leydig 775437Vyriad P-64-00436

[0164] Figure 69A is a schematic diagram showing plasmid maps for production of viruslike particles (VLPs) using Rous Sarcoma Virus (RSV) in a three-plasmid strategy without a packaging plasmid. Only some of the encoded component proteins are shown in the constructs.

[0165] Figures 69B-69D are a set of flow cytometry histograms showing the number (Count) of Jurkat cells, Jurkat cells with T cell receptor knocked out (Jurkat TCR-KO), and Jurkat cells with CD3 epsilon knocked out (Jurkat CD3-s KO) containing GFP 72 h.p.t. with VLPs prepared using a RSV Gag-Pro-GFP plasmid and VSV-G-WT plasmid and mixed with 1 pg, 0.5pg, 0.25 pg, 0.125, or 0.0625 pg of a capping protein fused with a UCHT1 scFv.

[0166] Figure 69E is a line graph showing the percentage of parental Jurkat cells, Jurkat TCR-KO, and Jurkat CD3-s KO cells containing GFP 72 h.p.t. with VLPs prepared using a RSV Gag-Pro-GFP plasmid and VSV-G-WT plasmid and mixed with 1 pg, 0.5pg, 0.25 pg, 0.125 pg, or 0.0625 pg of a capping protein fused with a UCHT1 scFv, also referred to as a trimer cap.

[0167] Figure 70A is a set of schematic diagram of the construct design of the CAP plasmids encoding recombinant proteins of a VSIV-G signal peptide (SP) fused N-terminal to CR123 fused to either helical peptide AA or helical peptide VL fused to a EGFml23 (SEQ ID NO: 36) fused to a Flag tag (SEQ ID NO: 66) with (G4S)x3 linker, GGGGS linker (SEQ ID NO:6), or GSGGSG linker (SEQ ID NO: 10) as labeled to be inserted into a VSV between the GFP and L proteins.

[0168] Figures 70B-70C are a set of micrographs showing GFP fluorescence in BHK-21 cells 3 days post transfection and in Vero-EGFR cells 22 hours post infection with CR123-PEP AA-EGFml23 (FIG. 70B) or CR123-PEP VL-EGFml23 (FIG. 70C) with G4S and (G4S)3 linker as labeled.

[0169] Figure 70D is a set of schematic diagram of the construct design of the CAP plasmids encoding recombinant proteins of a signal peptide (SP) fused N-terminal to CR123 fused to helical peptide VL fused to a EGFml23 (SEQ ID NO: 36) fused to a Flag tag (SEQ ID NO: 66) with (G4S)x3 linker, GGGGS linker (SEQ ID NO: 6), or GSGGSG linker (SEQ ID NO: 10) as labeled to be inserted into a VSV betw een the M and G-WT proteins.

[0170] Figure 70E is a set of micrographs showing GFP fluorescence in BHK-21 cells 3 days post transfection and in Vero-EGFR cells 22 hours post infection with CR123-PEP VL-EGFml23 with or without (G4S)3 linker as labeled.Leydig 775437Vyriad P-64-00437

[0171] Figures 71 A-71B are images of western blots showing binding of a VSIV-G antibody (VSV-G), VSIV N protein antibody (VSV-N), a VSIV M protein antibody (VSV-M), FLAG antibody (FLAG), and a GAPDH antibody (GAPDH) in either the cell lysate of VSV infected cells (FIG. 71A) or virion particles (FIG. 71B) with the CR123-PEP VL-EGFml23 or CR123-PEP AA-EGFml23 as labeled.

[0172] Figures 72A-72B are a set of cytometer images showing GFP positive Vero-parental cells, Vero cells expressing the EGF receptor (Vero-EGFR), K-562 parental cells and K-562 cells expressing the EGF receptor (K562-EGFR) infected using VSV virion particles with the CR123-PEP VL-EGFml23 or CR123-PEP AA-EGFml23 inserted between the GFP and L protein or M and G protein of VSV as labeled, at 24 hours post infection (hpi) (FIG. 72A) or 48 hpi (FIG. 72B).

[0173] Figures 72C-72D are bar graphs showing the number of GFP positive Vero-parental cells, Vero cells expressing the EGF receptor (Vero-EGFR), K-562 parental cells and K-562 cells expressing the EGF receptor (K562-EGFR) infected using VSV virion particles with the CR123-PEP VL-EGFml23 or CR123-PEP AA-EGFml23 inserted between the GFP and L protein or M and G protein of VSV as labeled, at 24 hours post infection (hpi) (FIG. 72C) or 48 hpi (FIG. 72D).

[0174] Figures 73A-73B are a set of cytometer images showing GFP positive Vero-parental cells, Vero cells expressing the EGF receptor (Vero-EGFR), K-562 parental cells and K-562 cells expressing the EGF receptor (K562-EGFR) infected using VSV virion particles with the CR123-PEP AA-EGFml23 inserted between the GFP and L protein of VSV as labeled, at 24 hours post infection (hpi) (FIG. 73A) or 48 hpi (FIG. 73B).

[0175] Figures 73C-73D are bar graphs showing the number of GFP positive Vero-parental cells, Vero cells expressing the EGF receptor (Vero-EGFR), K-562 parental cells and K-562 cells expressing the EGF receptor (K562-EGFR) infected using VSV virion particles with the CR123-PEP AA-EGFml23 inserted between the GFP and L protein of VSV as labeled, at 24 hours post infection (hpi) (FIG. 73C) or 48 hpi (FIG. 73D)

[0176] Figure 74 shows a summary of the workflow for mixing wild type VSV with purified UCHT1-VL-CR123 or UCHT1-AA-CR123 recombinant proteins.

[0177] Figure 75 is a bar graph showing the results of a sandwich ELISA assay using a capture antibody specific to WT VSIV-G and a detection antibody recognizing FLAG tag on the bound protein as measured by OD values, for WT-VSV virion particles mixed withLeydig 775437Vyriad P-64-00438different amounts of CR123-PEP VL-UCHT1 or CR123-PEP AA-UCHT1 purified proteins as labeled at dilutions of 1:30 and 1:90.

[0178] Figures 76A-76B are a set of micrographs showing GFP fluorescence in Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 16 hours post infection with WT-VSV virion particles mixed with different amounts of CR123-PEP VL-UCHT1 or CR123-PEP AA-UCHT1 purified proteins as labeled.

[0179] Figure 76C is a bar graph showing the number of GFP positive Jurkat cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells, and Nalm-6 cells 16 hours post infection with WT-VSV virion particles mixed with different amounts of CR123-PEP VL-UCHT1 or CR123-PEP AA-UCHT1 purified proteins as labeled.

[0180] Figure 77A is a schematic diagram of VSV-GFP constructs with sequences encoding VSV N protein (SEQ ID NO: 112), VSV P protein (SEQ ID NO: 113), VSV M protein (SEQ ID NO: 114), VSV G-WT protein (SEQ ID NO: 115), GFP (SEQ ID NO: 116), and VSV L protein (SEQ ID NO: 117), and a sequence encoding the CAP protein of a VSIV-G signal peptide (SP) (SEQ ID NO: 59) fused N-terminal to CR1, CR2, and CR3 (LDLR) (CR1+2+3, which is the same as CR123) (SEQ ID NOs: 1, 2, and 3) fused to helical-peptide-VL (SEQ ID NO: 26) fused to a mutant EGF ligand (EGFml23) (SEQ ID NO: 36) fused to a Flag tag (SEQ ID NO: 66), with (G4S)x3 linker, GGGGS linker (SEQ ID NO: 6), and GSGGSG linker (SEQ ID NO: 10).

[0181] Figures 77B-77C are images of a western blot showing binding of a VSIV-G antibody, polyclonal VSV antibody, and either a GAPDH antibody (GAPDH) or p24 antibody in either the cell lysate (FIG.77B) or virion pellet (FIG. 77C) of cells transduced with plasmids encoding WT VSIV-G alone or in combination with a plasmid encoding a recombinant CAP protein of FIG. 77 A as labeled.

[0182] Figures 77D-77E are bar graphs showing the number of GFP+ CHO cells, CHO cells expressing human EGFR (CHO HuEGFR), HT1080 cells, HT1080 cells with EGFR knocked out (HT1080-EGFR KO), HEK-293T cells, HEK-293T cells expressing human EGFR (HEK-293T HuEGFR), HeLa cells, and HeLa cells with EGFR knocked out (HeLa-EGFR KO) (FIG. 77D) or K562 cells, K562 cells expressing human EGFR (K562 -HuEGFR), E) 3 days after transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or with the recombinant CAP proteins of FIG. 77A as labeled.Leydig 775437Vyriad P-64-00439

[0183] Figure 77F is a schematic diagram of VSV-GFP constructs with sequences encoding VSV N protein (SEQ ID NO: 112), VSV P protein (SEQ ID NO: 1 13), VSV M protein (SEQ ID NO: 114), VSV G-WT protein (SEQ ID NO: 115), GFP (SEQ ID NO: 116), and VSV L protein (SEQ ID NO: 117), and a sequence encoding the CAP protein of a VSIV-G signal peptide (SP) (SEQ ID NO: 59) fused N-terminal to CR1, CR2, and CR3 (LDLR) (CR1+2+3, which is the same as CR123) (SEQ ID NOs: 1, 2, and 3) fused to helical-peptide-VL (SEQ ID NO: 26) fused to an anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42 fused to a Flag tag (SEQ ID NO: 66), with (G4S)x3 linker, GGGGS linker (SEQ ID NO: 6). and GSGGSG linker (SEQ ID NO: 10).

[0184] Figure 77G is an image of a western blot showing binding of a VSIV-G antibody (a-VSV-G), polyclonal VSV antibody (a-VSV), and a Flag antibody (a-FLAG), in the supernatant of viruses produced with the constructs of 77F.

[0185] Figure 77H is a bar graph showing the number of GFP+ Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, TCR-KO Jurkat cells. SUP-T1 cells and SUP-T1 LDLR-KO cells 2 days after transduction with lentivirus containing an EGFP expression cassette and pseudotyped with WT VSIV-G alone or with the recombinant CAP proteins of FIG. 77F as labeled.

[0186] Figure 78 A shows a summary of the experimental design for testing the effect of the amount of purified CR 123 -PEP VL-UCHT1 protein for capping LVPs pseudotyped with VSIV-G- WT or VSVNJ-G-WT.

[0187] Figure 78B is a set of images of western blots showing binding of a VSIV-G antibody (aVSV(G)), VSVNJ-G antibody (aVSV(NJ)), a FLAG antibody (FLAG), and ap24 antibody (ap24) LVPs pseudotyped with VSIV-G- WT or VSVNJ-G-WT and mixed with 0.045 pg to 1.5 pg of purified CR123-PEP VL-EGFml23 protein as labeled.

[0188] Figures 79A-79B are a set of micrographs showing GFP fluorescence in Jurkat cells and Nalm-6 cells 5 days post transduction with LVPs pseudotyped with VSIV-G-WT (FIG. 79A) or VSVNJ-G-WT (FIG. 79B) and mixed with 0.045 pg to 1.5 pg of purified CR123-PEP VL-EGFml23 protein as labeled.

[0189] Figures 79C-79D are bar graphs showing the number of GFP positive Jurkat cells and Nalm-6 cells 5 days post transduction with LVPs pseudotyped with VSIV-G-WT (FIG.79C) or VSVNJ-G-WT (FIG. 79D) and mixed with 0.045 pg to 1.5 pg of purified CR123-PEP VL-EGFml23 protein as labeled.Leydig 775437Vyriad P-64-00440

[0190] Figure 79E shows a summary of the experimental design for testing the transduction and retargeting efficacy of different concentrations of the purified recombinant CAP protein with CR122 or CR133 for lentivirus pseudotyped with VSVNJ-G-WT.

[0191] Figures 79F-79I are bar graphs showing the number of GFP positive Jurkat cells and Nalm-6 cells 5 days post transduction with LVPs pseudotyped with VSVNJ-G-WT and mixed with different concentrations of the purified CR133 CAP protein (FIG. 79F) or the purified CR122 CAP protein (FIG. 79G) or the number of GFP positive cells normalized to the VSVNJ-G-WT no cap control (FIGS. 79I-79J) as labeled.

[0192] Figure 80A shows the experimental design of Example 12.

[0193] Figure 80B is a set of micrographs showing GFP fluorescence in PBMCs 3 days after transduction with the LVPs shown in Table 14.

[0194] Figures 80C-80D are a set of flow cytometry dot plots showing GFP expression in CD3+ cells (FIG. 80C) and GFP expression in CD5+ cells (FIG. 80D) from PBMCs 3 days after transduction with the LVPs shown in Table 14.

[0195] Figures 80E-80F are a set of flow cytometry histograms showing CD25 expression in CD3+ cells (FIG. 80E) and CD69 expression in CD3+ cells (FIG. 80F) from PBMCs 3 days after transduction with the LVPs shown in Table 14.

[0196] Figure 81 A shows a summary of the experimental design for testing the transduction and retargeting efficacy of lentiviruses containing a BCMA-CAR transgene pseudotyped with VSIV-G and bound to different concentrations of a purified recombinant CAP protein retargeted to CD3 in human PBMC.

[0197] Figures 81B-81D are a set of flow cytometry dot plots showing BCMA expression in CD3+ PBMCs from Donor 1 and Donor 2 infected with lentivirus pseudotyped with VSIV-G and mixed with different concentrations of purified recombinant CAP protein retargeted to CD3 as labeled.

[0198] Figure 8 IE is a line graph showing the percentage of BCMA CAR+ and CD3+ cells in CD45+ gated cells from Donor 1 and Donor 2 PBMCs treated with uncapped virus or virus capped with different concentrations of CAP protein.

[0199] Figures 81F-81H are line graphs showing the percent of BCMA CAR+ and CD3+ cells in CD45+ gated cells (FIG. 81F), the percent of CD69+ or CD25+ cells in CD3+ CD45+ gated cells (FIG. 81G), and the percent of CD4+ or CD8+ cells in CD3+ CD45+ gated cells (FIG. 81H) of PBMCs treated with virus capped with different concentrations of the CAP protein.Leydig 775437Vyriad P-64-00441

[0200] Figure 82A shows a summary of the experimental design for testing the transduction and retargeting efficacy and tumor killing ability of lentiviruses containing a BCMA-CAR transgene pseudotyped with VSIV-G and bound to a purified recombinant CAP protein retargeted to CD3 in human PBMCs.

[0201] Figure 82B is a set of flow cytometry dot plots showing BCMA expression in CD3+ PBMCs from Donor 1 and Donor 2 infected with lentivirus pseudotyped with VSIV-G and mixed with a high or low concentration of purified recombinant CAP protein retargeted to CD3 as labeled.

[0202] Figure 82C is a graph showing the total cell count on Day 10 after infection of PBMCs from Donor 1 and Donor 2 given mock treatment, uncapped lentivirus pseudotyped with VSIV-G, or lentivirus pseudotyped with VSIV-G and mixed with high or low concentration of CAP protein.

[0203] Figures 82D-82G are line graphs showing the percent viability and effector to target ratio of total PBMCs to OPM2-Fluc (FIGS. 82D-82E) or total PBMCs to U662B-Fluc (FIGS. 82F-82G) of PBMCs from Donor 1 and Donor 2 given mock treatment, uncapped lentivirus pseudotyped with VSIV-G, or lentivirus pseudotyped with VSIV-G and mixed with high or low concentration of CAP protein.

[0204] Figure 83A shows a summary of the experimental design for testing the transduction and retargeting efficacy of lentiviruses containing a BCMA-CAR transgene pseudotyped with VSIV-G and bound to a CAP protein in whole human blood that then has PBMCs isolated from whole blood.

[0205] Figures 83B-83C are fluorescent images of PBMCs isolated from the whole blood of Donor 1 (FIG. 83B) and Donor 2 (FIG. 83C) at 3, 5, and 6 days after treatment with uncapped lentivirus pseudotyped with VSIV-G or lentivirus pseudotyped with VSIV-G and bound to CAP protein as labeled.

[0206] Figure 84 is a schematic diagram showing the construct design of the plasmids encoding recombinant CAP proteins containing an IgGk signal peptide (SP), a 38 amino acid human peptide (nAChRal(H38)) or a 32 amino acid peptide (nAChRal(T32), or a combination of cysteine rich domain 1 (CRD1), cysteine rich domain 2 (CRD2), and cysteine rich domain 3 (CRD3) of the p75 neurotrophin receptor, also referred to as nerve growth factor receptor, an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL), the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42, and a Flag tag, fused directly to one another or viaLeydig 775437Vyriad P-64-00442different combinations of the GGGGS linker (SEQ ID NO: 6), GSGGSG linker (SEQ ID NO: 10), and the (G4S)3 linker as labeled.

[0207] Figure 85 is a schematic diagram showing the construct design of the plasmids encoding recombinant CAP proteins containing an IgGk signal peptide (SP); a 38 amino acid human peptide (nAChRal(H38)) or a 32 amino acid peptide (nAChRal(T32), or a combination of cysteine rich domain 1 (CRD1), cysteine rich domain 2 (CRD2), and cysteine rich domain 3 (CRD3) of the p75 neurotrophin receptor, also referred to as nerve growth factor receptor; an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL); the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42; and a Flag tag, fused directly to one another or via different combinations of the GGGGS linker (SEQ ID NO: 6), GSGGSG linker (SEQ ID NO: 10), and the (G4S)3 linker as labeled.

[0208] Figure 85 is a schematic diagram showing the construct design of the plasmids encoding recombinant CAP proteins containing an IgGk signal peptide (SP); a peptide of a modified Ephrin-B2 receptor (SEQ ID NOS: 158, 159, or 160) or a modified Ephrin-B3 receptor (SEQ ID NOS: 161, 162, or 163); an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (GCN4-pl (SEQ ID NO: 155), GCN4-pLl (SEQ ID NO: 156), or GCN4-Tetramer (SEQ ID NO: 157)); an anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42; and a Flag tag (SEQ ID NO: 66), fused directly to one another or via different combinations of the GGGGS linker (SEQ ID NO: 6), GSGGSG linker (SEQ ID NO: 10), and the (G4S)3 linker as labeled.

[0209] Figure 86 is a schematic diagram showing the construct design of the plasmids encoding recombinant CAP proteins containing an IgGk signal peptide (SP); a modified Nectin-4 protein (4GJT Nectin4-IgV (SEQ ID NO: 171 )), a modified Signaling Lymphocytic Activation Molecule Family Member 1 receptor (3ALX-SLAM150 (SEQ ID NO: 173)), or huSLAM (SEQ ID NO: 172); an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (GCN4-pl (SEQ ID NO: 155), GCN4-pLl (SEQ ID NO: 156), or GCN4-Tetramer (SEQ ID NO: 157)); an anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42; and a Flag tag (SEQ ID NO: 66), fused directly to one another or via different combinations of the GGGGS linker (SEQ ID NO: 6), GSGGSG linker (SEQ ID NO: 10), and the (G4S)3 linker as labeled.Leydig 775437Vyriad P-64-00443DETAILED DESCRIPTION

[0210] The entry of enveloped viruses into host cells is a multistep process that relies on interactions between viral envelope proteins and host cell receptors. These interactions can be mediated by multimeric glycoproteins that adopt trimeric or higher-order oligomeric structures. Oligomerization is a conserved architectural principle of viral glycoproteins across multiple viral families. The convergence of unrelated viruses on oligomeric entry proteins indicates that this geometry confers functional advantages. In the case of class I fusion proteins, including, for example, influenza hemagglutinin, HIV gp41, coronavirus spike proteins, filovirus GP, paramyxovirus fusion proteins, and vesicular stomatitis virus glycoprotein (VSIV-G), trimerization is an important structural feature. Without wishing to be bound by theory’, the pre-fusion state of these proteins is stabilized by inter-subunit interactions within the trimer; and upon triggering — e.g., by receptor binding, endosomal acidification, or protease cleavage — the trimer undergoes conformational rearrangements, where these rearrangements are cooperative and coordinated across the three protomers for viral fusion with the host membrane.

[0211] Beyond stabilizing pre-fusion states, oligomerization can also play an important role in receptor binding. Many viral glycoproteins engage receptors in a multivalent fashion, where a single receptor-ligand interaction may be relatively weak; but when three binding sites are presented in a symmetric array, the overall avidity can be dramatically increased. This can be important in the crowded and dynamic environment of the cell surface, where receptors may be sparsely distributed or partially shielded by glycans. As an example, the trimeric arrangement increases the likelihood that once one protomer binds, the other two are positioned to engage nearby receptors. The cooperative binding can help to cluster host receptors, which may be a important precursor for downstream signaling events that facilitate endocytosis or fusion.

[0212] The present disclosure is directed generally to the design and application of modular oligomerizing adaptor domains that function as structural “caps” to stabilize, orient, and / or geometrically enforce receptor-viral entry protein interactions.

[0213] In particular, the present disclosure relates to the use of an oligomerization domain, comprising a protein or peptide domain, domains that are capable of spontaneously assembling other desired proteins into stable oligomers, which caps oligomerization domain can also be fused to a heterologous functional moiety. These oligomerizing domains, also referred to herein as “caps.” provide a modular solution for enforcing oligomericLeydig 775437Vyriad P-64-00444arrangements, e.g.. a trimeric arrangement that is characteristic of many naturally occurring viral entry proteins. By applying such caps to, e g., receptor-binding fragments, viral glycoprotein derivatives, or synthetic ligands, the caps can restore or replicate the precise geometry important for efficient receptor binding and subsequent membrane fusion events. The caps of the present disclosure can replicate advantages of oligomerization in engineered constructs.

[0214] The caps are modular, meaning that a cap may be paired with different receptorbinding domains or ligands. These may include viral receptor-binding fragments, single-chain variable fragments (scFvs) of antibodies, nanobodies or Variable Heavy domain of Heavy chain (VHH), peptides, or synthetic ligands engineered to recognize particular cellular receptors. By separating ligand-receptor specificity from oligomerization, the present disclosure provides a universal solution that can be reused across multiple therapeutic indications. The modular nature also allows pre-characterized caps to be produced, validated, and stockpiled as “off-the-shelf’ components that can be fused to new ligands as needed.

[0215] The caps described in the present disclosure may be designed to be broadly adaptable across a wide spectrum of receptor-ligand interactions. An example is the interaction between low-density lipoprotein receptors (LDLRs) and VSIV-G. Another example is angiotensin-converting enzyme 2 (ACE2) and the receptor-binding domain (RBD) of coronavirus spike proteins. Coronaviruses, including SARS-CoV and SARS-CoV-2, rely on the trimeric spike protein to engage ACE2. The spike protein is a class I fusion protein with a pre-fusion trimeric architecture stabilized by inter-subunit contacts. In the context of retroviral infections, the interaction of CD4 and chemokine receptors CCR5 or CXCR4 with HIV envelope glycoproteins (Env) gp120 / gp41 represents another conserved trimeric entry pathway. HIV Env is a trimer of heterodimers, and the trimeric arrangement is important for maintaining the correct conformation of the gpl20-gp41 complex. The interaction of Ebola virus glycoprotein (GP) and its multiple receptors for entry offers another example. Ebola GP is a trimeric class I fusion protein whose correct assembly is important for receptor binding and fusion. Similarly, other filoviruses and paramyxoviruses, such as measles virus, utilize trimeric glycoproteins that interact with receptors including signaling lymphocytic activation molecule family member 1 (SLAMF1), also referred to as CD 150, and Nectin-4. These receptors are engaged by viral attachment proteins (H or G proteins), which naturally form trimers or tetramers. Another receptor is the transferrin receptor (TfR), which serves as an entry point for arenaviruses such as Machupo and Junin virus. The viral glycoprotein GP1Leydig 775437Vyriad P-64-00445interacts with TfR in a manner consistent with multivalent presentation. Similarly, sialic acid receptors, recognized by influenza hemagglutinin are additional examples. Additional fusogenic glycoproteins illustrate the universality of the approach. Influenza hemagglutinin (HA), a trimeric class I fusion protein, uses trimeric assembly to orient its receptor-binding sites toward sialic acid-containing receptors. Hepatitis C virus (HCV) employs its envelope glycoprotein E2, together with El, to engage CD81 and other co-receptors, with multivalent presentation of E2 being important. Sendai virus, a paramyxovirus, relies on its fusion (F) protein working in concert with hemagglutinin-neuraminidase (HN) to engage sialic acidbearing receptors, with trimeric F assembly being important for membrane fusion. Each of these systems highlights the important role of trimerization in maintaining fusogenic potential, and engineered caps provide a means of stabilizing pre-fusion conformations for vector targeting. In addition to viral receptors, the present disclosure contemplates the adaptation of cellular receptors relevant to oncology. For example, the CD3 receptor complex on T cells, which can be engaged by chimeric antigen receptors (CARs) or bispecific antibodies, can be targeted by trimerized scFvs against CD3s. Similarly, tumor-associated receptors such as HER2, EGFR, or PD-L1 may be targeted by trimerized ligands to enhance clustering and signaling. By applying modular caps, these ligands can be presented in a trimeric format that promotes receptor crosslinking, thereby increasing potency in therapeutic applications. The modular cap system can be suitable for use with integrins, which recognize trimeric motifs in extracellular matrix proteins, and heparan sulfate proteoglycans, which serve as attachment factors for herpesviruses and other pathogens. In each case, trimeric presentation of binding motifs is important for high-affinity engagement, and modular caps provide a method of enforcing this geometry.

[0216] In aspects, the present disclosure provides a recombinant protein system comprising: I) a first recombinant protein comprising a viral fusogenic membrane glycoprotein (FMG) or a functional fragment or derivative thereof, II) a second recombinant protein comprising (a) a targeting domain and (b) an oligomerization domain. In aspects, the second recombinant protein comprises: (c)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and

[0217] wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein; or (c)(2) an antigen binding domain,Leydig 775437Vyriad P-64-00446wherein the antigen binding domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein.

[0218] In aspects, the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding of the first recombinant protein is reduced or abolished for a binding domain of a receptor protein that is a separate binding domain from the binding domain of the receptor protein of the second recombinant protein.

[0219] In aspects, the second recombinant protein comprises an antigen binding domain, wherein the antigen binding domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein. In aspects, the antigen binding domain is a single chain variable fragment (scFv). In aspects, binding of the antigen binding domain does not interfere with the fusion capability of the viral FMG or functional fragment or derivative thereof of the first recombinant protein.

[0220] Without wishing to be bound by theory the antigen binding domain can neutralize the cell entry function of the viral FMG by (1) binding the viral FMG to prevent the natural receptor binding site from binding the natural receptor or (2) binding the viral FMG to inhibit fusion by blocking conformational changes of the viral FMG necessary' to fuse with the targeted cell. Antigen binding domains that neutralize the natural receptor binding of the viral FMG without neutralizing the fusion ability are preferred for retargeting lenti viruses. In aspects, the antigen binding domain binds at or near the natural receptor binding site of the viral FMG, sterically blocking the binding of the viral FMG to the natural receptor. In aspects, the viral FMG is of a vesiculovirus and the antigen binding domain binds at or near the CR2 and / or CR3 binding regions of LDLR. In aspects, the antigen binding domain comprises the antibody 1E9F9, 114, or anti-VSVG clone 6 as disclosed in CN12006385. In aspects, the ability of the antigen binding domains to bind the natural receptor and neutralize the natural receptor binding of the viral FMG without neutralizing the fusion ability' is not Ca2+dependent.

[0221] A "membrane-anchored glycoprotein” (MAG) is a glycoprotein associated with a lipid bilayer membrane. Association with a lipid bilayer can be covalently attached to theLeydig 775437Vyriad P-64-00447membrane. A MAG can be an integral protein, such as a transmembrane protein, or a peripheral protein associated with a surface of a membrane (inner surface or outer surface). In aspects, several peripheral MAGs can, e.g., coat a surface of a membrane. In aspects, several peripheral MAGs can coat a surface of a membrane with several separate MAGs coating the other surface of the membrane. A "‘viral membrane glycoprotein” (VMG) is a MAG that is from a virus or of a virus. A ‘‘fusogenic membrane glycoprotein” (FMG) is a MAG that comprises a glycoprotein capable of fusing lipid bilayers. A MAG can comprise an FMG, and a VMG can comprise an FMG. A MAG can comprise a cytoplasmic domain incapable of incorporation into certain membraned vesicles, e.g., enveloped delivery vehicles. A MAG comprising a cytoplasmic domain incapable of incorporation can, but does not necessarily, prevent a membraned vesicle from encapsulating cargo / payload, rendering the membraned vesicle incapable of delivery' of cargo / payload. The VMGs may be any suitable glycoprotein. For example, the VMGs may be a Type 1 membrane glycoprotein (N-terminus opposite the lumen, C-terminus inside the lumen) or a Type 2 membrane glycoprotein (C-terminus opposite the lumen, N-terminus inside the lumen).

[0222] In aspects, the first recombinant protein comprises a viral FMG or functional fragment or derivative thereof that has 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%. 84%. 83%. 82%. 81%. 80%. 79%. 78%. 77%. 76%. 75%.74%. 73%. 72%. 71%. 70%. 69%. 68%. 67%. 66%. 65%. 64%. 63%. 62%. 61%. or 60% sequence identity' compared to a viral FMG or functional fragment or derivative thereof described herein. In aspects, the viral FMG or functional fragment or derivative thereof contains one or more conservative amino acid substitutions that do not interfere with the fusion function of the viral FMG or functional fragment or derivative thereof.

[0223] As used herein, “functional fragment” of a viral FMG means a viral FMG that is not a full length viral FMG but is a portion of a parent viral FMG (e.g., a truncated form of a full length viral FMG), where the portion retains the fusion function of the parent full length viral FMG. As used herein, “functional derivative” or “functional variant” of a viral FMG means a viral FMG that has been modified, e.g., by conservative amino acid substitution, where the viral FMG retains the fusion function of the parent full length viral FMG. As used herein, “functional fragment or derivative” and “functional fragment or variant” encompass the meanings of both “functional fragment” and “functional derivative” / “functional variant”.

[0224] The “fusion function” of a viral FMG means that a viral FMG, when part of a virus, can initiate fusion of the virus with a target cell, e.g., such that the virus can infect theLeydig 775437Vyriad P-64-00448target cell. Such fusion can be due to the interaction of the viral FMG with a natural receptor or the interaction of the viral FMG with a different receptor (e.g., the viral FMG is blinded to a natural receptor, such that the viral FMG is engineered within the glycoprotein to reduce or abolish a natural receptor binding speci fici ty. and the viral FMG is re-targeted to a new receptor). As used herein, the term "natural receptor” refers to an endogenously expressed receptor in an organism that a viral FMG is capable of binding. Any viral FMG may have more than one natural receptor. The (c) binding domain of a receptor protein of the second recombinant protein can be any binding domain of a receptor protein that is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, including but not limited to any natural receptor of the viral FMG. As used herein, the term "receptor blinded” refers to a viral FMG with reduced or abolished binding specificity for a natural receptor. A viral FMG or functional fragment or derivative thereof described herein can have increased or decreased fusion efficiency compared to a wild type viral FMG. Increase in fusion efficiency specificity can be of any amount, e.g., increased by 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%. 100%, 200%, 500%, 1000%, or any range between these percentages. Decrease in fusion efficiency can be of any amount, e.g., decreased by 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 2%, 1%, or any range between these percentages. A functional fragment and / or functional derivative / functional variant of a viral FMG can be within a recombinant VMG comprising a viral FMG.

[0225] In aspects, the viral FMG or functional fragment or derivative thereof is of a Nipah virus (NiV) G glycoprotein, rhabdoviral G glycoprotein, a SARS-CoV-2 Spike (S) glycoprotein, aHIV-1 Envelope glycoprotein, an influenza hemagglutinin (HA) glycoprotein, an Ebola virus glycoprotein, a Hepatitis C virus (HCV) envelope 2 (E2) glycoprotein, a Machupo virus (MACV) spike glycoprotein (GP1), a Sendai virus hemagglutininneuraminidase (HN) glycoprotein, a virulent canine distemper virus (CDV) hemagglutinin (H) glycoprotein, or a rabies virus (RABV) G glycoprotein. In aspects, the viral FMG or functional fragment or derivative thereof is of a measle virus (MV) hemagglutinin (H) glycoprotein. In aspects, the virus G glycoproteins have a fusion function.

[0226] Rhabdoviruses are viruses within the family Rhabdoviridae. The viruses encode proteins denoted N (nucleoprotein), P (phosphoprotein), M (matrix protein), GLeydig 775437Vyriad P-64-00449(glycoprotein), and L (large protein, which is a polymerase), and the viruses appear to have a shape of a bullet when observed using electron microscopy. Dimensions of rhabdovirus virions can range from 100 nm to 430 nm in length and can range from 45 nm to 100 nm in diameter.

[0227] Rhabdoviral G glycoprotein mediates binding of rhabdovirus to a receptor on a cell, which binding then mediates entry of the rhabdovirus into the cell and infection of the cell. A rhabdoviral G glycoprotein or functional fragment or derivative thereof as described herein, including recombinant fusion proteins comprising the rhabdoviral G glycoprotein or functional fragment or derivative thereof, can be used to pseudotype a type of virus that is not the native / natural virus of the rhabdoviral G glycoprotein. In aspects, the rhabdoviral G glycoproteins described herein have a fusion function.

[0228] As used herein, a "pseudotype" of a virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. means a virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. comprising a molecule, e.g., a rhabdoviral G glycoprotein or functional fragment or derivative thereof (including a recombinant fusion protein comprising the rhabdoviral G glycoprotein or functional fragment or derivative thereof), that is not typically found in the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. Such a molecule can have a mutation (e.g., a substitution or deletion) that impacts the tropism of the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. The impact on tropism can be, e.g., to contribute to, direct, redirect, or completely change, or any combination thereof, the tropism of the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. when compared to the virus, membraned vesicle, enveloped delivery' vehicle, enveloped viral particle, or recombinant viral vector, etc. without the molecule and / or compared to the wild-type virus, membraned vesicle, enveloped delivery' vehicle, enveloped viral particle, or recombinant viral vector, etc. The impact on tropism can be, e.g., to target a cell that is different from the cell normally targeted by the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. and / or to not target a cell that is normally targeted by the virus, membraned vesicle, enveloped delivery’ vehicle, enveloped viral particle, or recombinant viral vector, etc.

[0229] In aspects, the viral FMG or functional fragment or derivative thereof is of a SARS-CoV-2 Spike glycoprotein comprising an SI and S2 subunit, and wherein the secondLeydig 775437Vyriad P-64-00450recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of an angiotensin-converting enzyme 2 (ACE2). In aspects, the viral FMG or functional fragment or derivative thereof is of a HIV-1 Envelope glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting w ith the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of (i) a CD4 receptor and (ii) a CCR5 receptor or a CXCR4 receptor. In aspects, the viral FMG or functional fragment or derivative thereof is of an influenza hemagglutinin (HA) glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a glycan receptor comprising a sialic acid residue. In aspects, the viral FMG or functional fragment or derivative thereof is of an Ebola virus glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a Niemann-Pick Cl protein (NPC1). In aspects, the viral FMG or functional fragment or derivative thereof is of aLeydig 775437Vyriad P-64-00451Hepatitis C virus (HCV) E2 glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a CD81 receptor. In aspects, the viral FMG or functional fragment or derivative thereof is of a Machupo virus glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a human transferrin receptor 1 (TfRl). In aspects, the viral FMG or functional fragment or derivative thereof is of a Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a glycan receptor comprising a sialic acid residue. In aspects, the viral FMG or functional fragment or derivative thereof is of a SLAM-binding ablated virulent canine distemper virus (CDV) hemagglutinin (H) glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of aNectin-4Leydig 775437Vvriad P-64-00452protein. In aspects, the binding domain of the receptor protein of the second recombinant protein is of a signaling lymphocytic activation molecule family member 1 (SLAMF1) receptor. In aspects, the binding domain of the receptor protein of the second recombinant protein is of a signaling lymphocytic activation molecule family member 1 (SLAMF1) receptor. In aspects, the viral FMG or functional fragment or derivative thereof is of a measles virus (MV) hemagglutinin (H) glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a (SLAMF1) receptor or a Nectin-4 protein.

[0230] In aspects, the viral FMG or functional fragment or derivative thereof is of a rabies virus (RABV) G glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a nicotinic acetylcholine receptor (nAChR). neural cell adhesion molecule (NCAM), p75 neurotrophin receptor, metabotropic glutamate receptor subtype 2 (mGluR2). or integrin [31. Rabies virus (RABV) is an enveloped, neurotropic virus whose surface glycoprotein (RABV-G) mediates host-cell attachment and entry. Lentz et al., Journal of Molecular Recognition, 3(2): 82-88 (1990), which is incorporated herein by reference in its entirety, discloses that the G glycoprotein of the rabies virus (RABV-G) binds to the al subunit of nAChR. Sajjanar et al., Neuropeptides, 57:59-64 (2016), which is incorporated herein by reference in its entirety, discloses that the al subunit of nAChR from multiples species binds RABV-G and that the Torpedo-derived al peptide (T32) showed strong binding activity to RABV. Without wishing to be bound by theory, this suggests that viruses that have nAChR as a natural receptor bind to or interact with a target cell via an interaction between the viral glycoprotein and the al subunit nAChR, which binding mediates virus entry into the cell and infection of the cell.Leydig 775437Vvriad P-64-00453Langevin et al., Journal of Biological Chemistry, 277(40): 37655-37662 (2002). which is incorporated herein by reference in its entirety, discloses that the G glycoprotein of the rabies virus (RABV-G) binds to the N-terminal cysteine rich domain of the p75 neurotrophin receptor (p75NTR), also referred to as nerve growth factor receptor (NGFR). Without wishing to be bound by theory, this suggests that viruses that have p75NTR / NGFR as a natural receptor bind to or interact ith a target cell via an interaction between the viral glycoprotein and the N-terminal cysteine rich domain p75NTR / NGFR, which binding mediates virus entry7into the cell and infection of the cell. As used herein, the terms “interacts with” and “interacting with” refer to any direct or indirect physical, chemical, or biological association between the proteins. This association may include covalent or non-covalent binding; and / or modulation or influence of activity, structure, or function in a way that has a measurable or observable effect within a system.

[0231] In aspects, the viral FMG or functional fragment or derivative thereof is of a Nipah virus (NiV) G glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a ephrin-B2 (EFNB2) receptor or ephrin-B3 (EFNB3) receptor.

[0232] In aspects, the viral FMG or functional fragment or derivative thereof is of a rhabdoviral G glycoprotein, and wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a cysteine rich region of a low density lipoprotein receptor (LDLR).

[0233] In aspects, the viral FMG or functional fragment or derivative thereof is of a rhabdoviral G glycoprotein, and wherein the binding domain of the receptor protein of the second recombinant protein is of a cysteine rich region of a low- density7lipoprotein receptorLeydig 775437Vvriad P-64-00454(LDLR). Low-density lipoprotein receptor (LDLR) is the natural receptor of Vesiculovirus Indiana (VSIV), which is a rhabdovirus. LDLR possesses 7 cysteine rich (CR) domains. As used herein, a “cysteine rich domain” refers to a distinct domain or repeat that contains a large number of cysteines. Nikolic et al., Nat. Comm., 9(1029): 1-12 (2018), which is incorporated herein by reference in its entirety, discloses that the G glycoprotein of the rhabdovirus vesicular stomatitis virus (VSIV-G) binds to the cysteine rich domains CR2 (SEQ ID NO: 2) and CR3 (SEQ ID NO: 3) of LDLR. The cysteine rich domain 4 (CR4) (SEQ ID NO: 4) of LDLR may also bind to VSIV-G. Zhai et al., Nat. Comm., 15(622): 1-16 (2024), which is incorporated herein by reference in its entirety, discloses that the glycoprotein of the alphavirus Getah virus binds to the cysteine rich domains CR4 (SEQ ID NO: 4) and CR5 of LDLR to mediate virus entry. Without wishing to be bound by theory, this suggests that viruses that have LDLR as a natural receptor bind to or interact with a target cell via an interaction between the viral glycoprotein and the CR domains of LDLR, which binding mediates virus entry into the cell and infection of the cell.

[0234] In aspects, (1) a binding domain of a receptor protein or (2) an antigen binding domain is N terminal to the oligomerization domain, optionally wherein the oligomerization domain is N terminal to the targeting domain, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein or wherein the antigen binding domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein.

[0235] In aspects, the second recombinant protein comprises a signal peptide, optionally N terminal to the binding domain of the receptor protein. As used herein, a “signal peptide” refers to a peptide involved in targeting a glycoprotein to the secretory pathway. In aspects, different signal peptides can be selected to improve glycoprotein targeting to the secretory pathway. In aspects, the signal peptide may be the naturally occurring signal peptide for the viral FMG. In aspects, the signal peptide comprises the amino acid sequence of a signal peptide as described herein. In aspects, the recombinant fusion protein comprises a signal peptide N-terminal to the targeting domain. In aspects, the signal peptide comprises an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 59.Leydig 775437Vyriad P-64-00455

[0236] In aspects, the disclosure provides a recombinant protein system described herein, comprising one or more linkers. Any suitable linker is contemplated, e.g., as disclosed in Chen et al., Adv. Drug. Deliv. Rev., 65(10: 1357-1369 (2013), which is incorporated herein by reference in its entirety.

[0237] In aspects, the oligomerization domain is N terminal to the targeting domain in the second recombinant protein and wherein the second recombinant protein comprises one or more linkers between (A)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein or (2) an antigen binding domain, wherein the antigen binding domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein and the oligomerization domain, (B) the oligomerization domain and the targeting domain, or (C) between both (A) and (B).

[0238] In aspects, flexible or semi-rigid linkers can be used, e.g., between a cap and ligand domain. These linkers can provide spacing where ligand domains are positioned outward from the trimerization hub in a geometry that permits simultaneous receptor engagement. In aspects, glycine-serine-rich flexible linkers may be used to provide mobility, while in other aspects, proline-rich or helical linkers may be used to enforce rigidity and defined spacing. The choice of linker can be tailored to the receptor geometry being targeted.

[0239] In aspects, the one or more linkers is flexible. Exemplary flexible linkers include, but are not limited to, e.g..(GGGGS) (SEQ ID NO: 6),GGGGSGGGGS (SEQ ID NO: 7),GGGGSGGGGSGGGGS (SEQ ID NO: 8),GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 9).GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 60), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 61), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 62), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 63),Leydig 775437Vyriad P-64-00456GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 64), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS(SEQ ID NO: 65),GSGGSG (SEQ ID NO: 10).GGGGGG (SEQ ID NO: 11),GGGGGGGG (SEQ ID NO: 12),VPGVGVPGVG (SEQ ID NO: 13),GSAGSAAGSGEF (SEQ ID NO: 14).AAASGGSGGGGSGGGGS (SEQ ID NO: 15).or AAASGGSGGGGSGGGGSGP (SEQ ID NO: 16).

[0240] In aspects, the one or more linkers is rigid. Exemplary rigid linkers include, but are not limited to, e.g.,PAPAP (SEQ ID NO: 17).EAAAKEAAAKEAAAK (SEQ ID NO: 18),EAAAKEAAAK (SEQ ID NO: 19),EAAAK (SEQ ID NO: 20), AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAAKA (SEQ ID NO: 21),AEAAAKEAAAKA (SEQ ID NO: 22),ESKYGPPCPPCP (SEQ ID NO: 23),CPPCPAPELLGGPSVF (SEQ ID NO: 24),and alanine-proline (AP) repeated for a total of 10 to 34 amino acids (SEQ ID NO: 25).

[0241] In aspects, the disclosure provides a recombinant protein system described herein comprising a tag for western detection or purification, optionally located at the C-terminus of the second recombinant protein. In aspects, the tag is a tag for western detection. In aspects, the tag is a tag for purification. In aspects the tag is a FLAG tag, GFP, or others. In aspects, the tag is located at the C terminus of the second recombinant protein, comprising a linker between the tag and the targeting domain. In aspects, the linker between the tag and the targeting domain is GSGGSG (SEQ ID NO: 10). In aspects, the tag comprises a cleavage site.

[0242] In aspects, the oligomenzation domain comprises: a variant of the GCN4 leucine / isoleucine zipper peptide with systematic isoleucine substitutions in the a and dLeydig 775437Vyriad P-64-00457positions of the heptad repeat comprising the amino acid sequence of SEQ ID NO: 27. a variant of the GCN4 leucine / isoleucine zipper peptide with systematic valine and leucine substitutions in the a and d positions respectively of the heptad repeat comprising the amino acid sequence of SEQ ID NO: 26, a C-terminal Foldon domain of a T4 fibritin (Foldon) comprising the amino acid sequence of SEQ ID NO: 28, a de novo designed trimeric coiled-coil peptide comprising the amino acid sequence of SEQ ID NO: 29, a laminin a2 chain C-terminal domain comprising the amino acid sequence of SEQ ID NO: 30, a collagen triple helix motif comprising the amino acid sequence of SEQ ID NO: 31, a self-assembling (3-sheet-rich peptide comprising the amino acid sequence of SEQ ID NO: 32, a coiled-coil heptad repeat region of a HA2 subunit of an Influenza hemagglutinin glycoprotein, a collagen XV derived non-collagenous C-terminal domain (NCI) comprising the amino acid sequence of SEQ ID NO: 33, a collagen XIX derived non-collagenous C-terminal domain (NC2) comprising the amino acid sequence of SEQ ID NO: 150, or a collagen XVIII derived non-collagenous C-terminal domain (NCI) comprising the amino acid sequence of SEQ ID NO: 34.

[0243] The GCN4 leucine / isoleucine zipper peptide has a short a-helical motif enriched in leucines or isoleucines at important positions, known as a heptad repeat, which drives trimerization through hydrophobic core formation. As used herein, an oligomerization domain comprising a variant of the GCN4 leucine / isoleucine zipper peptide with systematic substitutions in the a and d positions of the heptad repeat with alanine can be referred to as PEP-AA, systematic substitutions in the a and d positions of the heptad repeat with valine and leucine can be referred to as PEP-VL, and systematic substitutions in the a and d positions of the heptad repeat with isoleucine can be referred to as PEP-II. Previous reports have indicated that the PEP-AA peptide prevents oligomerization, while the PEP-VL and PEP-II peptides induce coiled-coil trimerization. Its extended rod-like geometry can be advantageous when spacing ligands away from a scaffold is necessary. A modified GCN4 leucine / isoleucine zipper peptide referred to as GCN4-pl (SEQ ID NO: 155) induces coiled-coil dimerization and modified GCN4 leucine / isoleucine zipper peptides referred to as GCN4-pLl (SEQ ID NO: 156) and GCN4-Tetramer (SEQ ID NO: 157) induce coiled-coil tetramerization

[0244] The Foldon domain is a short (27 residues) C-terminal motif forming a (3-propeller structure, that can stabilize a trimer through hydrophobic and hydrogen-bond interactions (Meier et al., " Structure and folding of the Foldon domain,’7J. Mol. Biol. (2004)). Without wishing to be bound by theory, this 27-amino-acid domain forms a compact |3-propeller-likeLeydig 775437Vvriad P-64-00458structure that spontaneously assembles into a stable trimer, where it folds independently of its native fibritin stalk. From a manufacturing standpoint, the foldon is compatible with a wide range of expression systems, including bacteria, insect, yeast, and mammalian cells. Its small size minimizes metabolic burden, and it does not require post-translational modifications such as glycosylation or hydroxylation to fold correctly.

[0245] Engineered sequences forming stable triple a-helical bundles typically contain specific amino acids (Leu, He, Vai) strategically placed to ensure stable hydrophobic core interactions. The heptad repeat sequence " IAAIKQE" is a well-characterized motif used in designing trimeric coiled-coil structures to create stable trimeric assemblies (Woolfson, “‘The design of coiled-coil structures and assemblies,’7A dv. Protein Chem. (2005)). As anon-limiting example, by placing hydrophobic residues in the a and d positions of a heptad repeat, and complementary charged residues in the e and g positions, these designs can achieve high thermal stability and exclusive trimer formation and also be quite flexible.

[0246] The laminin a2 chain C-terminal domain is a 25-residue segment enabling specific interactions that mediate the formation of a laminin heterotrimer with a2, (31, and yl subunits (Utani et al., " Laminin chain assembly: the C-terminal globular domains of the (31 and yl chains direct the specific dimer and trimer assembly," Journal of Biological Chemistry, 269 (30): 19167-19175 (1994)). As anon-limiting example, the present disclosure contemplates a cap system in which a therapeutic ligand, an immune-modulatory domain, and a stabilizing scaffold are co-assembled in a controlled 1:1:1 ratio. The laminin a2 motif informs the concept that trimerization can involve stabilizing geometry and also selective and functional assembly. For modular caps, this means that one can move beyond generic trimerization toward programmable trimerization. where only designated chains are incorporated. This could be used, for example, to construct viral vectors where targeting ligands are selectively paired with stabilizing domains, and / or where multiple receptor-binding specificities are encoded in a defined stoichiometry'.

[0247] The collagen triple helix motif comprises a repeating Gly-X-Y sequence, where X and Y are often proline or hydroxyproline that forms tightly wound triple helices stabilized by hydrogen bonds (Bella et al. “Crystal and molecular structure of a collagen-like peptide at 1.9 A resolution,” Science (1994)). This structure can be stable, resistant to proteolysis, and / or mechanically robust.

[0248] Peptides such as QQRFEWEFEQQ (SEQ ID NO: 32) spontaneously form (3-sheet structures stabilized by hydrogen bonding, enabling stable self-assembly into trimers or otherLeydig 775437Vvriad P-64-00459oligomers (Aggeli et al., “Responsive gels formed by the spontaneous self-assembly of peptides into polymeric P-sheet tapes,” Nature, 386(6622): 259-262 (1997)). Without wishing to be bound by theory, these achieve multimerization through P-sheet formation, spontaneously forming tapes and fibrils stabilized by hydrogen bonding and aromatic interactions. Design can bias these toward trimeric arrangements when the bias is otherwise non-trimeric. These can exhibit resistance to proteolysis and / or environmental stress.

[0249] A coiled-coil heptad repeat region in the HA2 subunit is important for trimer formation, stability, and function of influenza hemagglutinin. The HA2 subunit's coiled-coil is formed by a continuous a-helical region, but the exact sequence may vary among different influenza A strains (Wilson et al., “Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3 A resolution,” Nature (1981)).

[0250] The NC 1 domain contains intrinsic trimeric domains know n to drive stable trimer formation. The collagen XVIII NCI trimerization domain (TD) nucleates trimer formation of collagen XVIII and is stabilized by a combination of hydrophobic interactions and hydrogen bonds. Structural analysis reveals a three-bladed propeller-like architecture. It is stable and tolerant of fusion partners. The collagen XV NCI TD nucleates trimer formation of collagen XV and forms a similar architecture to collagen XVIII. The NC2 TD nucleates trimer formation of collagen XIX at either end and can facilitate formation of a chain-like architecture of triple helices. Because the collagen NCI and NC2 TDs are distinct from viral sequences, they may also present fewer immunogenicity problems.

[0251] These oligomerization domains collectively illustrate various sequences by which recombinant peptides can reliably form stable oligomers, including trimers.

[0252] In aspects, the viral FMG is untargeted. As used herein the term “untargeted” refers to a viral FMG that does not comprise a targeting domain. As used herein, the term “non-chimeric” refers to a viral FMG that does not comprise parts of different proteins.

[0253] Any suitable targeting domain can be used. As used herein in relation to viral FMGs, the term “chimeric” refers to a viral FMG that comprises parts of at least two different proteins, such as a rhabdoviral G glycoprotein and a targeting domain. “Targeting polypeptide” and “targeting domain” are used interchangeably herein. As used herein, the term “targeting domain” refers to a binding moiety (that can bind or that can be bound), such as a natural ligand, antibody, multispecific binding molecule, or others known in the art. The targeting domain can target any suitable cell type. Non-limiting examples of cell types include hematopoietic stem cells (HSC), T cells, monocytes, and NK cells. For HSC, non-Leydig 775437Vyriad P-64-00460limiting examples of markers that can be targeted by the targeting domain include, e.g., one or more ofCD34, CD46, CD90 (Thy-1), CD133, CD135 (Flt3) and CD201 (EPCR). ForT cells, non-limiting examples of markers that can be targeted by the targeting domain include, e.g., one or more of TRBC1, CD3, CD4, CD5, CD7, CD8 and CD30. For monocytes, nonlimiting examples of markers that can be targeted by the targeting domain include, e.g., one or more ofCD14, CDl lb, CD33, CD47, CD123 (IL-3Ra), CD116 / CD131, and CSF1R. For NK cells, non-limiting examples of markers that can be targeted by the targeting domain include, e.g., one or more ofB7-H6, CS1(SLAMF7), CD16 (FcyRIIIa), CD56, andNKG2D.

[0254] In aspects, a targeting domain specifically binds a cell surface molecule, e.g., an oligosaccharide, a receptor, cell surface marker, etc., expressed on the surface of a mammalian (e.g., human) eukaryotic cell. In aspects, a targeting domain binds a (e g., human) liver cell, a (e.g., human) brain cell, a (e.g., human) T cell, a (e.g., human) kidney cell, a (e.g., human) intestinal cell, a (e.g., human) lung cell, a (e.g., human) cancerous cell, or a (e.g., human) cell infected with heterologous pathogen. In aspects, the targeting domain binds a receptor expressed by a (e.g., human) liver cell, e.g., an asialoglycoprotein receptor, e.g., hASGRl. In aspects, the targeting domain binds a molecule expressed by a (e.g., human) neuronal cell, e.g., GABA, transferrin, etc. In aspects, the targeting domain binds a receptor or molecule expressed by a (e.g., human) T cell. e.g. CD3, CD4, CD8, T cell receptor (TCR), thrombopoietin receptor (TPO-R), which is also known as cMpl, cKit receptor, which is also known as CD117, etc. In aspects, the targeting domain binds CD63. In aspects, the targeting domain binds a molecule expressed by a (e.g., human) hematopoietic stem cell, e.g., CD34. In aspects, the targeting domain binds a molecule expressed by a (e.g., human) kidney cell. In aspects, the targeting domain binds a molecule expressed by a (e.g., human) muscle cell, e.g., an integrin. In aspects, the targeting domain binds a molecule expressed by a (e.g., human) cancerous cell, e.g., a tumor associated antigen, e.g., adipophilin, AIM-2, ALDHIAI, alpha-actimn-4, alpha-fetoprotein (“AFP”), ARTCI, B-RAF, BAGE-1, BCLX (L), BCR-ABL fusion protein b3a2, beta-catenin, BING-4, CA-125, CALCA, carcinoembryonic antigen (“CEA”), C ASP-5, C ASP-8, CD274, CD45, Cdc27, CDK12, CDK4, CDKN2A, CEA, CLPP, COA-1, CPSF, CSNKIAI, CTAGI, CTAG2, cyclin DI, Cyclin-Al, dek-can fusion protein, DKKI, EFTUD2, Elongation factor 2, ENAH (hMena), Ep-CAM, EpCAM, EphA3, epithelial tumor antigen (“ETA”), ETV6-AML1 fusion protein, EZH2, E6, E7, FGF5, FLT3-ITD, FNI, G250 / MN / CAIX, GAGE-1,2,8, GAGE- 3, 4, 5, 6, 7. GAS7. glypican-3, GnTV. gplOO / Pmell 7. GPNMB, HAUS3, Hepsin, HER-2 / neu, HERV-K-MEL, HLA-A1 1, HLA-A2, HLA-DOB,Leydig 775437Vyriad P-64-00461hsp70-2, IDOL IGF2B3. IL13Ralpha2, Intestinal carboxyl esterase. K-ras, Kallikrein 4, KIF20A, KK-LC-1, KKLCI, KM-HN-1, KMHNI also known as CCDCI 10, LAGE-I, LDLR-fucosyltransferaseAS fusion protein, Lengsin, M-CSF, MAGE- Al, MAGE-AIO, MAGE-A12, MAGE-A2, MAGE- A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-CI, MAGE-C2, malic enzyme, mammaglobin-A, MART2, MATN. MCIR. MCSP. mdm-2, MEI, Melan-A / MART-1, Meloe, Midkine, MMP-2, MMP-7, MUCI, MUC5AC, mucin, MUM-I, MUM-2, MUM-3, Myosin, Myosin class I, N-raw, NA88- A, neo-PAP, NFYC, NY-BR-I, NY-ESO-l / LAGE-2, OAI, OGT, OS-9, P polypeptide, p53, PAP, PAX5, PBF, pml-RARalpha fusion protein, polymorphic epithelial mucin C’PEM"). PPPIR3B. PRAME. PRDX5, PSA, PSMA. PTPRK, RAB38 / NY-MEL-1, RAGE-I, RBAF600, RGS5. RhoC, RNF43, RU2AS, SAGE, secemm 1, SIRT2, SNRPDI, SOXIO, Spl7, SPA17, SSX-2, SSX-4, STEAPI, survivin, SYT-SSXI or -SSX2 fusion protein, TAG-I, TAG-2, Telomerase, TGF-betaRII, TPBG, TRAG-3, Triosephosphate isomerase, TRP-l / gp75, TRP-2. TRP2-INT2, tyrosinase, tyrosinase (“TYR”), VEGF, WTI, XAGE-lb / GAGED2a, Kras, NYESOI. HPV E2, HPV E6, HPV E7, WT-I antigen (in lymphoma and other solid tumors), ErbB receptors, Melan A [MARTI], gp 100, tyrosinase, TRP-l / gp 75, and TRP-2 (in melanoma); MAGE-I and MAGE-3 (in bladder, head and neck, and non-small cell carcinoma); HPV EG and E7 proteins (in cervical cancer); Mucin [MUC-1] (in breast, pancreas, colon, and prostate cancers); prostate-specific antigen [PSA] (in prostate cancer); carcinoembryonic antigen [CEA] (in colon, breast, and gastrointestinal cancers), and such shared tumor-specific antigens as MAGE-2, MAGE-4, MAGE-6, MAGE-IO, MAGE-12, BAGE-1, CAGE-1,2,8, CAGE-3 TO 7, LAGE-I. NY-ESO-l / LAGE-2, NA-88, GnTV, TRP2-INT2, etc. In aspects, the targeting domain binds E6 and / or E7. In aspects, the targeting domain binds Her2. In aspects, the targeting domain binds CD63. In aspects, the targeting domain binds human glucagon receptor (hGCGR). In aspects, the targeting domain binds human ectonucleoside triphosphate diphosphohydrolase 3 (hENTPD3).

[0255] In aspects, the disclosure provides a recombinant protein system, wherein the targeting domain of the second recombinant protein is a ligand. In aspects, the ligand is epidermal growth factor (EGF), a mutant EGF (EFGml23) (SEQ ID NO: 36), stem cell factor (SCF) (SEQ ID NO: 37), thrombopoietin (TPO) (SEQ ID NO: 38), human hepatocyte growth factor (HGF) (SEQ ID NO: 39), erythropoietin (EPO), or type 1 insulin-like growth factor (IGF1) (SEQ ID NO: 40).Leydig 775437Vyriad P-64-00462

[0256] In aspects, at least one targeting domain is an antibody or portion thereof. In aspects, the antibody or portion thereof is a single-chain variable fragment (scFv), a nanobody, or a minibody. In aspects, the portion thereof is an antigen-binding fragment. In aspects, the antibody or portion thereof is a single chain fragment variable (scFv), an affibody, a diabody, a minibody, a nanobody, a single-domain antibody (sdAb), or a single heavy chain antibody. Also contemplated herein are polypeptide antibody constructs, monoclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), intrabodies, and anti-idiotypic (anti-Id) antibodies (including, e.g.. anti-Id antibodies to antigen specific TCR), Ig-DARTS, epitope-binding fragments of any of the above, and what is described in US Patent Publication No. 2007 / 0004909 and US Patent Publication No. 2009 / 0060910, each of which is incorporated herein by reference in their entireties). Also contemplated are immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e.. molecules that contain an antigen binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGI, IgG2, IgG3, IgG4, IgAI and IgA2) or subclass. In aspects, the targeting domain is an antibody comprising a variable domain that binds a cell surface protein on a target cell and a heavy chain constant domain. In aspects, the targeting domain is an antibody comprising a variable domain that binds a cell surface protein on a target cell and an IgG heavy chain constant domain. In aspects, the targeting domain is an antibody comprising a variable domain that binds a cell surface protein on a target cell and an IgG heavy chain constant domain.

[0257] In aspects, the targeting domain of the second recombinant protein is a single chain variable fragment (scFv). In aspects, the scFv binds epidermal growth factor receptor (EGFR), human epidermal grow th factor receptor 2 (Her2), cluster of differentiation 3 (CD3), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 7 (CD7), cluster of differentiation 117 (c-Kit), mucin-16 (MUC16), B cell maturation antigen (BCMA), or Nectin4. In aspects, the scFv binds CD3 and wherein the scFv is UCHT1.HuM291, OKT3, or TR66. In aspects, the scFv is UCHT1 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 41 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 42. In aspects, the scFv is HuM291 and wherein the scFv comprises a variable heavy’ chain (VH) comprising the amino acid sequence of SEQ ID NO: 43 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 44. In aspects, the scFv is OKT3 and wherein the scFvLeydig 775437Vyriad P-64-00463comprises a variable heavv chain (VH) comprising the amino acid sequence of SEQ ID NO: 45 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 46. In aspects, the scFv is TR66 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 47 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 48.

[0258] In aspects, the targeting domain of the second recombinant protein is a nanobody. In aspects, the nanobody binds epidermal growth factor receptor (EGFR), human epidermal grow th factor receptor 2 (Her2), cluster of differentiation 3 (CD3), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 7 (CD7), cluster of differentiation 117 (c-Kit), mucin- 16 (MUC16), B cell maturation antigen (BCMA), Nectin4, or T cell receptor (TCR). In aspects, the nanobody binds CD3. In aspects, the nanobody is an anti-CD3 epsilon nanobody (VHH-3-aCD3E) and wherein the nanobody comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 102. In aspects, the nanobody binds TCR. In aspects, the nanobody is an anti-T cell receptor protein nanobody (VHH 9-aTCR) and wherein the nanobody comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 103.

[0259] In aspects, the present disclosure provides a recombinant protein system, wherein the second recombinant protein comprises a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the binding domain of the receptor protein of the second recombinant protein comprises (i) cysteine rich domain 2 (CR2) of LDLR (SEQ ID NO: 2), (ii) cysteine rich domain 3 (CR3) of LDLR (SEQ ID NO: 3), (iii) cysteine rich domain 4 (CR4) of LDLR (SEQ ID NO: 4), or (iv) any combination of (i)-(iii). In aspects, the cysteine rich region comprises CR2 (SEQ ID NO: 2) of LDLR. In aspects, the cysteine rich region comprises CR3 (SEQ ID NO: 3) of LDLR. In aspects, the cysteine rich region comprises CR2 (SEQ ID NO: 2) of LDLR and CR3 (SEQ ID NO: 3) of LDLR. In aspects, the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1) and CR2 (SEQ ID NO: 2) of LDLR. In aspects, the cysteine rich region comprises two copies of CR2 (SEQ ID NO: 2) of LDLR. In aspects, the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1) and CR3 (SEQ ID NO: 3) of LDLR. InLeydig 775437Vyriad P-64-00464aspects, the cysteine rich region comprises two copies of CR3 (SEQ ID NO: 3) of LDLR. In aspects, the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1), CR2 (SEQ ID NO: 2) of LDLR, and CR3 (SEQ ID NO: 3) of LDLR. In aspects, the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR3-CR2-CR1. In aspects, the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR2-CR2. In aspects, the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR2-CR3. In aspects, the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR3-CR3. In aspects, the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR3-CR2-CR2, CR3-CR2-CR3. CR3-CR3-CR1, CR3-CR3-CR2, CR3-CR3-CR3, CR3-CR1-CR2, CR3-CR1-CR3, CR2-CR1-CR2, CR2-CR1-CR3, CR2-CR2-CR1, CR2-CR3-CR1, CR2-CR3-CR2, or CR2-CR3-CR31.

[0260] In aspects, the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1), CR2 (SEQ ID NO: 2) of LDLR, and CR3 (SEQ ID NO: 3) of LDLR.

[0261] In aspects, the present disclosure provides a recombinant protein system, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of a Flanders virus glycoprotein (FLAV-G) (SEQ ID NO: 49), a Chandipura virus glycoprotein (CHPV-G) (SEQ ID NO: 50), a Perinet virus glycoprotein (PERV-G) (SEQ ID NO: 51, a Piry virus glycoprotein (PIRYV-G) (SEQ ID NO: 52), a Fukuoka virus glycoprotein (FUKV-G) (SEQ ID NO: 53), a Joinjakaka virus glycoprotein (JOIV-G) (SEQ ID NO: 54), a Kumasi virus glycoprotein (KRV-G) (SEQ ID NO: 55), a Keuraliba virus glycoprotein (KEUV-G) (SEQ ID NO: 56), an Isfahan glycoprotein (ISFV-G), a Jurona glycoprotein (JURV-G), a Mediterranean Bat glycoprotein (MBV-G), a Malpais Spring glycoprotein (MSPV-G). a Radi glycoprotein (RADV-G), a Rhinolophus affinis-G, a Yug Bugdanavoc glycoprotein (YBV-G), a Yinshui Bat glycoprotein (YSBV-G), a Kimberley glycoprotein (KIMV-G), a Kanyawara glycoprotein (KYAV-G), a La Joya glycoprotein (LJV-G), a Mosquiero glycoprotein (MQOV-G), a Parry Creek glycoprotein (PCV-G), a Bas Congo glycoprotein (BASV-G), a Bovine Ephemeral fever glycoprotein (BEFV-G), a Curionopolis glycoprotein (CURV-G), a Drosophila melanogaster sigmavirus glycoprotein (DMelSV-G), aNiakha glycoprotein (NIAV-G), a Puerto almandras glycoprotein (PTAMV-G), or a Tupaia rhabdo virus (TUPTV-G). In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is from any rhabdoviral G glycoprotein or functional fragment or derivative thereof as provided herein.Leydig 775437Vvriad P-64-00465

[0262] In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus glycoprotein or a functional fragment or derivative thereof. In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana (V SIV), Vesiculovirus newjersey (V SNJV), Vesiculovirus carajas (VSCV), or Vesiculovirus alagoas (VS AV). Vesiculovirus Indiana, also referred to as vesicular stomatitis virus (VSV) is a rhabdovirus, having a natural receptor of the low-density lipoprotein receptor (LDLR) or very low density lipoprotein receptor (VLDLR), which are expressed on the cell membrane of many types of cells. In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana (SEQ ID NO: 57). In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus newjersey (SEQ ID NO: 58).

[0263] In aspects, the rhabdoviral G glycoprotein is substantially intact. As used herein, a “substantially intact’ ’ rhabdoviral G glycoprotein means a rhabdoviral G glycoprotein that is a functional fragment of the rhabdoviral G glycoprotein, where the rhabdoviral G glycoprotein has each of the domains of a rhabdoviral G glycoprotein, the domains as defined in Roche et al., Cell. Mol. Life Sci., 65: 1716-1728 (2008), which is incorporated herein by reference in its entirety. In aspects, the rhabdoviral G glycoprotein is a functional fragment or derivative thereof.

[0264] In aspects, the recombinant protein system comprises a rhabdoviral G glycoprotein or functional fragment or derivative thereof engineered to reduce or abolish its natural receptor binding specificity. In aspects, the rhabdoviral G glycoprotein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity. In aspects, the mutation could maintain or partially maintain the rhabdoviral G glycoprotein binding of a natural receptor binding domain and enhance folding and configuration changes of the rhabdoviral G glycoprotein on the membrane, enhance rhabdoviral G glycoprotein induced fusion of membrane, or increase transduction efficiency of an EDV displaying the rhabdoviral G glycoprotein. In aspects, the rhabdoviral G glycoprotein comprises a mutation at one or more positions corresponding to H8, K47, Y209, and K354 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57). In aspects, the mutation is a substitution. In aspects, the substitution is with a Q. In aspects, the mutation is a substitution at three or more positions corresponding to H8, K47, Y209, and K.354 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57). The US Patent Publication No. 2020 / 0216502 is incorporated herein by reference in its entirety. In aspects, the mutation is a deletion. In aspects, theLeydig 775437Vvriad P-64-00466mutation is a single deletion at the position corresponding to K47 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).

[0265] It has been found that a Vesiculovirus Indiana rhabdoviral G glycoprotein having a deletion of K47 reduces or abolishes the natural receptor binding speci fici ty of the rhabdoviral G glycoprotein while unexpectedly retaining full function of the G protein in other respects. In particular, this feature is seen when incorporated into a lentiviral vector. However, when used in a VSIV vector, there is a second site mutation (F405I) generated in the VSIV-G protein during the virus amplification. This mutation leads to the loss of detargeting effect caused by the deletion on K47 residue. Without wishing to be bound by theory, this phenomenon may be due to VSIV being a replicating virus, whereas lentivirus is a non-replicating virus.

[0266] Vesiculovirus Indiana glycoprotein having H8 and / or K47 deletions, when incorporated into a lentiviral system, can support production of functional pseudotyped lentivirus and successful cell transduction. The H8 and / or K47 deletions, but not Y209 or R354 deletions or Y209 / R354 deletion combinations, demonstrated generation and rescue of pseudotyped lentivirus with low to no LDLR background binding.

[0267] Amino acid positions of other rhabdoviral G gly coproteins or functional fragments or derivatives thereof that are "‘positions corresponding to” the amino acids discussed above can be determined using a global sequence alignment algorithm (see, e.g., Madeira et al., Nuc. Acids Res., 5O(W1): W276-W279 (2022), which is incorporated herein by reference in its entirety) comparing the base rhabdoviral G glycoprotein to another rhabdoviral G glycoprotein.

[0268] In aspects, the rhabdoviral G glycoprotein of the first recombinant protein is inactivated to a lesser degree by serum, LDL, or vLDL compared to a rhabdoviral G glycoprotein not of the recombinant protein system. Reduction in inhibition can be of any amount, e.g., reduced by 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%. 85%, 84%. 83%. 82%. 81%. 80%. 79%. 78%. 77%. 76%. 75%. 74%. 73%.72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%. 15%. 14%. 13%. 12%. 11%. 10%. 9%, 8%, 7%, 6%, 5%, 4%, 3%. 2%, 1%, or any range between these percentages.Leydig 775437Vyriad P-64-00467

[0269] In aspects, the disclosure provides a recombinant protein system, wherein the first recombinant protein is fused to the second recombinant protein, optionally wherein the first recombinant protein is N-terminal to the second recombinant protein. In aspects, the first recombinant protein is N-terminal to the second recombinant protein, comprising a linker between the first recombinant protein and the second recombinant protein. In aspects, the second recombinant protein is N-terminal to the first recombinant protein, comprising a linker between the second recombinant protein and the first recombinant protein

[0270] In aspects, the disclosure provides a recombinant protein system, wherein the viral FMG of the first recombinant protein forms a bond with the binding domain of the receptor protein of the second recombinant protein. In aspects, the bond is a covalent bond. In aspects, the formation of the covalent bond is spontaneous. In aspects, the bond is a non-covalent bond. In aspects, the formation of the non-covalent bond is spontaneous.

[0271] It is known in the art that the VSIV-G or a functional fragment or derivative thereof forms functional trimers because trimerization stabilizes the VSIV-G pre-fusion structure and enables the coordinated conformational changes important for membrane fusion. The trimeric form of VSIV-G is important for viral entry, allowing the fusion domains to insert into the host membrane and bring viral and cellular membranes together. Without trimerization, VSIV-G is known to mediate fusion less efficiently.

[0272] These viral FMG interactions with receptor proteins are important determinants of viral host range, tissue tropism, and pathogenicity. Table 1 shows the viral FMG, receptor protein, and the known oligomerization form or forms.Leydig 775437Vyriad P-64-00468Table 1

[0273] In aspects, the disclosure provides a dimer comprising two recombinant protein systems described herein, wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other second recombinant protein, wherein the viral FMG of each first recombinant protein is bound to the viral FMG of the other first recombinant protein, and wherein the second recombinant proteins each comprise a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.Leydig 775437Vyriad P-64-00469

[0274] In aspects, the disclosure provides a trimer comprising three recombinant protein systems and as described herein, wherein the oligomerization domain of each second recombinant proteins is bound to the oligomerization domain of the other two second recombinant proteins, wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other two first recombinant proteins, and wherein the second recombinant proteins each comprise a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0275] In aspects, the disclosure provides a tetramer comprising four recombinant protein systems as described herein, wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other three second recombinant proteins, wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other three first recombinant proteins, and wherein the second recombinant proteins each comprise a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0276] In aspects, a dimer, trimer, or tetramer described herein comprises at least two different binding domains of (1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, and wherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein, (2) an antigen binding domain, wherein the antigen bindingLeydig 775437Vyriad P-64-00470domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein, or both (1) and (2).

[0277] Dimers of viral FMGs or functional fragments or derivatives thereof, may have one or two targeting domains. Trimers of viral FMGs or functional fragments or derivatives thereof, may have one. two, or three targeting domains. Tetramers of viral FMGs or functional fragments or derivatives thereof, may have one, two, three, or four targeting domains. The number of targeting domains in the oligomer is the occupancy of the oligomer, wherein the oligomer may have full occupancy (two targeting domains in a dimer or three targeting domains in a trimer), partial occupancy (targeting domains on fewer than all viral FMGs or functional fragments or denvatives thereof of the oligomer, e.g., one targeting domain in a dimer; one or two targeting domains in a trimer), or no occupancy (no targeting domain in the oligomer). In aspects, oligomers of viral FMGs or functional fragments or derivatives thereof having full occupancy or partial occupancy comprise targeting domains with the same identity (i.e., two identical targeting domains or three identical targeting domains). In aspects, oligomers of viral FMGs or functional fragments or derivatives thereof having full occupancy or partial occupancy comprise at least two different targeting domains (e.g., two or three distinct targeting domains). In aspects, a dimer, trimer, or tetramer as described herein comprises at least two different targeting domains.

[0278] In aspects, the disclosure provides a membraned vesicle comprising a recombinant protein system described herein. In aspects, the membraned vesicle is a gesicle or an exosome. In aspects, the membraned vesicle comprises a dimer, trimer, or tetramer as described herein.

[0279] As used herein, a '“membraned vesicle” is a vesicle bound (delimited) by a lipid bilayer. In aspects, the membraned vesicle is either naturally-derived or engineered. A membraned vesicle can be cell-derived and thus be a cell-derived enveloped particle (CDEP). In aspects, the present disclosure provides a membraned vesicle comprising, consisting essentially of, or consisting of a recombinant fusion protein as described herein.

[0280] In aspects, the vesicle is a gesicle or an exosome. A gesicle can be as described in Mangeot et al., Mol. Ther., 19: 1656-1666 (2011), which is incorporated herein by reference in its entirety, where overexpression of glycoprotein of VSIV-G in human cells induced release of fusogenic vesicles. As used herein, an '“exosome” refers to a lipid bilayer vesicle ranging in size from approximately 30 nm to 150 nm in diameter, secreted by eukaryotic cells via the endosomal pathway, and containing biologically active molecules such as proteins,Leydig 775437Vvriad P-64-00471lipids, RNA, or DNA. An exosome typically originates from multivesicular bodies (MVBs) and is released into the extracellular environment through exocytosis. Exosomes are known to sen e as intercellular communication vehicles and may be utilized for diagnostic, therapeutic, or drug delivery applications. Examples of exosomes are provided in Li et al., European Journal of Medicinal Chemistry 207: 112784 (2020); Yang et al., Adv. Mater. 29: 1605604 (2017); U. S. Pat. No. 10,195,290; and U. S. Patent Application Publication No. 2018 / 0028600, each of which is incorporated herein by reference in its entirety.

[0281] In aspects, the disclosure provides an enveloped delivery' vehicle comprising a recombinant protein system described herein. In aspects, the enveloped delivery vehicle comprises a dimer, trimer, or tetramer as described herein.

[0282] As used herein, an “enveloped viral particle” is a vesicle bound (delimited) by a lipid bilayer and has the ability to infect a cell and produce additional enveloped viral particles. An enveloped viral particle can include one or more components of a virus, in addition to a rhabdoviral G glycoprotein or functional fragment or derivative thereof or recombinant fusion protein thereof. Exemplary components of a virus include, without limitation, the gctg,pol, or env gene or gene product of lentivirus. In aspects, the present disclosure provides an enveloped viral particle comprising, consisting essentially of, or consisting of a recombinant fusion protein as described herein.

[0283] A “virus-like particle” as used herein means an enveloped viral particle that cannot produce additional virus-like particles (i.e., is replication-incompetent). Virus-like particles (VLPs) are non-infectious and mimic the conformation of their parental viruses but lack the viral genetic material required for replication. A VLP can contain genetic material / nucleic acid not associated with self-replication. VLPs can preserves the high packaging efficiency and target-specificity of certain viruses while greatly minimizing the risk of host genome integration. Because VLPs do not replicate or integrate into the host genome, they are often associated with lower cytotoxicity and reduced immunogenic risk compared to replication-competent viral systems. In aspects, the present disclosure provides a virus-like particle comprising a recombinant protein system as described herein.

[0284] In aspects, membraned vesicles, cell-derived enveloped particles, enveloped viral particles, and virus-like particles can encapsulate proteins, lipids, nucleic acids, etc. for delivery, such that membraned vesicles, cell-derived enveloped particles, enveloped viral particles, and virus-like particles can be considered “enveloped delivery vehicles.”Leydig 775437Vyriad P-64-00472

[0285] An “enveloped delivery vehicle” (EDV) can encapsulate a cargo or payload. Any suitable cargo or payload of an EDV is contemplated herein, including, but not limited to, e.g., a protein, a lipid, a nucleic acid, a small molecule, a therapeutic agent, a gene editing system, such as CRISPR Cas, and any combination thereof.

[0286] In aspects, the disclosure provides a recombinant viral vector comprising a nucleotide encapsulated by a membraned vesicle described herein or an enveloped viral particle described herein.

[0287] In aspects, the disclosure provides a composition comprising a pharmaceutically acceptable carrier and a membraned vesicle described herein, an enveloped viral particles described herein, or a recombinant viral vectors described herein.

[0288] In aspects, the disclosure provides a method of delivering a payload to a target cell, the method comprising contacting the target cell with a membraned vesicle described herein, an enveloped viral particles described herein, a recombinant viral vectors described herein, or a composition described herein. In aspects, the target cell is in vitro or ex vivo. In aspects, the target cell is in vivo. In aspects, the payload is a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain. In aspects, the CAR has antigenic specificity for CD 19, CD20, CD22, DLL3, B7H3, or BCMA. In aspects, the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28a or CD8a. In aspects, the transmembrane domain is the transmembrane domain of CD28 or CD8. In aspects, the intracellular signaling domain comprises a costimulatory domain and an activating domain. In aspects, the costimulatory domain is 4- IBB. In aspects, the activating domain is CD3zeta. In aspects, the payload is a transgene or gene editing system.

[0289] CD19, CD20, CD22, and BCMA are antigens expressed primarily on B cells and desirable targets for CAR T cells to treat hematologic malignancies. CD20 is a pan-B-cell surface antigen expressed predominantly on mature B cells and in a broad range of mature B-cell malignancies and has stable cell surface expression. CD20 is suitable target for CAR T cells due its absence on hematopoietic stem cells and terminally differentiated plasma cells, which allows B-cell regeneration after treatment and limits irreversible marrow or plasmacell injury. CD22, also known as Siglec-2, is a B-cell-restricted inhibitory coreceptor involved in regulation of B-cell receptor signaling. CD22 is a suitable target for CAR T cells because most mature peripheral B cells express CD22, and it is also present on many B-cell leukemias and lymphomas.Leydig 775437Vvriad P-64-00473

[0290] DLL3 and B7-H3 are antigens expressed on solid tumors and desirable targets for CAR T cells to treat solid tumors. DLL3 is an atypical inhibitory Notch ligand that is aberrantly overexpressed in neuroendocrine cancers, especially small cell lung cancer and other neuroendocrine carcinomas, while showing low to minimal expression in most healthy adult tissues. In healthy cells DLL3 is primarily associated with intracellular trafficking and Golgi-localized biology, but in malignant neuroendocrine states it becomes pathologically overexpressed and detectable on the tumor-cell surface. B7-H3, also known as CD276, is a B7-family immune-regulatory molecule with minimal expression in healthy cells, cell-surface expression is high across many pediatric and adult solid tumors, as well as the within the tumor microenvironment, including stromal elements and tumor vasculature in some malignancies.

[0291] In aspects, the disclosure provides a retroviral vector expression system comprising one or more nucleotide sequences encoding a recombinant protein system described herein. In aspects, the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on separate plasmids. In aspects, the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on the same plasmid. In aspects, the retroviral vector expression system comprises a vector construct and helper constructs that are each on separate plasmids. In aspects, the retroviral vector expression system is a lentiviral vector expression system or a Rous sarcoma virus (RSV) vector expression system. A rhabdoviral G glycoprotein or functional fragment or derivative thereof as described herein can be expressed within a retroviral vector expression system to pseudotype the vector and alter the tropism of the vector.

[0292] Rous sarcoma virus (RSV) is an alpharetrovirus and member of the family Retroviridae. RSV has an RNA genome that encodes gag, pol, and env genes that are translated to Gag, Gag-Pol, and Env polyproteins. The RSV Gag polyprotein can be cleaved to form a matrix protein (MA), a p2a protein, a p2b protein, a plO protein, capsid protein (CA), a spacer peptide, a nucleocapsid protein (NC), and apl5 protease protein (PR). The RSV Gag proteins are capable of self-assembly into VLPs. The RSV Pol polyprotein can be cleaved to form a reverse transcriptase protein (RT) and an integrase protein (IN). Any suitable RSV strain can be used in the context of the present disclosure.

[0293] Notably, RSV lacks certain lentiviral regulatory genes such as Tat and Rev, allowing for development of particle systems that avoid incorporating such regulatoryLeydig 775437Vyriad P-64-00474proteins. Additionally, while other viruses used to generate VLPs, such as the lentiviral HIV-1 and the gammaretroviral murine leukemia virus (MLV), have mammalian hosts, the RSV has an avian host. Therefore, the avian nature of the host of RSV reduces the likelihood of off target infection of RSV VLPs in mammals, compared to VLPs derived from HIV-1 or MLV.

[0294] As used herein, a “vector construct” comprises a nucleic acid of interest, e.g.. encoding a rhabdoviral G glycoprotein or functional fragment or derivative thereof, or recombinant protein thereof, as described herein, and “helper constructs” comprise proteins useful for the formation of, e.g., virions. Such helper constructs can encode, e.g., structural proteins, and can be packaging vectors that are, e.g., plasmids.

[0295] In aspects, the retroviral vector expression system comprises a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain. In aspects, the CAR has antigenic specificity for CD 19, CD20, CD22, DLL3, B7H3, or BCMA. In aspects, the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28a or CD8a. In aspects, the transmembrane domain is the transmembrane domain of CD28 or CD8. In aspects, the intracellular signaling domain comprises a costimulatory domain and an activating domain. In aspects, the costimulatory domain is 4-1 BB. In aspects, the activating domain is CD3zeta. In aspects, the retroviral vector expression system comprises one or more nucleotide sequences encoding a transgene or gene editing system. In aspects, the gene editing system comprises one or more nucleases, such as CRISPR-Cas9, CasMINI, TALENs, or zinc finger nucleases, as well as guide RNAs or other molecules that direct the nucleases to specific genomic loci.

[0296] In aspects, the disclosure provides a rhabdoviral vector expression system comprising one or more nucleotide sequences encoding a recombinant protein system as described herein. In aspects, the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on separate plasmids. In aspects, the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on the same plasmid. In aspects, the rhabdoviral vector expression system comprises a vector construct and helper constructs that are each on separate plasmids. In aspects, the rhabdoviral vector expression system is a vesiculovirus expression system.

[0297] In aspects, the disclosure provides a rhabdoviral vector expression system comprising one or more plasmids encoding: (a) a nucleoprotein (N), a phosphoprotein (P), aLeydig 775437Vvriad P-64-00475matrix protein (M), a glycoprotein (G), and a large polymerase protein (L). each of Vesiculovirus Indiana (VSIV); and (b) the recombinant protein system described herein and a transgene. In aspects, the rhabdoviral vector encodes in 5’ to 3’ order the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, the transgene, and the large polymerase protein, the rhabdoviral vector encodes the recombinant protein system between the nucleoprotein and the phosphoprotein, between the phosphoprotein and the matrix protein, between the matrix protein and the glycoprotein, or between the transgene and the large polymerase protein. In aspects, the rhabdoviral vector expression system comprises one or more nucleotide sequences encoding a transgene or gene editing system, optionally wherein: (a) the rhabdoviral vector expression system is engineered to express human interferon (3 (IFN0); (b) the rhabdoviral vector expression system is engineered to express a sodium iodide symporter (NIS); (c) the transgene comprises a nucleotide sequence encoding an IL-12 polypeptide, or a functional fragment or derivative thereof; (d) the transgene is a is a template for a positive sense transcript encoding the IL- 12 polypeptide, or a functional fragment or derivative thereof; (e) the IL- 12 polypeptide, or the functional fragment or derivative thereof, comprises an IL-12 p40 subunit, or a functional fragment or derivative thereof; or (f) the IL-12 polypeptide, or the functional fragment or derivative thereof, comprises an IL-12 p35 subunit, or a functional fragment or derivative thereof.

[0298] In aspects, the disclosure provides a method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising:(a) transfecting or transducing a packaging host cell with a retroviral vector expression system or a rhabdoviral vector expression system described herein; and (b) recovering the membraned vesicle, enveloped viral particle, or recombinant viral vector produced by the transfected or transduced packaging host cell. In aspects, the retroviral vector expression system or the rhabdoviral vector expression system comprises one or more nucleic acids encoding (i) a recombinant fusion protein, and (ii) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein. In aspects, the ratio of (i) to (ii) is 1:3.

[0299] In aspects, the disclosure provides a method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with a retroviral vector expression system as described herein or a rhabdoviral vector expression system as described herein, wherein the host cell is ex vivo or is within a subject. In aspects, the retroviral vector expression system or the rhabdoviral vectorLeydig 775437Vyriad P-64-00476expression system comprises one or more nucleic acids encoding (a) a recombinant fusion protein, and (b) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein, wherein the ratio of (a) to (b) is 1:3.

[0300] In aspects, transfecting or transducing a packaging host cell comprises transfecting or transducing with at least one packaging plasmid. ‘Transfecting” and “transfection” as used herein means non-viral means of introducing nucleic acid into a cell. “Transducing” and “transduction” as used herein means use of viral means of introducing nucleic acid into a cell.

[0301] In aspects, any method of making an enveloped delivery vehicle, lentivirus. retroviral vector expression system, recombinant viral vector, etc. as described herein can comprise transduction in a medium comprising a poloxamer-based chemical adjuvant. In aspects, the poloxamer-based chemical adjuvant is selected from vectofusin-1, pol oxamer Fl 08, and Lentiboost™. In aspects, the method of making comprises a spinoculation step at the beginning of transduction.

[0302] In aspects, the disclosure provides a plasmid comprising one or more nucleotide sequences encoding a recombinant protein system described herein.

[0303] In aspects, the disclosure provides a method of treating a disease in a mammal, comprising administering a composition described herein, a retroviral vector expression system described herein, or a rhabdoviral vector expression system described herein.

[0304] In aspects, a composition described herein can be used in a vaccine platform.

[0305] The mammal may be any suitable mammal. Mammals include, but are not limited to, the order Rodentia, such as mice, and the order Lagomorpha, such as rabbits. The mammal can be from the order Carnivora, including Felines (cats) and Canines (dogs). The mammal can be from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perissodactyla, including Equines (horses). The mammal can be of the order Primates, Cebids, or Simioids (monkeys) or of the order Anthropoids (humans and apes). In aspects, the mammal is a human.

[0306] In aspects, the disease is a genetic disease. In aspects, the disease is a cancer. In aspects, the disease is a lymphoma, such as a B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma (MCL), a marginal zone lymphoma. Burkitt lymphoma, lymphoplasmacytic lymphoma, primary central nervous system (CNS) lymphoma, primary effusion lymphoma, or hairy cell leukemia. In aspects, the cancer isLeydig 775437Vyriad P-64-00477small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC). breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma (HCC), glioblastoma (GBM), renal cell carcinoma (RCC), prostate cancer, head & neck cancer (HNSCC), sarcoma, mesothelioma, urothelial (bladder), thyroid cancer, melanoma, or neuroblastoma. In aspects, the cancer is a non-hematological cancer.In aspects, the disease is beta-thalassemia, anemia, sickle cell disease, Gaucher disease, Parkinson disease, immunologic deficiency syndromes, mucopolysaccharidosis III, severe combined immunodeficiency disease, hepatitis C, chronic hepatitis C, pancytopenia, X-linked combined immunodeficiency diseases, epidermolysis bullosa, solid tumors, melanoma, Fanconi anemia, adenosine deaminase deficiency, granulomatous disease, chronic cystic fibrosis, HIV infections, HIV seropositivity, Hodgkin’s lymphoma, Bruton type agammaglobulinemia, Hemophilia A, arthritis, or choroidal neovascularization. In other aspects, the disease is any disease or condition that can be treated by delivery of a transgene. In other aspects, the disease is any disease or condition that can be treated by delivery of a gene editing system.

[0307] As used herein, “treatment” or “treat” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop, and also includes addressing a medical condition or disease with the objective of improving or stabilizing an outcome in a mammal being treated. “Treating,” “treat.” and “treatment” have grammatically corresponding meanings. In the context of cancer, the terms “treat” or “treating” or “treatment” can, among other things, refer to inducing apoptosis of cancerous cells, reducing the size of a cancerous tumor, delaying the growth of tumors, or inducing or enhancing an immune response against one or more cancerous cells, where the immune response has the effect of inducing apoptosis, reducing the size of a tumor, or the like. The terms “treat,” “treating,” “treatment,” “therapeutically effective,” “prevention,” etc. used herein do not necessarily imply 100% or complete treatment / prevention / etc. Rather, there are varying degrees, which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the membraned vesicles, enveloped viral particles, recombinant viral vectors, etc. as described herein and methods as described herein can provide any amount of any level of treatment. Furthermore, the treatment provided by the described method can include the treatment of one or more conditions or symptoms of the disease or condition being treated.Leydig 775437Pvriad P-64-00478

[0308] In aspects, a method of treating comprises administering a composition as described herein or a retroviral vector expression system as described herein, comprising a viral FMG or functional fragment or derivative thereof or recombinant protein thereof, and subsequently administering a composition as described herein or a retroviral vector expression system as described herein, comprising a different viral FMG or functional fragment or derivative thereof or recombinant protein thereof. The subsequent administration may be within hours, days, months, or years of the first administration, with scheduling to be determined by patient needs. Multiple rounds of subsequent administrations may be performed, using the same or different viral FMGs as determined by the patient needs. Without wishing to be bound by theory, it is believed that administering a different viral FMG or functional fragment or derivative thereof reduces the likelihood of decreased effectiveness due to any immune response that is directed against the first viral FMG or functional fragment or derivative thereof. A viral FMG or functional fragment or derivative thereof or recombinant protein thereof described herein can be the first administered, and a viral FMG or functional fragment or derivative thereof or recombinant protein thereof as described herein that has a different viral FMG than the first viral FMG or functional fragment or derivative thereof or recombinant protein thereof can be the subsequently administered viral FMG or functional fragment or derivative thereof or recombinant protein thereof. This sequence of events can be termed “re-dosing”.

[0309] In aspects, the administration can be in vitro or ex vivo. In aspects, the ex vivo administration comprises harvesting blood from a mammal and contacting the blood with a composition described herein, a retroviral vector expression system described herein, or a rhabdoviral vector expression system described herein. In aspects, the ex vivo administration comprises generating immunological cells from the blood of a mammal. In aspects, the generated immunological cells are CAR T cells.

[0310] In aspects, the administration is in vivo. In aspects, the administration is intravenous. In aspects, the administration is intraperitoneal.

[0311] Direct in vivo genetic modification of immune effector cells represents an alternative paradigm to ex vivo manipulation. In vivo programming enables immune effector cells to be genetically modified within the physiological environment of the subject, including within peripheral blood, lymphoid tissues, or tumor-draining lymph nodes. This approach may facilitate the genetic programming of immune effector cells that naturally traffic to tumor sites, enable modification of tissue-resident or tumor-infiltratingLeydig 775437Vyriad P-64-00479lymphocytes, and permit ongoing generation of newly programmed effector cells over time. In addition, in vivo modification may allow genetic programming to occur within anatomical compartments that are relevant to the initiation and maintenance of anti-tumor immune responses.

[0312] The use of EDVs and viral vectors for in vivo delivery of nucleic acids encoding CAR constructs provides a platform for stable genetic modification of immune effector cells within a subject. In the context of solid tumors, in vivo generation of CAR-expressing immune effector cells may provide biological advantages, including programming of immune cells within tumor-draining lymph nodes, engagement of endogenous immune priming pathways, continuous replenishment of effector populations, and the potential for spatially distributed generation of engineered cells across relevant anatomical compartments.Additionally, in vivo programming may permit immune effector cells to undergo activation, expansion, and differentiation in response to antigen exposure within the tumor microenvironment.

[0313] In aspects, the disclosure provides a method of making a viral FMG dimer, trimer, or tetramer, the method comprising: (i) transfecting or transducing a packaging host cell with a retroviral vector expression system described herein or a rhabdoviral vector expression system as described herein; and (ii) recovering the viral FMG dimer, trimer, or tetramer. Viral FMG dimers and viral FMG trimers may be prepared using any suitable method.

[0314] An important consideration for the successful deployment of viral vectors, engineered immunogens, and therapeutic reagents is the ability to manufacture them at scale, with, e.g., reproducible quality, high functional titers, and / or compliance with regulatory standards such as current Good Manufacturing Practices (cGMP).

[0315] In aspects, the caps can achieve higher functional titers. Without wishing to be bound by theory, the caps assist envelope proteins in assembling correctly and consistently into oligomers, e.g., trimers; for example, by nucleating assembly through a dedicated trimerization domain, a cap may reduce the prevalence of misfolded monomers or dimers, thereby increasing the proportion of fully functional particles.

[0316] In aspects, the caps can improve purification and product quality. For example, use of viral vectors and virus-derived particles may involve purification to remove host cell proteins, DNA, and defective particles. In aspects, the caps can produce homogeneous particle populations in which all envelope proteins incorporate in the same stabilized trimeric form. This uniformity can simplify purification processes. In aspects, the caps can provide aLeydig 775437Vyriad P-64-00480single, fully functional envelope protein that is both retargeted and fusion-competent. This can simplify the upstream production process and can reduce costs by eliminating the use of dual plasmids or co-expression strategies. Also, homogeneity conferred by caps can support regulatory' compliance and quality control.

[0317] In aspects, the caps can provide scalability and modularity, both of which can be important for rapid response to emerging therapeutic needs. Because the caps are modular, they can be pre-characterized and validated as universal components. New receptor-binding ligands, whether, e.g., scFvs, nanobodies, peptides, or viral fragments, can be fused to preexisting caps without requiring re-optimization of trimerization. This can enable rapid prototyping and can reduce development timelines. In a manufacturing context, it means that production facilities can rely on a standardized platform rather than developing custom processes for each new ligand. The result is a system that supports “off-the-shelf’ production pipelines, where caps and ligands can be mixed and matched to generate new vectors with minimal delay.

[0318] An additional consideration is stability during storage and transport.Biopharmaceutical products, including viral vectors, often are stored for extended periods and shipped under vary ing environmental conditions. Instability' of the product increases costs and reduces accessibility. In aspects, a cap described herein can enhance stability by maintaining envelope proteins in a correctly folded trimeric conformation. This can reduce the risk of aggregation or denaturation during storage, which can extend shelflife and enable broader distribution.

[0319] In aspects, the disclosure provides a method of stabilizing a recombinant protein system described herein, the method comprising maintaining the system at pH 7.4 with 0.1 to 2 mM of Ca2+. In aspects, the buffer is HEPES (2-[4-(2-hydroxyethyl)piperazin-l-yl]ethanesulfonic acid) or Tris (Tris(hydroxymethyl)aminomethane). In aspects, the method comprises maintaining the system with human serum albumin (HSA). In aspects, the HSA is 1% HSA.

[0320] Andersen et al., BMC Biochem., 4:7 (2003), which is incorporated herein by reference in its entirety, discloses that binding to CR domains of LDLR is Ca2+dependent because Ca2+ion biding to the CR domains of LDLR is important for correctly folding and stabilizing LDLR. Andersen et al. further discloses that Ca2+binds to LDLR-related CR domains with an average Ca2+Kd of 10.6 μM. with many CR domains generally around 10-20 μM. Nikolic et al. discloses that VSIV-G is able to bind the CR2 and CR3 domains ofLeydig 775437Vyriad P-64-00481LDLR under conditions of 2 mM Ca2+. Without wishing to be bound by theory, this suggests that rhabdoviral binding to CR domains of LDLR would be stabilized under conditions of 10 pM Ca2+or greater, such as 0.1 to 2 mM Ca2+.

[0321] Commonly owned International Patent Application No. PCT / US2026 / 027142, titled “VIRAL VECTORS, COMPONENTS THEREOF, AND USES OF THE VECTORS AND COMPONENTS THEREOF FOR PRODUCTION AND DELIVERY OF A PAYLOAD,” fded on May 7, 2026, and having Attorney Docket No. 775537, is incorporated herein by reference in its entirety.

[0322] The below are certain aspects of the disclosure.

[0323] 1. A recombinant protein system comprising:I) a first recombinant protein comprising a viral fusogenic membrane glycoprotein (FMG) or a functional fragment or derivative thereof,II) a second recombinant protein comprising (a) a targeting domain and (b) an oligomerization domain.

[0324] 2. The recombinant protein system of aspect 1, wherein the second recombinant protein comprises: (c)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, andwherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein; or(c)(2) an antigen binding domain, wherein the antigen binding domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein.

[0325] 3. The recombinant protein system of aspect 2, wherein the second recombinant protein comprises (c)(1). and wherein the binding of the first recombinant protein is reduced or abolished for a binding domain of a receptor protein that is a separate binding domain from the binding domain of the receptor protein of the second recombinant protein.

[0326] 4. The recombinant protein system of aspect 1, wherein the second recombinant protein comprises (c)(2).

[0327] 5. The recombinant protein system of aspect 4, wherein the antigen binding domain is a single chain variable fragment (scFv).Leydig 775437Vyriad P-64-00482

[0328] 6. The recombinant protein system of aspect 4 or 5, wherein binding of the antigen binding domain does not interfere with the fusion capability of the viral FMG or functional fragment or derivative thereof of the first recombinant protein.

[0329] 7. The recombinant protein system of any one of aspects 1-6, wherein the viral FMG or functional fragment or derivative thereof is of a Nipah virus (NiV) G glycoprotein, rhabdo viral G glycoprotein, a SARS-CoV-2 Spike (S) glycoprotein, a HIV-1 Envelope glycoprotein, an influenza hemagglutinin (HA) glycoprotein, an Ebola virus glycoprotein, a Hepatitis C virus (HCV) envelope 2 (E2) glycoprotein, a Machupo virus (MACV) spike glycoprotein (GP1), a Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein, a virulent canine distemper virus (CDV) hemagglutinin (H) glycoprotein, or a rabies virus (RABV) G glycoprotein.

[0330] 8. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a SARS-CoV-2 Spike glycoprotein comprising an S 1 and S2 subunit, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of an angiotensinconverting enzy me 2 (ACE2).

[0331] 9. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of aHIV-1 Envelope glycoprotein, and wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of (i) a CD4 receptor and (ii) a CCR5 receptor or a CXCR4 receptor.

[0332] 10. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of an influenza hemagglutinin (HA) glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a glycan receptor comprising a sialic acid residue.

[0333] 11. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of an Ebola virus glycoprotein, and wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a Niemann-Pick Cl protein (NPC1).Leydig 775437Vyriad P-64-00483

[0334] 12. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Hepatitis C virus (HCV) E2 glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a CD81 receptor.

[0335] 13. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Machupo virus glycoprotein, and wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a human transferrin receptor 1 (TfRl).

[0336] 14. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Sendai virus hemagglutininneuraminidase (HN) glycoprotein, andwherein the second recombinant protein comprises (c)(1). and wherein the binding domain of the receptor protein of the second recombinant protein is of a glycan receptor comprising a sialic acid residue.

[0337] 15. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a SLAM-binding ablated virulent canine distemper virus (CDV) hemagglutinin (H) glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of aNectin-4 protein.

[0338] 16. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a rabies virus (RABV) G glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a nicotinic acetylcholine receptor (nAChR). neural cell adhesion molecule (NCAM), p75 neurotrophin receptor, metabotropic glutamate receptor subtype 2 (mGluR2), or integrin β1.

[0339] 17. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of aNipah virus (NiV) G glycoprotein, andLeydig 775437Vyriad P-64-00484wherein the second recombinant protein comprises (c)(1). and wherein the binding domain of the receptor protein of the second recombinant protein is of a ephrin-B2 (EFNB2) receptor or ephrin-B3 (EFNB3) receptor.

[0340] 18. The recombinant protein system of any one of aspects 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a rhabdoviral G glycoprotein, and wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a cysteine rich region of a low density lipoprotein receptor (LDLR).

[0341] 19. The recombinant protein system of any one of aspects 2-18, wherein the (c)(1) or (c)(2) is N terminal to the oligomerization domain, optionally wherein the oligomerization domain is N terminal to the targeting domain.

[0342] 20. The recombinant protein system of any one of aspects 1-19, wherein the second recombinant protein comprises a signal peptide.

[0343] 21. The recombinant protein system of aspect 20, wherein the signal peptide comprises an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 59.

[0344] 22. The recombinant protein system of aspect 1, comprising one or more linkers.

[0345] 23. The recombinant protein system of any one of aspects 2-21, comprising one or more linkers.

[0346] 24. The recombinant protein system of aspect 23, wherein the oligomerization domain is N terminal to the targeting domain in the second recombinant protein and wherein the second recombinant protein comprises one or more linkers between (A) the (c)(1) or (c)(2) and the oligomerization domain, (B) the oligomerization domain and the targeting domain, or (C) between both (A) and (B).

[0347] 25. The recombinant protein system of any one of aspects 22-24, wherein the one or more linkers is flexible.

[0348] 26. The recombinant protein system of aspect 25, wherein the one or more linkers is(GGGGS) (SEQ ID NO: 6),GGGGSGGGGS (SEQ ID NO: 7),GGGGSGGGGSGGGGS (SEQ ID NO: 8),GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 9), GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 60), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 61),Leydig 775437Vyriad P-64-00485GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 62).GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 63), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 64), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 65),GSGGSG (SEQ ID NO: 10),GGGGGG (SEQ ID NO: 11),GGGGGGGG (SEQ ID NO: 12),VPGVGVPGVG (SEQ ID NO: 13).GSAGSAAGSGEF (SEQ ID NO: 14),AAASGGSGGGGSGGGGS (SEQ ID NO: 15), orAAASGGSGGGGSGGGGSGP (SEQ ID NO: 16).

[0349] 27. The recombinant protein system of any one of aspects 22-24, wherein the one or more linkers is rigid.

[0350] 28. The recombinant protein system of aspect 27, wherein the linker is PAPAP (SEQ ID NO: 17),EAAAKEAAAKEAAAK (SEQ ID NO: 18),EAAAKEAAAK (SEQ ID NO: 19).EAAAK (SEQ ID NO: 20), AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAAKA (SEQ ID NO: 21),AEAAAKEAAAKA (SEQ ID NO: 22).ESKYGPPCPPCP (SEQ ID NO: 23),CPPCPAPELLGGPSVF (SEQ ID NO: 24), andalanine-proline (AP) repeated for a total of 10 to 34 amino acids (SEQ ID NO: 25).

[0351] 29. The recombinant protein system of any one of aspects 1-28, comprising a tag for western detection or purification, optionally located at the C-terminus of the second recombinant protein.

[0352] 30. The recombinant protein system of aspect 29, wherein the tag is a tag for western detection.

[0353] 31. The recombinant protein system of aspect 29, wherein the tag is a tag for purification.Leydig 775437Vyriad P-64-00486

[0354] 32. The recombinant protein system of any one of aspects 29-31, wherein the tag is located at the C terminus of the second recombinant protein, comprising a linker between the tag and the targeting domain.

[0355] 33. The recombinant protein system of aspect 32, wherein the linker between the tag and the targeting domain is GSGGSG (SEQ ID NO: 10).

[0356] 34. The recombinant protein system of any one of aspects 1-33, wherein the oligomerization domain comprises:a variant of the GCN4 leucine / isoleucine zipper peptide with systematic isoleucine substitutions in the a and d positions of the heptad repeat comprising the amino acid sequence of SEQ ID NO: 27,a variant of the GCN4 leucine / isoleucine zipper peptide with systematic valine and leucine substitutions in the a and d positions respectively of the heptad repeat comprising the amino acid sequence of SEQ ID NO: 26,a C-terminal Foldon domain of a T4 fibritin (Foldon) comprising the amino acid sequence of SEQ ID NO: 28,a de novo designed trimeric coiled-coil peptide comprising the amino acid sequence of SEQ ID NO: 29,a laminin α2 chain C-terminal domain comprising the amino acid sequence of SEQ ID NO: 30,a collagen triple helix motif comprising the amino acid sequence of SEQ ID NO: 31, a self-assembling β-sheet-rich peptide comprising the amino acid sequence of SEQ ID NO: 32,a coiled-coil heptad repeat region of a HA2 subunit of an Influenza hemagglutinin glycoprotein,a collagen XV derived non-collagenous C-terminal domain (NCI) comprising the amino acid sequence of SEQ ID NO: 33,a collagen XIX derived non-collagenous C-terminal domain (NC2) comprising the amino acid sequence of SEQ ID NO: 150, ora collagen XVIII derived non-collagenous C-terminal domain (NCI) comprising the amino acid sequence of SEQ ID NO: 34.

[0357] 35. The recombinant protein system of any one of aspects 1-34, wherein the targeting domain of the second recombinant protein is a ligand.Leydig 775437Vyriad P-64-00487

[0358] 36. The recombinant protein system of aspect 35, wherein the ligand is epidermal growth factor (EGF), a mutant EGF (EFGml23) (SEQ ID NO: 36), stem cell factor (SCF) (SEQ ID NO: 37), thrombopoietin (TPO) (SEQ ID NO: 38), human hepatocyte grow th factor (HGF) (SEQ ID NO: 39), ery thropoietin (EPO), or type 1 insulin-like growth factor (IGF1) (SEQ ID NO: 40).

[0359] 37. The recombinant protein system of any one of aspects 1-34, wherein the targeting domain of the second recombinant protein is a single chain variable fragment (scFv).

[0360] 38. The recombinant protein system of aspect 37, wherein the scFv binds epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her2), cluster of differentiation 3 (CD3), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 7 (CD7), cluster of differentiation 117 (c-Kit), mucin-16 (MUC16), B cell maturation antigen (BCMA), orNectin4.

[0361] 39. The recombinant protein system of aspect 38, wherein the scFv binds CD3 and wherein the scFv is UCHT1, HuM291, OKT3, or TR66.

[0362] 40. The recombinant protein system of aspect 39, wherein the scFv is UCHT1 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 41 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 42.

[0363] 41. The recombinant protein system of aspect 39, wherein the scFv is HuM291 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 43 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 44.

[0364] 42. The recombinant protein system of aspect 39, wherein the scFv is OKT3 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 45 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 46.

[0365] 43. The recombinant protein system of aspect 39, wherein the scFv is TR66 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 47 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 48.

[0366] 44. The recombinant protein system of any one of aspects 1-34, wherein the targeting domain of the second recombinant protein is a nanobody.Leydig 775437Vyriad P-64-00488

[0367] 45. The recombinant protein system of aspect 44, wherein the nanobody binds epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her2), cluster of differentiation 3 (CD3), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 7 (CD7), cluster of differentiation 117 (c-Kit), mucin-16 (MUC16), B cell maturation antigen (BCMA), Nectin4. or T cell receptor (TCR).

[0368] 46. The recombinant protein system of aspect 45, wherein the nanobody binds CD3.

[0369] 47. The recombinant protein sy stem of aspect 46, wherein the nanobody is an anti- CD3 epsilon nanobody (VHH-3-aCD3E) and wherein the nanobody comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 102.

[0370] 48. The recombinant protein system of aspect 45, wherein the nanobody binds TCR.

[0371] 49. The recombinant protein system of aspect 48, wherein the nanobody is an anti- T cell receptor protein nanobody (VHH 9-aTCR) and wherein the nanobody comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 103.

[0372] 50. The recombinant protein system of any one of aspects 18-49, wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein comprises (i) cysteine rich domain 2 (CR2) of LDLR (SEQ ID NO: 2). (n) cysteine rich domain 3 (CR3) of LDLR (SEQ ID NO: 3), (m) cysteine rich domain 4 (CR4) of LDLR (SEQ ID NO: 4), or (iv) any combination of (i)-(iii).

[0373] 51. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises CR2 (SEQ ID NO: 2) of LDLR.

[0374] 52. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises CR3 (SEQ ID NO: 3) of LDLR.

[0375] 53. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises CR2 (SEQ ID NO: 2) of LDLR and CR3 (SEQ ID NO: 3) of LDLR.

[0376] 54. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1) and CR2 (SEQ ID NO: 2) of LDLR.

[0377] 55. The recombinant protein system of aspect 54, wherein the cysteine rich region comprises two copies of CR2 (SEQ ID NO: 2) of LDLR.Leydig 775437Vyriad P-64-00489

[0378] 56. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1) and CR3 (SEQ ID NO: 3) ofLDLR.

[0379] 57. The recombinant protein system of aspect 56, wherein the cysteine rich region comprises two copies of CR3 (SEQ ID NO: 3) ofLDLR.

[0380] 58. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises cysteine rich domain 1 (CR1) ofLDLR (SEQ ID NO: 1), CR2 (SEQ ID NO: 2) of LDLR, and CR3 (SEQ ID NO: 3) ofLDLR.

[0381] 59. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR3-CR2-CR1.

[0382] 60. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR2-CR2.

[0383] 61. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR2-CR3.

[0384] 62. The recombinant protein system of aspect 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR3-CR3.

[0385] 63. The recombinant protein system of any one of aspects 18-62, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of a Flanders virus glycoprotein (FLAV-G) (SEQ ID NO: 49), a Chandipura virus glycoprotein (CHPV-G) (SEQ ID NO: 50), a Perinet virus glycoprotein (PERV-G) (SEQ ID NO: 51, a Piry virus glycoprotein (PIRYV-G) (SEQ ID NO: 52), a Fukuoka virus glycoprotein (FUKV-G) (SEQ ID NO: 53), a Joinjakaka virus glycoprotein (JOIV-G) (SEQ ID NO: 54). a Kumasi virus glycoprotein (KRV-G) (SEQ ID NO: 55), a Keuraliba virus glycoprotein (KEUV-G) (SEQ ID NO: 56), an Isfahan glycoprotein (ISFV-G), a Jur on a glycoprotein (JURV-G), a Mediterranean Bat glycoprotein (MBV-G), a Malpais Spring glycoprotein (MSPV-G), a Radi glycoprotein (RADV-G), aRhinolophus affinis-G, a Yug Bugdanavoc glycoprotein (YBV-G), a Yinshui Bat glycoprotein (YSBV-G), a Kimberley glycoprotein (KIMV-G), a Kanyawara glycoprotein (KYAV-G), a La Joy a glycoprotein (LJV-G), a Mosquiero glycoprotein (MQOV-G), a Parry Creek glycoprotein (PCV-G), a Bas Congo glycoprotein (BASV-G), a Bovine Ephemeral fever glycoprotein (BEFV-G), a Curionopolis glycoprotein (CURV-G), a Drosophila melanogaster sigmavirus glycoprotein (DMelSV-G), aNiakha glycoprotein (NIAV-G), a Puerto almandras glycoprotein (PTAMV-G), or a Tupaia rhabdo virus (TUPTV-G).Leydig 775437Vvriad P-64-00490

[0386] 64. The recombinant protein system of any one of aspects 18-62, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus glycoprotein or a functional fragment or derivative thereof.

[0387] 65. The recombinant protein system of aspect 64, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana.Vesiculovirus newjersey, Vesiculovirus carajas, or Vesiculovirus alagoas.

[0388] 66. The recombinant protein system of aspect 65, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana (SEQ ID NO: 57).

[0389] 67. The recombinant protein system of aspect 65, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus newjersey (SEQ ID NO: 58).

[0390] 68. The recombinant protein system of any one of aspects 18-67, wherein the rhabdoviral G glycoprotein is substantially intact.

[0391] 69. The recombinant protein system of any one of aspects 18-67, wherein the rhabdoviral G glycoprotein is a functional fragment or derivative thereof.

[0392] 70. The recombinant protein system of any one of aspects 18-69, comprising a rhabdoviral G glycoprotein or functional fragment or derivative thereof engineered to reduce or abolish its natural receptor binding specificity.

[0393] 71. The recombinant protein system of aspect 70, wherein the rhabdoviral G glycoprotein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

[0394] 72. The recombinant protein system of aspect 71, wherein the rhabdoviral G glycoprotein comprises a mutation at one or more positions corresponding to H8, K47, Y209, and K354 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).

[0395] 73. The recombinant protein system of aspect 71 or 72, wherein the mutation is a substitution.

[0396] 74. The recombinant protein system of aspect 73, wherein the substitution is with a Q.

[0397] 75. The recombinant protein system of any one of aspects 71-74, wherein the mutation is a substitution at three or more positions corresponding to H8, K47, Y209, and K354 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).Leydig 775437Vyriad P-64-00491

[0398] 76. The recombinant protein system of aspect 71 or 72, wherein the mutation is a deletion.

[0399] 77. The recombinant protein system of aspect 76, wherein the mutation is a single deletion at the position corresponding to K47 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).

[0400] 78. The recombinant protein system of any one of aspects 18-77, wherein the rhabdoviral G glycoprotein of the first recombinant protein is inactivated to a lesser degree by serum, LDL, or vLDL compared to a rhabdoviral G glycoprotein not of the recombinant protein system.

[0401] 79. The recombinant protein system of any one of aspects 1-78, wherein the first recombinant protein is fused to the second recombinant protein, optionally wherein the first recombinant protein is N-terminal to the second recombinant protein.

[0402] 80. The recombinant protein system of aspect 79, wherein the first recombinant protein is N-terminal to the second recombinant protein, comprising a linker between the first recombinant protein and the second recombinant protein.

[0403] 81. The recombinant protein system of aspect 79, wherein the second recombinant protein is N-terminal to the first recombinant protein, comprising a linker between the second recombinant protein and the first recombinant protein.

[0404] 82. The recombinant protein system of any one of aspects 1-81, wherein the viral FMG of the first recombinant protein forms a bond with the binding domain of the receptor protein of the second recombinant protein.

[0405] 83. The recombinant protein system of aspect 82, wherein the bond is a covalent bond.

[0406] 84. The recombinant protein system of aspect 83, wherein the formation of the covalent bond is spontaneous.

[0407] 85. The recombinant protein system of aspect 82, wherein the bond is a non-covalent bond.

[0408] 86. The recombinant protein system of aspect 85, wherein the formation of the non-covalent bond is spontaneous.

[0409] 87. A dimer comprising two recombinant protein systems of any one of aspects 2- 86,wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other second recombinant protein,Leydig 775437Vyriad P-64-00492wherein the viral FMG of each first recombinant protein is bound to the viral FMG of the other first recombinant protein, andwherein the second recombinant proteins comprise (c)(1), and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0410] 88. A trimer comprising three recombinant protein systems of any one of aspects 2-86,wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other two second recombinant proteins,wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other two first recombinant proteins, andwherein the second recombinant proteins comprise (c)(1), and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0411] 89. A tetramer comprising four recombinant protein systems of any one of aspects 2-86,wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other three second recombinant proteins,wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other three first recombinant proteins, andwherein the second recombinant proteins comprise (c)(1), and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

[0412] 90. The dimer of aspect 87, the trimer of aspect 88, or the tetramer of aspect 89, comprising at least two different viral FMGs.

[0413] 91. The dimer of aspect 87 or 90, the trimer of aspect 88 or 90, or the tetramer of aspect 89 or 90, comprising at least two different binding domains of the receptor proteins.

[0414] 92. The dimer of aspect 87, 90, or 91, the trimer of aspect 88, 90, or 91, or the tetramer of aspect 89, 90, or 91 comprising at least two different targeting domains.

[0415] 93. A membraned vesicle comprising the recombinant protein system of any one of aspects 1-86.

[0416] 94. The membraned vesicle of aspect 93, wherein the membraned vesicle is a gesicle or an exosome.Leydig 775437Vyriad P-64-00493

[0417] 95. A membraned vesicle comprising the dimer of aspect 87, 90, 91, or 92, the trimer of aspect 88, 90, 91, or 92, or the tetramer of aspect 89, 90, 91, or 92.

[0418] 96. An enveloped delivery vehicle comprising the recombinant protein system of any one of aspects 1-86.

[0419] 97. An enveloped delivery vehicle comprising the dimer of aspect 87. 90. 91, or 92, the trimer of aspect 88, 90, 91, or 92, or the tetramer of aspect 89, 90, 91, or 92.

[0420] 98. A recombinant viral vector comprising a nucleotide encapsulated by the membraned vesicle of any one of aspects 93-95 or the enveloped viral particle of aspect 96 or 97.

[0421] 99. A composition comprising a pharmaceutically acceptable carrier and the membraned vesicle of any one of aspects 93-95, the enveloped viral particle of aspect 96 or 97, or the recombinant viral vector of aspect 98.

[0422] 100. A method of delivering a payload to a target cell, the method comprising contacting the target cell with the membraned vesicle of any one of aspects 93-95, the enveloped viral particle of aspect 96 or 97, the recombinant viral vector of aspect 98, or the composition of aspect 99.

[0423] 101. The method of aspect 100, wherein the target cell is contacted in vitro or ex vivo.

[0424] 102. The method of aspect 100, wherein the target cell is contacted in vivo.

[0425] 103. The method of any one of aspects 100-102, wherein the payload is a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

[0426] 104. The method of aspect 103, wherein the CAR has antigenic specificity for CD 19, CD20, CD22, DLL3, B7H3, or BCMA.

[0427] 105. The method of aspect 103 or 104, wherein the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28a or CD8a.

[0428] 106. The method of any one of aspects 103-105. wherein the transmembrane domain is the transmembrane domain of CD28 or CD8.

[0429] 107. The method of any one of aspects 103-106, wherein the intracellular signaling domain comprises a costimulatory domain and an activating domain.

[0430] 108. The method of aspect 107, wherein the costimulatory domain is 4-1BB.

[0431] 109. The method of aspect 107 or 108, wherein the activating domain is CD3zeta.Leydig 775437Vyriad P-64-00494

[0432] 110. The method of any one of aspects 100-102. wherein the payload is a transgene or gene editing system.

[0433] 111. A retroviral vector expression system comprising one or more nucleotide sequences encoding the recombinant protein system of any one of aspects 1-86.

[0434] 112. The retroviral vector expression system of aspect 111, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on separate plasmids.

[0435] 113. The retroviral vector expression system of aspect 111, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on the same plasmid.

[0436] 114. The retroviral vector expression system of any one of aspects 111-113, wherein the retroviral vector expression system comprises a vector construct and helper constructs that are each on separate plasmids.

[0437] 115. The retroviral vector expression system of any one of aspects 111-114, wherein the retroviral vector expression system is a lentiviral vector expression system or a Rous sarcoma virus (RSV) vector expression system.

[0438] 116. The retroviral vector expression system of any one of aspects 111-115, comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

[0439] 117. The retroviral vector expression system of aspect 116, wherein the CAR has antigenic specificity for CD19, CD20, CD22, DLL3, B7H3, or BCMA.

[0440] 118. The retroviral vector expression system of aspect 116 or 117, wherein the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28a or CD8a

[0441] 119. The retroviral vector expression system of any one of aspects 116-118, wherein the transmembrane domain is the transmembrane domain of CD28 or CD8.

[0442] 120. The retroviral vector expression system of any one of aspects 116-119, wherein the intracellular signaling domain comprises a costimulatory domain and an activating domain.

[0443] 121. The retroviral vector expression system of aspect 120, wherein the costimulatory domain is 4-1BB.

[0444] 122. The retroviral vector expression system of aspect 120 or 121, wherein the activating domain is CD3zeta.Leydig 775437Vyriad P-64-00495

[0445] 123. The retroviral vector expression system of any one of aspects 111-115, comprising one or more nucleotide sequences encoding a transgene or gene editing system.

[0446] 124. A rhabdoviral vector expression system comprising one or more nucleotide sequences encoding the recombinant protein system of any one of aspects 1-86.

[0447] 125. The rhabdoviral vector expression system of aspect 124, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on separate plasmids.

[0448] 126. The rhabdoviral vector expression system of aspect 124, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on the same plasmid.

[0449] 127. The rhabdoviral vector expression system of any one of aspects 124-126, wherein the rhabdoviral vector expression system comprises a vector construct and helper constructs that are each on separate plasmids.

[0450] 128. The rhabdoviral vector expression system of any one of aspects 124-127, wherein the rhabdoviral vector expression system is a vesiculovirus expression system.

[0451] 129. A rhabdoviral vector expression system comprising one or more plasmids encoding:(a) a nucleoprotein (N), a phosphoprotein (P), a matrix protein (M). a glycoprotein (G), and a large polymerase protein (L), each of Vesiculovirus Indiana (VSIV); and(b) the recombinant protein system of any one of aspects 1-86 and a transgene.

[0452] 130. The rhabdoviral vector expression system of aspect 129, wherein the rhabdoviral vector encodes in 5’ to 3’ order the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, the transgene, and the large polymerase protein.

[0453] 131. The rhabdoviral vector expression system of aspect 129 or 130, wherein the rhabdoviral vector encodes the recombinant protein system between the nucleoprotein and the phosphoprotein, between the phosphoprotein and the matrix protein, between the matrix protein and the glycoprotein, or between the transgene and the large polymerase protein.

[0454] 132. The rhabdoviral vector expression system of any one of aspects 124-131, comprising one or more nucleotide sequences encoding a transgene or gene editing system, optionally wherein:(a) the rhabdoviral vector expression system is engineered to express human interferon 0 (IFN0);Leydig 775437Vyriad P-64-00496(b) the rhabdoviral vector expression system is engineered to express a sodium iodide symporter (NTS);(c) the transgene comprises a nucleotide sequence encoding an IL-12 polypeptide, or a functional fragment or derivative thereof;(d) the transgene is a is a template for a positive sense transcript encoding the IL-12 polypeptide, or a functional fragment or derivative thereof;(e) the IL- 12 polypeptide, or the functional fragment or derivative thereof, comprises an IL-12 p40 subunit, or a functional fragment or derivative thereof; or(I) the IL- 12 polypeptide, or the functional fragment or derivative thereof, comprises an IL- 12 p35 subunit, or a functional fragment or derivative thereof.

[0455] 133. A method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising:(a) transfecting or transducing a packaging host cell with the retroviral vector expression system of any one of aspects 111-123 or the rhabdoviral vector expression system of any one of aspects 124-132; and(b) recovering the membraned vesicle, enveloped viral particle, or recombinant viral vector produced by the transfected or transduced packaging host cell.

[0456] 134. The method of aspect 133, wherein the retroviral vector expression system or the rhabdoviral vector expression system comprises one or more nucleic acids encoding (i) a recombinant fusion protein, and (ii) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein.

[0457] 135. The method of aspect 134, wherein the ratio of (i) to (ii) is 1:3.

[0458] 136. A method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with the retroviral vector expression system of any one of aspects 111-123 or the rhabdoviral vector expression system of any one of aspects 124-132, wherein the host cell is ex vivo.

[0459] 137. A method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with the retroviral vector expression system of any one of aspects 111-123 or the rhabdoviral vector expression system of any one of aspects 124-132, wherein the host cell is within a subject.

[0460] 138. The method of aspect 136 or 137, wherein the retroviral vector expression system or the rhabdoviral vector expression system comprises one or more nucleic acids encoding (a) a recombinant fusion protein, and (b) a rhabdoviral G glycoprotein or functionalLeydig 775437Vyriad P-64-00497fragment or derivative thereof that is not within a recombinant fusion protein, wherein the ratio of (a) to (b) is 1:3.

[0461] 139. A plasmid comprising one or more nucleotide sequences encoding the recombinant protein system of any one of aspects 1-86.

[0462] 140. A composition of aspect 99, a retroviral vector expression system of any one of aspects 111-123, or a rhabdoviral vector expression system of any one of aspects 124-132 for use in treating a disease in a mammal.

[0463] 141. The composition, retroviral vector expression system, or rhabdoviral vector expression system of aspect 140, wherein the mammal is a human.

[0464] 142. The composition, retroviral vector expression system, or rhabdoviral vector expression system of aspect 140 or 141, wherein the disease is a genetic disease.

[0465] 143. The composition, retroviral vector expression system, or rhabdoviral vector expression system of aspect 140 or 141, wherein the disease is a cancer.

[0466] 144. The composition, retroviral vector expression system, or rhabdoviral vector expression system of any one of aspects 140-143, wherein the administration is intravenous.

[0467] 145. The composition, retroviral vector expression system, or rhabdoviral vector expression system of any one of aspects 140-144, wherein the administration is intraperitoneal.

[0468] 146. A method of making a viral FMG dimer, trimer, or tetramer, the method comprising:(i) transfecting or transducing a packaging host cell with the retroviral vector expression system of any one of aspects 111-123 or the rhabdoviral vector expression system of any one of aspects 124-132: and(ii) recovering the viral FMG dimer, trimer, or tetramer.

[0469] 147. A method of stabilizing a recombinant protein system of any one of aspects 18 and 50-62, the method comprising maintaining the system at pH 7.4 with 0.1 to 2 mM of Ca2+.

[0470] 148. The method of aspect 147, wherein the buffer is HEPES (2-[4-(2-hydroxyethyl)piperazin-l-yl]ethanesulfonic acid) or Tris (Tris(hydroxymethyl)aminomethane).

[0471] 149. The method of aspect 147 or 148, wherein the method comprises maintaining the system with human serum albumin (HSA).

[0472] 150. The method of aspect 149, wherein the HSA is 1% HSA.Leydig 775437Vvriad P-64-00498

[0473] It shall be noted that the preceding are merely examples of aspects of the disclosure. Other exemplary' aspects are apparent from the entirety of the description herein. It will also be understood by one of ordinary' skill in the art that each of these aspects may be used in various combinations with the other aspects provided herein.

[0474] The following examples further illustrate aspects of the disclosure, but, of course, should not be construed as in any way7limiting its scope.EXAMPLE 1

[0475] This example demonstrates the development of expression vectors encoding recombinant proteins comprising a targeting domain, an oligomerization peptide, and a binding domain of a receptor protein that binds to a viral FMG and expression vectors encoding a recombinant viral FMG, the use of these expression vectors to pseudotype lentivirus, and the specificity of lentivirus pseudotyped with trimers of the recombinant viral FMG bound to the binding domain of a receptor protein fused to an oligomerization peptide fused to a targeting domain.

[0476] To develop blinded and retargeted viral FMGs for pseudotyping membraned vesicles, constructs were designed using apCG-4MCll expression vector with sequences encoding the wild type G glycoprotein of the rhabdovirus Vesiculovirus Indiana (VSIV-G-WT) (SEQ ID NO: 57), and separate constructs were designed encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the cysteine rich regions 1, 2, and 3 (CR1+2+3. which is the same as CR123) (SEQ ID NOs: 1, 2, and 3) of LDLR, which binds to VSIV-G, fused to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26) or helical peptide- AA (PEP-AA) (SEQ ID NO: 35)) fused to a mutant EGF ligand (EGFml23) (SEQ ID NO: 36) fused to a Flag tag (SEQ ID NO: 66) as shown in FIG. 1 A. The helical peptide- AA derived from the GCN4 leucine / isoleucine zipper peptide, which was known to prevent oligomerization and form monomers was used as a non-oligomerization control to test the effect of induced oligomerization, specifically trimerization, in helical peptide-VL containing constructs.

[0477] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1:1 ratio a plasmid encoding a VSIV-G and a plasmid encoding the recombinant protein with the fused CR regions of LDLR, oligomerizing peptide, and EGFml23 ligand. 72 hoursLeydig 775437Vyriad P-64-00499post-transfection, virus was collected, clarified, and concentrated. 72 hours post-transfection for the lentivirus production, the cell lysates were collected and subjected to western blotting with anti-VSIV-G, anti-FLAG, anti-EGF, and anti-GAPDH antibodies (FIG. IB). The collected lentivirus particles were titered using p24 ELISA and quantified as shown in Table 2. The p24 ELISA was performed according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL).Table 2

[0478] To test the blinding and targeting efficacy of these constructs K-562 cells and K- 562 cells expressing the EGF receptor (EGFR+) were seeded at 50000 cells per well and transduced with 1000 lentiviral particles per cell and either not centrifuged or centrifuged at 2000 RPM for 30 minutes at 4 °C. Centrifugation improves contact between virus and cells and was tested to determine if transduction efficiency was improved. 72 hours post transduction plates were collected and fluorescence images were taken by Nikon microscope with 10x objective lens and an exposure of 100 ms for the non-centrifuged cells (FIGS. 2A- 2B) and the centrifuged cells (FIGS. 2C-2D). Additional fluorescent images were taken by CEL1GO for cytometry measurements for the non-centrifuged cells (FIGS. 3A-3B) and the centrifuged cells (FIGS. 3C-3D).

[0479] The WT VSIV-G pseudotyped lentivirus transduced high levels of GFP expression in both K-562 cells and K-562 EGFR+ cells, while a control lentivirus pseudotyped with a VSIV-G engineered to have reduced or abolished LDLR binding with Q substitutions at residues K47, Y209, and R354 (VSIV-G-QQQ) transduced low levels of GFP expression in both K-562 cells and K-562 EGFR+ cells, indicating that WT VSIV-G pseudotyped lentiviruses can effectively transduce K-562 cells while the VSIV-G-QQQLeydig 775437Vyriad P-64-004100pseudotyped lentiviruses, with reduced or abolished LDLR binding, cannot effectively transduce K-562 cells. The lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins with CR1, CR2, and CR3 region fused to the PEP-AA peptide and fused to the EGFml23 ligand showed strong GFP expression in K-562 cells and even higher GFP expression in EGFR+ K-562 cells. A comparison of the GFP expression in K-562 cells transduced by the WT VSIV-G pseudotyped lentivirus alone and those transduced with WT VSIV-G and the blinding and retargeting recombinant protein with the PEP-AA peptide suggest that WT VSIV-G was partially blinded by the CR1, CR2, and CR3 regions of the blinding and retargeting recombinant protein. A comparison of the GFP expression in EGFR+ K-562 cells transduced by the WT VSIV-G pseudotyped lentivirus alone and those transduced with WT VSIV-G and the blinding and retargeting recombinant protein with the PEP-AA peptide suggest that WT VSIV-G was partially retargeted to the EGF receptor by the EGFml23 ligand region of the blinding and retargeting recombinant protein. The GFP expression in the K-562 cells transduced with WT VSIV-G and the blinding and retargeting recombinant protein with the PEP-VL oligomerizing peptide pseudotyped lentivirus was lower than in the VSIV-G-QQQ pseudotyped lentivirus, suggesting that the WT VSIV-G had strongly reduced or abolished binding to LDLR. The GFP expression in the EGFR+ K-562 cells transduced by WT VSIV-G and the blinding and retargeting recombinant protein with the PEP-VL oligomerizing peptide pseudotyped lentivirus was higher than in the VSIV-G-QQQ pseudotyped lentivirus, suggesting that the EGFml23 ligand targeting domain retargeted the VSIV-G to bind EGFR and fuse with the cell.

[0480] The fold increase of GFP positive (GFP+) cell number in K-562 cells expressing the EGF receptor (EGFR+) compared to K-562 cells that were transduced by lentivirus pseudotyped with WT VSIV-G and a blinding and retargeting recombinant protein was calculated (FIG. 3E). The fold increase w as approximately 20 to 70 for blinding and retargeting recombinant proteins with the PEP-VL peptide and approximately 0 for blinding and retargeting recombinant proteins with the PEP-AA peptide. Without wishing to be bound by theory, as the PEP-AA peptide has been reported to prevent oligomerization and the PEP-VL peptide induces trimerization these results suggest that trimers of the recombinant protein of the CR1, CR2, and CR3 regions, PEP-VL oligomerizing peptide, and EGFml23 ligand were able to reduce or abolish the LDLR binding of WT VSIV-G and retarget VSIV-G to EGFR, while non-oligomerized recombinant proteins with PEP-AA were less effective at blinding and retargeting VSIV-G.Leydig 775437Vyriad P-64-004101

[0481] The centrifugation step during transduction and the absence or inclusion of G4S or (G4S)x3 linkers in the recombinant protein between the targeting domain, oligomerizing peptide, and / or CR1, CR2, and CR3 regions did not seem to strongly impact transduction levels. These results suggest that lentiviruses or other enveloped delivery vehicles pseudotyped with VSIV-G and trimers of the recombinant protein of the CR1, CR2, and CR3 regions, PEP-VL oligomerizing peptide, and a targeting domain would be effective at targeting specific cell populations and delivering a payload.EXAMPLE 2

[0482] This example demonstrates the development of expression vectors encoding recombinant proteins comprising an anti-CD3 scFv targeting domain, an oligomerization peptide, and CR binding domains of LDLR that binds to VSIV-G and expression vectors encoding a recombinant VSIV-G, the use of these expression vectors to pseudotype lentivirus, and the specificity of lentivirus pseudotyped with trimers of the recombinant VSIV-G bound to the CR binding domains of LDLR fused to an oligomerization peptide fused to an anti-CD3 scFv targeting domain.

[0483] To develop blinded and retargeted viral FMGs for pseudotyping membraned vesicles, constructs were designed using apCG-4MCll expression vector with sequences encoding the wild type VSIV-G (SEQ ID NO: 57) or VSIV-G-QQQ (SEQ ID NO: 68), and separate constructs were designed encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR, fused to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26) or helical peptide- AA (PEP-AA) (SEQ ID NO: 35)) fused to the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42 fused to a Flag tag (SEQ ID NO: 66) as shown in FIG. 4.

[0484] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1:1 ratio a plasmid encoding a VSIV-G and a plasmid encoding the recombinant protein with the fused CR1, CR2, and CR3 regions of LDLR, oligomerizing peptide PEP-VL or PEP-AA, and the UCHT1 scFv. 72 hours post-transfection, virus was collected, clarified, and concentrated. 72 hours post-transfection for the lentivirus production, the cell lysates were collected and subjected to western blotting with anti -VSIV-G, anti -FLAG, and anti-GAPDH antibodies (FIG. 4B). The collected lentivirus particles were titered using p24 ELISA andLeydig 775437Vyriad P-64-004102quantified as shown in Table 3. The p24 ELISA was performed according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL).Table 3

[0485] To test the blinding and targeting efficacy of these constructs Jurkat cells, which express CD3, and Nalm-6 cells, which do not express CD3, were seeded at 50000 cells per well and transduced with 1000 lentiviral particles per cell and either not centrifuged or centrifuged at 2000 RPM for 30 minutes at 4 °C. Centrifugation improves contact between virus and cells and was tested to determine if transduction efficiency was improved. 72 hours post transduction plates were collected and fluorescence images were taken by Nikon microscope with 10x objective lens and an exposure of 100 ms for the non- centrifuged cells (FIGS. 5A-5B) and the centrifuged cells (FIGS. 5C-5D). Additional fluorescent images were taken by CELIGO for cy tometry measurements for the non-centrifuged cells (FIGS. 6A-6B) and the centrifuged cells (FIGS. 6C-6D).

[0486] The WT VSIV-G pseudotyped lentivirus transduced high levels of GFP expression in both Jurkat cells (CD3+) and Nalm-6 cells (CD3-), while the VSIV-G-QQQ pseudotyped lentivirus transduced low levels of GFP expression in both Jurkat cells and Nalm-6 cells, indicating that WT VSIV-G pseudotyped lenti viruses can effectively transduce both Jurkat and Nalm-6 cells while the VSIV-G-QQQ pseudotyped lentiviruses, with reduced or abolished LDLR binding, cannot effectively transduce Jurkat and Nalm-6 cells. The lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins with CR1, CR2, and CR3 region fused to the PEP-AA peptide and fused to the anti-CD3 scFv UCHT1 showed strong GFP expression in Jurkat cells and even higher GFP expression in Nalm-6Leydig 775437Vyriad P-64-004103cells. Without wishing to be bound by theory, the level of GFP expression in the Nalm-6 cells could be explained by the higher endogenous expression of LDLR in Nalm-6 than in Jurkat cells and K-562 cells. A comparison of the GFP expression in Nalm-6 cells transduced by the WT VSIV-G pseudotyped lentivirus alone and those transduced with WT VSIV-G and the blinding and retargeting recombinant protein with PEP-AA pseudotyped lentivirus suggest that WT VSIV-G was partially blinded by the CR1, CR2, and CR3 regions of the blinding and retargeting recombinant protein with PEP-AA. A comparison of the GFP expression in Jurkat cells transduced by the WT VSIV-G pseudotyped lentivirus alone and those transduced with WT VSIV-G and the blinding and retargeting recombinant protein with PEP-AA suggest that WT VSIV-G was partially retargeted to the CD3 receptor by the UCHT1 scFv region of the blinding and retargeting recombinant protein. The GFP expression in the Nalm-6 cells transduced with WT VSIV-G and the blinding and retargeting recombinant protein with PEP-VL pseudoty ped lentivirus was lower than in the WT VSIV-G pseudotyped lentivirus but not quite as low as the VSIV-G-QQQ pseudotyped lentivirus, suggesting that the WT VSIV-G had strongly reduced binding to LDLR by PEP-VL induced trimerization. Without wishing to be bound by theory, the LDLR blinding of VSIV-G caused by binding the CR regions of the blinding and retargeting recombinant protein may be impacted by the size of the targeting domain, UCHT1, which is larger than the EGFml23 ligand. The GFP expression in the Jurkat cells transduced by WT VSIV-G and the blinding and retargeting recombinant protein with the PEP-VL oligomerizing peptide pseudotyped lentivirus was higher than in the VSIV-G-QQQ pseudoty ped lentivirus but not quite as high as in the WT VSIV-G pseudotyped lentivirus, suggesting that the anti-CD3 UCHT1 scFv retargeted the VSIV-G to bind CD3 and fuse with the cell.

[0487] The fold increase of GFP positive (GFP+) cell number in Jurkat cells (CD3+) compared to Nalm-6 cells (CD3-) that were transduced by lentivirus pseudotyped with WT VSIV-G and a blinding and retargeting recombinant protein was calculated (FIG. 6E). The fold increase was approximately 2 to 10 for blinding and retargeting recombinant proteins with the PEP-VL peptide and approximately 0 for blinding and retargeting recombinant proteins with the PEP-AA peptide. Consistent with the results for the blinding and retargeting recombinant proteins with EGFml23, these results suggest that trimers of the recombinant protein of the CR1, CR2, and CR3 regions, PEP-VL oligomerizing peptide, and UCHT1 scFv were able to reduce or abolish the LDLR binding of WT VSIV-G and retarget VSIV-G to CD3 receptors, while non-oligomerized recombinant proteins with PEP-AA were lessLeydig 775437Vyriad P-64-004104effective at blinding and retargeting VSIV-G. The centrifugation during transduction and the absence or inclusion of G4S or (G4S)x3 linkers in the recombinant protein between the targeting domain, oligomerizing peptide, and / or CR1, CR2, and CR3 regions did not seem to strongly impact transduction levels.EXAMPLE 3

[0488] This example demonstrates the development of expression vectors encoding recombinant proteins comprising an anti-CD3 scFv targeting domain, an oligomerization peptide, and one or more CR binding domains of LDLR that binds to VSIV-G and expression vectors encoding a recombinant VSIV-G, the use of these expression vectors to pseudotype lentivirus, and the specificity of lentivirus pseudotyped with trimers of the recombinant VSIV-G bound to one or more of the CR binding domains of LDLR fused to a trimerization peptide fused to an anti-CD3 scFv targeting domain.

[0489] To develop blinded and retargeted viral FMGs for pseudotyping membraned vesicles, constructs were designed using apCG-4MCll expression vector with sequences encoding the wild type VSIV-G (SEQ ID NO: 57) or VSIV-G-QQQ (SEQ ID NO: 68), and separate constructs were designed encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to a trimerization peptide derived from the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin fused to the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42, or fused directly to the UCHT1 scFv, and fused to a Flag tag (SEQ ID NO: 66) as shown in FIG. 7A. The constructs lacking the Foldon domain were used as controls to test the effect of induced oligomerization, specifically trimerization, in Foldon trimerization peptide containing constructs.

[0490] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1: 1 ratio a plasmid encoding a VSIV-G and a plasmid encoding the recombinant protein with the fused CR1, CR2, and CR3 regions or CR3 region alone of LDLR, with or without the Foldon trimerization peptide, and with the UCHT1 scFv. 72 hours post-transfection, virus was collected, clarified, and concentrated. 72 hours post-transfection for the lentivirus production, the cell lysates were collected and subjected to western blotting with anti-VSIV-G, anti-FLAG, and anti-GAPDH antibodies (FIG. 7B). The collected lentivirus particles were titered using p24 ELISA and quantified as shown in Table 4. The p24 ELISA was performedLeydig 775437Vyriad P-64-004105according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL).Table 4

[0491] To test the blinding and targeting efficacy of these constructs Jurkat cells, which express CD3, and Nalm-6 cells, which do not express CD3, were seeded at 50000 cells per well and transduced with 1000 lentiviral particles per cell and either not centrifuged or centrifuged at 2000 RPM for 30 minutes at 4 °C. Centrifugation improves contact between virus and cells and was tested to determine if transduction efficiency was improved. 72 hours post transduction plates were collected and fluorescence images were either taken by Nikon microscope with 10x objective lens and an exposure of 100 ms for the non-centrifuged cells (FIGS. 8A-8B) and for the centrifuged cells (FIGS. 8C-8D). Additional fluorescent images were taken by CELIGO for cytometry measurements for the non-centrifuged cells (FIGS. 9A-9B) and for the centrifuged cells (FIGS. 9C-9D).

[0492] The WT VSIV-G pseudoty ped lentivirus transduced high levels of GFP expression in both Jurkat cells (CD3+) and Nalm-6 cells (CD3-), while the VSIV-G-QQQ pseudotyped lentivirus transduced low levels of GFP expression in both Jurkat cells and Nalm-6 cells, indicating that WT VSIV-G pseudotyped lentiviruses can effectively transduce both Jurkat and Nalm-6 cells while the VSIV-G-QQQ pseudotyped lentiviruses, with reduced or abolished LDLR binding, cannot effectively transduce Jurkat and Nalm-6 cells. The lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins with CR1, CR2, and CR3 region fused to the anti-CD3 scFv UCHT1 without any trimerizing peptide showed strong GFP expression in both Jurkat cells and Nalm-6 cells and the lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins with just CR3 region fused to the anti-CD3Leydig 775437Vyriad P-64-004106scFv UCHT1 without any oligomerizing peptide showed even higher GFP expression in Jurkat cells and Nalm-6 cells. A comparison of the GFP expression in Jurkat cells and Nalm-6 cells transduced by the VSIV-G-QQQ pseudotyped lentivirus, WT VSIV-G pseudotyped lenti virus, and those transduced with WT VSIV-G and the blinding and retargeting recombinant protein without the Foldon trimerizing peptide pseudotyped lentivirus suggest that WT VSIV-G binding to LDLR was partially reduced by the CR1, CR2, and CR3 regions of the blinding and retargeting recombinant protein and less reduced by the CR3 region alone. The GFP expression in the Nalm-6 cells transduced with WT VSIV-G and the blinding and retargeting recombinant protein with CR1, CR2, and CR3 and Foldon trimerizing peptide pseudotyped lentivirus was much lower than in the WT VSIV-G pseudotyped lentivirus but not quite as low as the VSIV-G-QQQ pseudotyped lentivirus and the GFP expression in the Nalm-6 cells transduced with WT VSIV-G and the blinding and retargeting recombinant protein with CR3 and Foldon trimerizing peptide pseudotyped lentivirus was lower than in the WT VSIV-G pseudotyped lentivirus but not as low as the VSIV-G-QQQ pseudotyped lentivirus, suggesting that the CR1, CR2, and CR3 region of the recombinant strongly reduced LDLR binding of WT VSIV-G and the CR3 region of the recombinant protein also reduces LDLR binding of WT VSIV-G, but not as strongly as CR1, CR2, and CR3 together. A comparison of the GFP expression in Jurkat cells transduced by the VSIV-G-QQQ pseudotyped lentivirus, the WT VSIV-G pseudotyped lentivirus alone, and those transduced with WT VSIV-G and the blinding and retargeting recombinant protein with a Foldon trimerizing peptide with either CR1, CR2, and CR3 or just CR3 suggest that WT VSIV-G was partially retargeted to the CD3 receptor by the UCHT1 scFv region of the blinding and retargeting recombinant protein. The GFP expression in the Jurkat cells transduced by WT VSIV-G and the blinding and retargeting recombinant protein with the Foldon trimerizing peptide pseudotyped lentivirus was higher than in the VSIV-G-QQQ pseudotyped lentivirus but not quite as high as in the WT VSIV-G pseudotyped lentivirus for recombinant protein with CR1, CR2, and CR3, but comparably higher for recombinant protein with just CR3, suggesting that the anti-CD3 UCHT1 scFv retargeted the VSIV-G to bind CD3 and fuse with the cell, but the blinding and retargeting recombinant protein with just the CR3 region had increased transduction because LDLR binding was not reduced as much as with CR1, CR2, and CR3.

[0493] The fold increase of GFP positive (GFP+) cell number in Jurkat cells (CD3+) compared to Nalm-6 cells (CD3-) that were transduced by lentivirus pseudotyped with WTLeydig 775437Vyriad P-64-004107VSIV-G and a blinding and retargeting recombinant protein (FIG. 9E). The fold increase was approximately 2 to 30 for blinding and retargeting recombinant proteins with the Foldon peptide and approximately 0 for blinding and retargeting recombinant proteins without the Foldon peptide. The reduced LDLR binding and in the recombinant proteins with the Foldon trimerizing peptide compared to the recombinant protein without the Foldon trimerizing peptide suggests that trimers of the recombinant protein of the CR1, CR2, and CR3 or just CR3 regions, Foldon trimerizing peptide, and UCHT1 scFv were able to reduce or abolish the LDLR binding of WT VSIV-G and retarget VSIV-G to CD3 receptors, while nonoligomerized recombinant proteins without an oligomerizing peptide were less effective at blinding and retargeting VSIV-G. The fold increase was higher for blinding and retargeting recombinant proteins with no linker between the UCHT1 scFv and the Foldon peptide compared to those with a linker, approximately 30 for the no linker recombinant protein compared to approximately 3-4 for the linker recombinant proteins with CR123 and approximately 5 for the no linker recombinant protein compared to approximately 2 for the tinker recombinant proteins with CR3. Unlike Examples 2 and 3 with the GCN4 derived PEP-VL, absence of the G4S or (G4S)x3 linkers between the Foldon trimerizing peptide and the targeting domain showed reduced background infection on the Nalm-6 cells and increase in linker length increased the background infection suggesting the linker length or not having a linker has a strong impact on the VSIV-G masking to LDLR blinding. Without wishing to be bound by theory, these results suggest that the addition of linkers may impact the function of the Foldon peptide, possibly by impacting the folding of the Foldon peptide. The centrifugation during transduction regions did not seem to strongly impact transduction levels.

[0494] To determine if the blinding and retargeting recombinant proteins bind to the surface of the lentivirus nanoparticle tracking analysis (NTA) was performed. Total particle concentration was determined by NTA using scatter mode on a Particle Metrix ZetaView x30 TWIN. The total particle concentration consisted of particles >60nm (based on silica beads), including both lentiviral and non-lentiviral particles. To analyze particles with protein markers of interest, the lentiviral preparation were then stained for fluorescent NTA (fNTA) using fluorescently conjugated antibodies to either the VSIV-G or the Flag-tag epitope on the LDLR masking protein, independently. Concentrations were then determined using the ZetaView x30 TWIN in fluorescent mode for each marker (FIG. 10A). For all three analyses, 11 -positions were analyzed and statistically analyzed by Particle Explorer Software. InLeydig 775437Vyriad P-64-004108addition to concentration, the particle diameter for each particle analyzed was determined by the ZetaView x30 TWIN and a histogram distribution for each sample was provided. This was performed in both scatter and fluorescent modes of the instrument. The particle size at the peak / mode of the distribution for each sample was graphed (FIG. 10B). These values should be representative of the lentiviral particles, especially with fluorescent staining, as the lentiviral particles should be the most abundant particle in the preparation.EXAMPLE 4

[0495] This example demonstrates the efficacy of expression vectors encoding recombinant proteins comprising an anti-CD3 scFv targeting domain, an oligomerization peptide, and one or more CR binding domains of LDLR that binds to VSIV-G and expression vectors encoding a recombinant VSIV-G for pseudotyping lentivirus. and the specificity of lenti virus pseudotyped with trimers of the recombinant VSIV-G bound to one or more of the CR binding domains of LDLR fused to a trimerization peptide fused to an anti-CD3 scFv targeting domain.

[0496] To further test the efficacy of blinded and retargeted viral FMGs for pseudotyping membraned vesicles, constructs were used with a pCG-4MC11 expression vector with sequences encoding the wild type VSIV-G (SEQ ID NO: 57), VSIV-G-QQQ (SEQ ID NO: 68), VSIV-G-dK47 (SEQ ID NO: 104), or the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42 fused to VSIV-G-dK47 and separate constructs were designed encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, either fused to an oligomerization peptide derived from the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin or an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26)) fused to the anti-CD3 scFv UCHT1, or fused directly to the UCHT1 scFv, and fused to a Flag tag (SEQ ID NO: 66) as shown in FIG. 11 A. The construct lacking an oligomerization peptide domain was used as a control to test the effect of induced oligomerization, specifically trimerization, in Foldon peptide and helical peptide VL containing constructs.

[0497] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1:1 ratio a plasmid encoding a VSIV-G and a plasmid encoding the recombinant protein with the fused CR1, CR2, and CR3 regions or CR3 region alone of LDLR, with or withoutLeydig 775437Vyriad P-64-004109the Foldon or helical peptide VL oligomerization peptide, and with the UCHT1 scFv. 72 hours post-transfection, virus was collected, clarified, and concentrated. 72 hours posttransfection for the lentivirus production, lentivirus particles were collected and titered using p24 ELISA and quantified as shown in Table 5 and FIG. 1 IB. The p24 ELISA was performed according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL).Table 5

[0498] To determine if the blinding and retargeting recombinant proteins bind to the surface of the lentivirus nanoparticle tracking analysis (NTA) was performed. Total particle concentration was determined by NTA using scatter mode on a Particle Metrix ZetaView x30 TWIN. The total particle concentration consisted of particles >60nm (based on silica beads), including both lentiviral and non-lentiviral particles. To analyze particles with protein markers of interest, the lentiviral preparation were then stained for fluorescent NTA (fNTA) using fluorescently conjugated antibodies to either the VSIV-G or the Flag-tag epitope on theLeydig 775437Vyriad P-64-004110LDLR masking protein, independently. Concentrations were then determined using the ZetaView x30 TWIN in fluorescent mode for each marker (FIG. 11 C). For all three analyses, 11-positions were analyzed and statistically analyzed by Particle Explorer Software.

[0499] To test the blinding and targeting efficacy of these constructs Jurkat cells (CD3+ / LDLR+). Nalm-6 cells (CD3- / LDLR+), Jurkat cells with low density lipoprotein receptor knocked out (LDLR-KO) (CD3+ / LDLR-), and Jurkat cells with T cell receptor knocked out (TCR-KO), which have low levels of CD3 expression (Low CD3 / LDLR+ / TCR-), were seeded at 50000 cells per well and transduced with 1000 lentiviral particles per cell and either not centrifuged or centrifuged at 2000 RPM for 30 minutes at 22 °C.Centrifugation improves contact between virus and cells and was tested to determine if transduction efficiency was improved. 72 hours post transduction plates were collected and fluorescence images were either taken by Nikon microscope with 10x objective lens and an exposure of 100 ms for the for the centrifuged cells (FIGS. 12A-12D) and non-centrifuged cells (FIGS. 13A-13D). Additional fluorescent images were taken by CELIGO for cytometry measurements for the centrifuged cells (FIGS. 14A-14D) and non-centrifuged cells (FIGS.15A-15D). The number of GFP+ Jurkat and Nalm-6 cells were quantified in bar graphs for the centrifuged cells (FIG. 16A) and non-centrifuged cells (FIGS. 16B).

[0500] The WT VSIV-G pseudotyped lentivirus transduced high levels of GFP expression in Jurkat cells (CD3+ / LDLR+), Nalm-6 cells (CD3- / LDLR+), TCR-KO Jurkat cells, and LDLR-KO Jurkat cells (CD3+ / LDLR-) while the VSIV-G-QQQ pseudotyped lentivirus transduced low levels of GFP expression in Jurkat, Nalm-6, TCR-KO, and LDLR-KO Jurkat cells indicating that WT VSIV-G pseudotyped lenti viruses can effectively transduce Jurkat. Nalm-6, TCR-KO. and LDLR-KO Jurkat cells while the VSIV-G-QQQ pseudotyped lentiviruses, with reduced or abolished LDLR binding, cannot effectively transduce Jurkat, Nalm-6, TCR-KO, and LDLR-KO Jurkat cells. The ability of WT VSIV-G pseudotyped lentiviruses to effectively transduce LDLR-KO Jurkat cells suggest that WT VSIV-G is able to bind another natural receptor besides LDLR. The lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins containing the anti-CD3 scFv UCHT1 and CR3 of LDLR but no oligomerizing peptide (UCHT1-(G4S)3-CR3) showed transduction in both Jurkat cells and Nalm-6 cells, suggesting these pseudotyped lentiviruses are still capable of binding LDLR. Without wishing to be bound by theory, these results could suggest that some of the WT VSIV-G pseudotyping the lentiviruses are bound to the recombinant protein UCHT1-(G4S)3-CR3 and some are unbound, which could allow these pseudotypedLeydig 775437Vyriad P-64-004I lllentiviruses to bind cells with both LDLR and CD3 receptors. All the lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins containing the anti-CD3 scFv UCHT1, an oligomerizing peptide, and CR123 or CR3 of LDLR showed high levels of transduction in Jurkat cells and low or no transduction in Nalm-6 cells, suggesting these pseudotyped lentiviruses have reduced or abolished LDLR binding and are efficiently retargeted to cells with CD3 receptors.

[0501] The fold increase of GFP positive (GFP+) cell number in Jurkat cells (CD3+) compared to Nalm-6 cells (CD3-) that were transduced by lentivirus pseudotyped with WT VSIV-G and a blinding and retargeting recombinant protein was quantified (FIG. 16C). All the blinding and retargeting recombinant proteins with the Foldon or helical peptide VL oligomerizing peptides demonstrated a fold increase of at least 12. The blinding and retargeting recombinant proteins with the helical peptide VL that demonstrated with the greatest fold increase was the recombinant protein with (G4S)3 linkers between both the targeting domain UCHT1 and the helical peptide VL and between the helical peptide VL and the CR123 regions, both when centrifuged during transduction (886 fold increase) and not centrifuged during transduction (186 fold increase).

[0502] To test the role of the concentration of the lentiviral particles of these constructs Jurkat cells (CD3+ / LDLR+) and Nalm-6 cells (CD3- / LDLR+) were seeded at 50000 cells per well and transduced with 100, 50, 25, 12.5 6.25. or 3.1 VSIV-G-WT pseudotyped lentiviral particles per cell as a control or 1000, 500, 250, 125, 62.5, or 31 lentiviral particles per cell and centrifuged at 2000 RPM for 30 minutes at 22 °C. 72 hours post transduction plates were collected and fluorescence images were either taken by Nikon microscope with 10x objective lens and an exposure of 80 ms (FIGS. 17A-17H). Additional fluorescent images were taken by CELIGO for cytometry measurements (FIGS. 18A-18H). The number of GFP+ Jurkat and Nalm-6 cells were quantified in bar graphs (FIG. 19).

[0503] To test the blinding and targeting efficacy of helical peptide VL containing constructs in different cell types Jurkat cells (CD3+ / moderate LDLR expression); Nalm-6 cells (CD3- / moderate LDLR expression); K.-562 cells, derived from myeloid leukemia (CD3- / moderate LDLR expression); Skov-3 cells, derived from ovarian carcinoma (CD3- / high LDLR expression), A-549 cells, derived from lung adenocarcinoma (CD3- / high LDLR expression); HT1080 cells, derived from fibrosarcoma (CD3- / moderate to high LDLR expression); HEK293 cells, derived from embryonic kidney (CD3- / high LDLR expression); and PC3 cells, derived from prostate carcinoma (CD3- / high LDLR expression) wereLeydig 775437Vyriad P-64-004112transduced with lentivirus pseudotyped with WT VSIV-G and a blinding and retargeting recombinant protein containing helical peptide VL. Transduction efficiency was calculated based on the percentage of GFP+ cells as show n in Table 6 and FIG. 20.Table 6

[0504] These results demonstrate that the lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins containing the anti-CD3 scFv UCHT1, VL helical peptide, and CR123 of LDLR were able to transduce multiple cell ty pes, showing efficient transduction in A549, HEK293, HT1080 and PC3 cells. Additionally, the lentiviruses with WT VSIV-G and the recombinant proteins containing UCHT1, VL helical peptide, and CR123 showed decreased transduction efficiency compared to the lentivirus with WT VISV-G alone, suggesting the recombinant proteins recombinant proteins containing UCHT1, VL helical peptide, and CR123 were able to reduce binding of the WT VSOV-G to LDLR. Without wishing to be bound by theory, these results may be due to the different expression level ofLeydig 775437Vyriad P-64-004113LDLR receptors, their isotypes, and different LDLR family members present in the cell surface of these cell types that could contribute to effective binding and transduction while still reducing the binding of WT VSIV-G to LDLR. For cell lines including K-562, Skov3 and Nalm-6, the transduction efficiency of the lentiviruses with WT VSIV-G and the recombinant proteins containing UCHT1, VL helical peptide, and CR123 was much lower compared to the lentivirus with WT VISV-G alone, suggesting the binding to LDLR of the WT-VSIV-G was strongly reduced or abolished by the recombinant proteins.EXAMPLE 5

[0505] This example demonstrates the development of expression vectors encoding recombinant proteins comprising one or more CR binding domains of LDLR that binds to VSIV-G, an oligomerization peptide, and an anti-CD3 to anti-T cell receptor (TCR) nanobody targeting domain and expression vectors encoding a recombinant VSIV-G, the use of these expression vectors to pseudotype lentivirus, and the specificity of lentivirus pseudoty ped VSIV-G bound to one or more of recombinant proteins of the CR binding domains of LDLR fused to an oligomerization peptide fused to an anti-CD3 or anti-TCR nanobody targeting domain.

[0506] To develop blinded and retargeted viral FMGs for pseudotyping membraned vesicles, constructs were designed using apCG-4MCll expression vector with sequences encoding the wild type VSIV-G (SEQ ID NO: 57) and separate constructs were designed encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1, CR2. and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR or just the CR3 (SEQ ID NO: 3) of LDLR, fused directly or by a (G4S)3 linker to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26) or an oligomerization peptide derived from the C-terminal Foldon domain (SEQ ID NO: 28) of T4 fibritin, and fused directly or by a (G4S)3 linker or G4S linker to the anti-CD3 epsilon nanobody (VHH-3-aCD3E) (SEQ ID NO: 102) or an anti-TCR nanobody (VHH 9-aTCR) (SEQ ID NO: 103), and fused by a GSGGSG linker (SEQ ID NO: 10) to a FLAG tag (SEQ ID NO: 66) as show n in FIGS. 21A-21B.

[0507] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1: 1 ratio a plasmid encoding WT VSIV-G and a plasmid encoding the recombinant protein with the fused CR1, CR2, and CR3 regions or CR3 region alone of LDLR, the helicalLeydig 775437Vyriad P-64-004114VL oligomerization peptide, the anti-CD3 nanobody VHH-3-aCD3E or the anti-TCR nanobody VHH 9-aTCR, and FLAG tag. 72 hours post-transfection, virus was collected, clarified, and concentrated. 72 hours post-transfection for the lentivirus production, the cell lysates and virion pellets were collected and subjected to western blotting with anti-VSIV-G, anti-FLAG, and anti-p24 antibodies (FIGS. 22A-22B). The collected lentivirus particles were titered using p24 ELISA and quantified as shown in Table 7. The p24 ELISA was performed according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL). The collected lentivirus particles also underwent a sandwich ELISA assay using an anti-VSIV-G antibody as the capture antibody and an anti-FLAG antibody for detection to confirm the presence of complexes of VSIV-G and recombinant protein containing a CR123 or CR3, helical VL or Foldon oligomerization peptide, anti-CD3 or anti-TCR nanobody, and FLAG tag at 1:30, 1:90, and 1:270 dilutions (FIG. 25B). These results demonstrated that all the tested recombinant proteins formed complexes with the VSIV-G pseudotyping lentivirus, suggesting the CR123 of the recombinant protein and the VSIV-G pseudotyping lentivirus are binding.Table 7Leydig 775437Vyriad P-64-004115

[0508] To test the blinding and targeting efficacy of these constructs Jurkat cells (CD3+ / LDLR+), Nalm-6 cells (CD3- / LDLR+), LDLR-KO Jurkat cells (CD3+ / LDLR-), and TCR-KO Jurkat cells (Low CD3 / LDLR+ / TCR-), were seeded at 50000 cells per well and transduced with 1000 lentiviral particles per cell and centrifuged at 2000 RPM for 30 minutes at 4 °C. 72 hours post transduction plates were collected and fluorescence images were taken by Nikon microscope with 10x objective lens and an exposure of 100 ms (FIGS. 23A-23D). Additional fluorescent images were taken by CELIGO for cytometry measurements (FIGS.24A-24D) and quantified in a bar graph (FIG. 25A).

[0509] The WT VSIV-G pseudotyped lentivirus transduced a GFP expression in a large number of Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, and TCR-KO Jurkat cells indicating that WT VSIV-G pseudotyped lentiviruses can effectively transduce Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, and TCR-KO Jurkat cells. The lentiviruses pseudotyped with WT VSIV-G and the recombinant proteins with CR123, helical VL peptide and the anti-CD3 scFv UCHT1 transduced a large number of Jurkat cells (approximately 21,000) and LDLR-KO Jurkat cells (approximately 34,000), fewer TCR-KO Jurkat cells (approximately 2,800) and very few Nalm-6 cells (approximately 55), suggesting that the recombinant protein is able to at least partially blind the VSIV-G binding to LDLR and retarget the binding to CD3. The lentiviruses pseudo typed with WT VSIV-G and the recombinant proteins with CR123, helical VL peptide and the anti-TCR nanobody VHH9-aTCR ((VHH9-aTCR)-(G4S)3-VL PEP-(G4S)3-CR123) transduced a larger number of Jurkat cells compared to Nalm-6 cells, suggesting that the recombinant protein is able to at least partially blind the VSIV-G binding to LDLR and retarget the binding to CD3. Without wishing to be bound by theory, the ELISA results demonstrated that WT-VSIV-G and the CR123 of the recombinant proteins bind well suggesting the lower levels of transduction may be due to lower affinity of the nanobody targeting domains compared to the scFv targeting domains.EXAMPLE 6

[0510] This example demonstrates the development of expression vectors encoding recombinant proteins comprising a targeting domain, an oligomerization peptide, and a binding domain of a receptor protein that binds to a viral FMG and expression vectors encoding a recombinant viral FMG, the use of these expression vectors to pseudotype lentivirus, and the specificity of lentivirus pseudotyped with trimers of the recombinant viralLeydig 775437Vyriad P-64-004116FMG bound to the binding domain of a receptor protein fused to an oligomerization peptide fused to a targeting domain.

[0511] To develop blinded and retargeted viral FMGs for pseudotyping membraned vesicles, constructs were designed using apCG-4MCll expression vector with sequences encoding the wild type G glycoprotein of the rhabdovirus Vesiculovirus indiana (VSIV-G-WT) (SEQ ID NO: 57), and separate constructs were designed encoding the signal peptide of IgGk (SEQ ID NO: 5) fused to the CR1 and two copies of the CR3 (SEQ ID NOs: 1 and 3) of LDLR, fused to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL), hCollagen XIX NC2, hCollagen XV NCI, or hCollagen XVIII NCI. fused to the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42 fused to a Flag tag (SEQ ID NO: 66) as shown in FIGS. 26A-26B. PEP-VL variant constructs were designed with 0-8 heptad repeats (SEQ ID NOS128-135), with a “trimmed"’ variant of PEP-VL with the first three amnio acid residues at the N-terminal and the last five amino acids of the C-terminal of the 4 heptad repeat removed (SEQ ID NO: 139), and an untargeted control with a 4 heptad repeat and no UCHT1 scFv.

[0512] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1: 1 ratio of a plasmid encoding a VSIV-G and a plasmid encoding the recombinant protein with the fused CR1+CR3+ CR3 regions of LDLR, oligomerizing peptide PEP-VL hCollagen XIX NC2, hCollagen XV NCI, or hCollagen XVIII NCI, and the UCHTl scFv.72 hours post-transfection, virus was collected, clarified, and concentrated. 72 hours posttransfection for the lentivirus production, the cell lysates (FIG. 26C-26D) were collected and subjected to western blotting with anti-VSIV-G, anti-FLAG, and anti-GAPDH antibodies and the virion pellets (FIGS. 26-E-26F) were collected and subjected to western blotting with anti-VSIV-G, anti-FLAG, and anti-p24 antibodies. The collected lentivirus particles were titered using p24 ELISA and quantified as shown in Table 8. The p24 ELISA was performed according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL). The western blot of the cell lysates indicated that the VSIV-G and CAP proteins were expressed and the western blot of the virion pellets indicates VSIV-G and CAP proteins were incorporated into the virion.Leydig 775437Vyriad P-64-004117Table 8

[0513] To test the blinding and targeting efficacy of these constructs Jurkat cells (CD3+ / LDLR+). Nalm-6 cells (CD3- / LDLR+), LDLR-KO Jurkat cells (CD3+ / LDLR-), and TCR-KO Jurkat cells (Low CD3 / LDLR+ / TCR-), were transduced as in Example 4. 4 days post transduction plates were collected and fluorescence images were taken. 4 days post transduction samples were collected for flow cy tometry’ and flow analysis was performed measuring the percent of GFP positive cells as quantified in Table 9 and shown in Figure 26G.Table 9. Flow data (% GFP cells) for different VL pep variants LVs - Day 4Leydig 775437Vyriad P-64-004119

[0514] The WT VSIV-G pseudotyped lentivirus with no CAP transduced GFP expression in a large number of Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, and TCR-KO Jurkat cells indicating that WT VSIV-G pseudotyped lentiviruses can effectively transduce Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, and TCR-KO Jurkat cells. The WT VSIV-G pseudotyped lentivirus with the untargeted CAP transduced low to no GFP expression in Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, and TCR-KO Jurkat cells suggesting that the CAP protein was able to blind the VSIV-G binding to LDLR. The WT VSIV-G pseudotyped lentivirus with the PEP-VL CAPs containing less than 4 complete heptad repeats (0-3 hpt and the trimmed 4 hpt) transduced GFP expression in Jurkat cells, Nalm-6 cells, LDLR-KO Jurkat cells, and TCR-KO Jurkat cells while those with the PEP-VL CAPs containing 4 or more heptad repeats (4-8 hpt) transduced GFP expression in Jurkat cells and Nalm-6 cells, but low to no GFP expression in LDLR-KO Jurkat cells and TCR-KO Jurkat cells suggesting that at least 4 heptad repeats are important to blind the VSIV-G binding to LDLR. The WT VSIV-G pseudotyped lentivirus with the hCollagen XIX NC2, hCollagen XV NCI, or hCollagen XVIII NCI CAPs transduced GFP expression in Jurkat cells and Nalm-6 cells, but low to no GFP expression in LDLR-KO Jurkat cells and TCR-KO Jurkat cells suggesting that all the hCollagen CAPs were able to at least partially blind the VSIV-G binding to LDLR and retarget the binding to CD3.EXAMPLE 7

[0515] This example demonstrates the role of the ratio of expression vectors encoding recombinant proteins comprising an anti-CD3 scFv targeting domain, an oligomerization peptide, and one or more CR binding domains of LDLR that binds to VSIV-G to expression vectors encoding a recombinant VSIV-G in pseudotyping lentivirus, the role of the ratio of these constructs in transduction efficiency of the pseudotyped lentivirus, and the role of different concentration methods and centrifugation of the pseudotyped lentivirus with the cells to be transduced in transduction efficiency.

[0516] To determine the role of the ratio of expression vectors encoding recombinant proteins comprising an anti-CD3 scFv targeting domain, an oligomerization peptide, and one or more CR binding domains of LDLR that binds to VSIV-G to expression vectors encoding a recombinant VSIV-G in pseudotyping lentivirus and transduction efficiency of the pseudotyped lentivirus, constructs were used with apCG-4MCll expression vector with sequences encoding the wild type VSIV-G (SEQ ID NO: 57), VSIV-G with a single deletionLeydig 775437Vyriad P-64-004120at residue K47 (VSIV-dK47 or VSIV-AK47) (SEQ ID NO: 104) to reduce or abolish binding to LDLR, VSIV-dK47 fused to the anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 41 and a VL of SEQ ID NO: 42, and a recombinant protein of CR1, CR2, and CR3 (SEQ ID NOs: 1, 2, and 3) of LDLR, fused to an oligomerization peptide derived from the GCN4 leucine / isoleucine zipper peptide (helical peptide VL (PEP-VL) (SEQ ID NO: 26) by a (G4S)3 linker, fused to the anti-CD3 scFv UCHT1 by a G4S linker (UCHT1-G4S-VL PEP-(G4S)3-CR123).

[0517] To produce lentiviruses, HEK-293T packaging cells were transfected with a packaging plasmid, a plasmid encoding an EGFP expression cassette (SEQ ID NO: 67), and at a 1:0, 10:1, 5:1, 3:1. 1:1, 1:3, 1:5, or 1:10 ratio aplasmid encoding UCHT1-G4S-VL PEP-(G4S)3-CR123 and a plasmid encoding WT VSIV-G, with a total amount of 3 pg of plasmid DNA as shown in FIG. 27A. 72 hours post-transfection, virus was collected, clarified, and concentrated using either polyethylene glycol (PEG 8000) or ultracentrifugation. 72 hours post-transfection for the lentivirus production, the cell lysates and concentrated virion pellets were collected and subjected to western blotting with anti-VSIV-G, anti-FLAG, and anti-p24 antibodies (FIGS. 27B-27C). The collected lentivirus particles concentrated by PEG 8000 or ultracentrifugation were titered using p24 ELISA and quantified as shown in Table 10. The p24 ELISA was performed according to the manufacturer’s instructions and the p24 levels were quantified as viral particles per mL (VP / mL).Leydig 775437Vyriad P-64-004121Table 10

[0518] The PEG 8000 concentrated lentivirus particles collected at 72 hours posttransfection also underwent a sandwich ELISA assay using an anti-VSIV-G antibody as the capture antibody and an anti-FLAG antibody for detection to confirm the presence of complexes of VSIV-G and recombinant protein containing a CR123 or CR3, helical VL or Foldon oligomerization peptide, anti-CD3 or anti-TCR nanobody, and FLAG tag at 1:30 and 1:90 dilutions, as shown in Table 11 and FIG. 27D. These results demonstrated that all the tested recombinant proteins formed complexes with the VSIV-G pseudotyping the lentivirus, suggesting the CR123 of the recombinant protein and the ...

Claims

Leydig 775437Vyriad P-64-004460CLAIMS:

1. A recombinant protein system comprising:I) a first recombinant protein comprising a viral fusogenic membrane glycoprotein (FMG) or a functional fragment or derivative thereof,II) a second recombinant protein comprising (a) a targeting domain and (b) an oligomerization domain.

2. The recombinant protein system of claim 1, wherein the second recombinant protein comprises: (c)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with the viral FMG or a functional fragment or derivative thereof of the first recombinant protein, andwherein the viral FMG or functional fragment or derivative thereof of the first recombinant protein is capable of binding to or interacting with the binding domain of the receptor protein of the second recombinant protein; or(c)(2) an antigen binding domain, wherein the antigen binding domain specifically binds the viral FMG or functional fragment or derivative thereof of the first recombinant protein.

3. The recombinant protein system of claim 2, wherein the second recombinant protein comprises (c)(1). and wherein the binding of the first recombinant protein is reduced or abolished for a binding domain of a receptor protein that is a separate binding domain from the binding domain of the receptor protein of the second recombinant protein.

4. The recombinant protein system of claim 1, wherein the second recombinant protein comprises (c)(2).

5. The recombinant protein system of claim 4, wherein the antigen binding domain is a single chain variable fragment (scFv).

6. The recombinant protein system of claim 4 or 5, wherein binding of the antigen binding domain does not interfere with the fusion capability of the viral FMG or functional fragment or derivative thereof of the first recombinant protein.Leydig 775437Vyriad P-64-0044617. The recombinant protein system of any one of claims 1-6. wherein the viral FMG or functional fragment or derivative thereof is of a Nipah virus (NiV) G glycoprotein, rhabdo viral G glycoprotein, a SARS-CoV-2 Spike (S) glycoprotein, a HIV-1 Envelope glycoprotein, an influenza hemagglutinin (HA) glycoprotein, an Ebola virus glycoprotein, a Hepatitis C virus (HCV) envelope 2 (E2) glycoprotein, a Machupo virus (MACV) spike glycoprotein (GP1), a Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein, a virulent canine distemper virus (CDV) hemagglutinin (H) glycoprotein, or a rabies virus (RABV) G glycoprotein.

8. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a SARS-CoV-2 Spike glycoprotein comprising an S 1 and S2 subunit, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of an angiotensinconverting enzyme 2 (ACE2).

9. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of aHIV-1 Envelope glycoprotein, and wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of (i) a CD4 receptor and (ii) a CCR5 receptor or a CXCR4 receptor.

10. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of an influenza hemagglutinin (HA) glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a glycan receptor comprising a sialic acid residue.

11. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of an Ebola virus glycoprotein, andLeydig 775437Vyriad P-64-004462wherein the second recombinant protein comprises (c)(1). and wherein the binding domain of the receptor protein of the second recombinant protein is of a Niemann-Pick Cl protein (NPC1).

12. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Hepatitis C virus (HCV) E2 glycoprotein, andwherein the second recombinant protein comprises (c)(1). and wherein the binding domain of the receptor protein of the second recombinant protein is of a CD81 receptor.

13. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Machupo virus glycoprotein, and wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a human transferrin receptor 1 (TfRl).

14. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Sendai virus hemagglutininneuraminidase (HN) glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a glycan receptor comprising a sialic acid residue.

15. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a SLAM-binding ablated virulent canine distemper virus (CDV) hemagglutinin (H) glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of aNectin-4 protein.

16. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a rabies virus (RABV) G glycoprotein, andLeydig 775437Vyriad P-64-004463wherein the second recombinant protein comprises (c)(1). and wherein the binding domain of the receptor protein of the second recombinant protein is of a nicotinic acetylcholine receptor (nAChR), neural cell adhesion molecule (NCAM), p75 neurotrophin receptor, metabotropic glutamate receptor subtype 2 (mGluR2), or integrin pi.

17. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a Nipah virus (NiV) G glycoprotein, andwherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein is of a ephrin-B2 (EFNB2) receptor or ephrin-B3 (EFNB3) receptor.

18. The recombinant protein system of any one of claims 1-7, wherein the viral FMG or functional fragment or derivative thereof is of a rhabdoviral G glycoprotein, and wherein the second recombinant protein comprises (c)(1). and wherein the binding domain of the receptor protein of the second recombinant protein is of a cysteine rich region of a low density lipoprotein receptor (LDLR).

19. The recombinant protein system of any one of claims 2-18, wherein the (c)(1) or (c)(2) is N terminal to the oligomerization domain, optionally wherein the oligomerization domain is N terminal to the targeting domain.

20. The recombinant protein system of any one of claims 1-19, wherein the second recombinant protein comprises a signal peptide.

21. The recombinant protein sy stem of claim 20, wherein the signal peptide comprises an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 59.

22. The recombinant protein system of claim 1, comprising one or more linkers.

23. The recombinant protein system of any one of claims 2-21, comprising one or more linkers.

24. The recombinant protein system of claim 23, wherein the oligomerization domain is N terminal to the targeting domain in the second recombinant protein and whereinLeydig 775437Vyriad P-64-004464the second recombinant protein comprises one or more linkers between (A) the (c)(1) or (c)(2) and the oligomerization domain, (B) the oligomerization domain and the targeting domain, or (C) between both (A) and (B).

25. The recombinant protein system of any one of claims 22-24, wherein the one or more linkers is flexible.

26. The recombinant protein system of claim 25, wherein the one or more linkers is(GGGGS) (SEQ ID NO: 6),GGGGSGGGGS (SEQ ID NO: 7).GGGGSGGGGSGGGGS (SEQ ID NO: 8),GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 9).GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 60),GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 61),GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 62),GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 63),GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 64),GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS(SEQ ID NO: 65),GSGGSG(SEQ ID NO: 10),GGGGGG (SEQ ID NO: 11),GGGGGGGG (SEQ ID NO: 12),VPGVGVPGVG (SEQ ID NO: 13),Leydig 775437Vyriad P-64-004465GSAGSAAGSGEF (SEQ ID NO: 14).AAASGGSGGGGSGGGGS (SEQ ID NO: 15), or AAASGGSGGGGSGGGGSGP (SEQ ID NO: 16).

27. The recombinant protein system of any one of claims 22-24, wherein the one or more linkers is rigid.

28. The recombinant protein system of claim 27, wherein the linker is PAPAP (SEQ ID NO: 17),EAAAKEAAAKEAAAK (SEQ ID NO: 18),EAAAKEAAAK (SEQ ID NO: 19),EAAAK (SEQ ID NO: 20), AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAAKA (SEQ ID NO: 21),AEAAAKEAAAKA (SEQ ID NO: 22),ESKYGPPCPPCP (SEQ ID NO: 23),CPPCPAPELLGGPSVF (SEQ ID NO: 24), andalanine-proline (AP) repeated for a total of 10 to 34 amino acids (SEQ ID NO: 25).

29. The recombinant protein sy stem of any one of claims 1-28, comprising a tag for western detection or purification, optionally located at the C-terminus of the second recombinant protein.

30. The recombinant protein sy stem of claim 29, wherein the tag is a tag for western detection.

31. The recombinant protein system of claim 29, wherein the tag is a tag for purification.Leydig 775437Vyriad P-64-00446632. The recombinant protein system of any one of claims 29-31, wherein the tag is located at the C-terminus of the second recombinant protein, comprising a linker between the tag and the targeting domain.

33. The recombinant protein system of claim 32, wherein the linker between the tag and the targeting domain is GSGGSG (SEQ ID NO: 10).

34. The recombinant protein system of any one of claims 1-33, wherein the oligomerization domain comprises:a variant of the GCN4 leucine / isoleucine zipper peptide with systematic isoleucine substitutions in the a and d positions of the heptad repeat comprising the amino acid sequence of SEQ ID NO: 27,a variant of the GCN4 leucine / isoleucine zipper peptide with systematic valine and leucine substitutions in the a and d positions respectively of the heptad repeat comprising the amino acid sequence of SEQ ID NO: 26,a C-tenninal Foldon domain of a T4 fibritin (Foldon) comprising the amino acid sequence of SEQ ID NO: 28,a de novo designed trimeric coiled-coil peptide comprising the amino acid sequence of SEQ ID NO: 29,a laminin a2 chain C-terminal domain comprising the amino acid sequence of SEQ ID NO: 30,a collagen triple helix motif comprising the amino acid sequence of SEQ ID NO: 31, a self-assembling β-sheet-rich peptide comprising the amino acid sequence of SEQ ID NO: 32,a coiled-coil heptad repeat region of a HA2 subunit of an Influenza hemagglutinin glycoprotein,a collagen XV derived non-collagenous C-terminal domain (NCI) comprising the amino acid sequence of SEQ ID NO: 33,Leydig 775437Vyriad P-64-004467a collagen XIX derived non-collagenous C-terminal domain (NC2) comprising the amino acid sequence of SEQ ID NO: 150, ora collagen XVIII derived non-collagenous C-terminal domain (NCI) comprising the amino acid sequence of SEQ ID NO: 34.

35. The recombinant protein system of any one of claims 1-34, wherein the targeting domain of the second recombinant protein is a ligand.

36. The recombinant protein system of claim 35, wherein the ligand is epidermal growth factor (EGF), a mutant EGF (EFGml23) (SEQ ID NO: 36), stem cell factor (SCF) (SEQ ID NO: 37), thrombopoietin (TPO) (SEQ ID NO: 38), human hepatocy te growth factor (HGF) (SEQ ID NO: 39), erythropoietin (EPO). or type 1 insulin-like growth factor (IGF1) (SEQ ID NO: 40).

37. The recombinant protein sy stem of any one of claims 1-34, wherein the targeting domain of the second recombinant protein is a single chain variable fragment (scFv).

38. The recombinant protein sy stem of claim 37, wherein the scFv binds epidermal growth factor receptor (EGFR). human epidermal growth factor receptor 2 (Her2), cluster of differentiation 3 (CD3), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 7 (CD7), cluster of differentiation 117 (c-Kit), mucin- 16 (MUC16), B cell maturation antigen (BCMA), orNectin4.

39. The recombinant protein system of claim 38, wherein the scFv binds CD3 and wherein the scFv is UCHT1, HuM291, OKT3, or TR66.

40. The recombinant protein system of claim 39, wherein the scFv is UCHT1 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 41 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 42.

41. The recombinant protein system of claim 39, wherein the scFv is HuM291 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequenceLeydig 775437Vyriad P-64-004468of SEQ ID NO: 43 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 44.

42. The recombinant protein system of claim 39, wherein the scFv is 0KT3 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 45 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 46.

43. The recombinant protein system of claim 39, wherein the scFv is TR66 and wherein the scFv comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 47 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 48.

44. The recombinant protein system of any one of claims 1-34, wherein the targeting domain of the second recombinant protein is a nanobody.

45. The recombinant protein system of claim 44, wherein the nanobody binds epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her2), cluster of differentiation 3 (CD3), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 7 (CD7), cluster of differentiation 117 (c-Kit), mucin-16 (MUC16), B cell maturation antigen (BCMA), Nectin4. or T cell receptor (TCR).

46. The recombinant protein system of claim 45, wherein the nanobody binds CD3.

47. The recombinant protein system of claim 46, wherein the nanobody is an anti-CD3 epsilon nanobody (VHH-3-aCD3E) and wherein the nanobody comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 102.

48. The recombinant protein system of claim 45, wherein the nanobody binds TCR.

49. The recombinant protein sy stem of claim 48, wherein the nanobody is an anti-T cell receptor protein nanobody (VHH 9-aTCR) and wherein the nanobody comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 103.Leydig 775437Vyriad P-64-00446950. The recombinant protein system of any one of claims 18-49, wherein the second recombinant protein comprises (c)(1), and wherein the binding domain of the receptor protein of the second recombinant protein comprises (i) cysteine rich domain 2 (CR2) of LDLR (SEQ ID NO: 2), (ii) cysteine rich domain 3 (CR3) of LDLR (SEQ ID NO: 3), (iii) cysteine rich domain 4 (CR4) of LDLR (SEQ ID NO: 4), or (iv) any combination of (i)-(iii).

51. The recombinant protein system of claim 50, wherein the cysteine rich region comprises CR2 (SEQ ID NO: 2) of LDLR.

52. The recombinant protein system of claim 50, wherein the cysteine rich region comprises CR3 (SEQ ID NO: 3) of LDLR.

53. The recombinant protein system of claim 50, wherein the cysteine rich region comprises CR2 (SEQ ID NO: 2) of LDLR and CR3 (SEQ ID NO: 3) of LDLR.

54. The recombinant protein system of claim 50, wherein the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1) and CR2 (SEQ ID NO: 2) of LDLR.

55. The recombinant protein system of claim 54, wherein the cysteine rich region comprises two copies of CR2 (SEQ ID NO: 2) of LDLR.

56. The recombinant protein system of claim 50, wherein the cysteine rich region comprises cy steine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1) and CR3 (SEQ ID NO: 3) of LDLR.

57. The recombinant protein system of claim 56, wherein the cysteine rich region comprises two copies of CR3 (SEQ ID NO: 3) of LDLR.

58. The recombinant protein system of claim 50, wherein the cysteine rich region comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 1), CR2 (SEQ ID NO: 2) of LDLR, and CR3 (SEQ ID NO: 3) of LDLR.

59. The recombinant protein system of claim 50, wherein the cysteine rich region comprises fromN- to C-terminus cysteine rich domains (CRs) of CR3-CR2-CR1.Leydig 775437Vyriad P-64-00447060. The recombinant protein system of claim 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR2-CR2.

61. The recombinant protein system of claim 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR2-CR3.

62. The recombinant protein system of claim 50, wherein the cysteine rich region comprises from N- to C-terminus cysteine rich domains (CRs) of CR2-CR3-CR3.

63. The recombinant protein system of any one of claims 18-62, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of a Flanders virus glycoprotein (FLAV-G) (SEQ ID NO: 49), a Chandipura virus glycoprotein (CHPV-G) (SEQ ID NO: 50), a Perinet virus glycoprotein (PERV-G) (SEQ ID NO: 51, a Piry virus glycoprotein (PIRYV-G) (SEQ ID NO: 52), a Fukuoka virus glycoprotein (FUKV-G) (SEQ ID NO: 53), a Joinjakaka virus glycoprotein (JOIV-G) (SEQ ID NO: 54), a Kumasi virus glycoprotein (KRV-G) (SEQ ID NO: 55), a Keuraliba virus glycoprotein (KEUV-G) (SEQ ID NO: 56), an Isfahan glycoprotein (ISFV-G), a Jurona glycoprotein (JURV-G), a Mediterranean Bat glycoprotein (MBV-G), a Malpais Spring glycoprotein (MSPV-G), a Radi glycoprotein (RADV-G), a Rhinolophus affmis-G, a Yug Bugdanavoc glycoprotein (YBV-G), a Yinshui Bat glycoprotein (YSBV-G), a Kimberley glycoprotein (KIMV-G), a Kanyawara glycoprotein (KYAV-G), a La Joya glycoprotein (LJV-G), a Mosquiero glycoprotein (MQOV-G), a Parry Creek glycoprotein (PCV-G), a Bas Congo glycoprotein (BASV-G), a Bovine Ephemeral fever glycoprotein (BEFV-G), a Curionopolis glycoprotein (CURV-G), a Drosophila melanogaster sigmavirus glycoprotein (DMelSV-G), aNiakha glycoprotein (NIAV-G), a Puerto almandras glycoprotein (PTAMV-G), or a Tupaia rhabdo virus (TUPTV-G).

64. The recombinant protein system of any one of claims 18-62, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus glycoprotein or a functional fragment or derivative thereof.

65. The recombinant protein system of claim 64, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana, Vesiculovirus newjersey. Vesiculovirus carajas, or Vesiculovirus alagoas.Leydig 775437Vyriad P-64-00447166. The recombinant protein system of claim 65, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana (SEQ ID NO: 57).

67. The recombinant protein system of claim 65, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus newjersey (SEQ ID NO: 58).

68. The recombinant protein system of any one of claims 18-67, wherein the rhabdoviral G glycoprotein is substantially intact.

69. The recombinant protein system of any one of claims 18-67, wherein the rhabdoviral G glycoprotein is a functional fragment or derivative thereof.

70. The recombinant protein system of any one of claims 18-69, comprising a rhabdoviral G glycoprotein or functional fragment or derivative thereof engineered to reduce or abolish its natural receptor binding specificity.

71. The recombinant protein system of claim 70, wherein the rhabdoviral G glycoprotein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

72. The recombinant protein system of claim 71, wherein the rhabdoviral G glycoprotein comprises a mutation at one or more positions corresponding to H8, K47, Y209, and K354 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).

73. The recombinant protein system of claim 71 or 72, wherein the mutation is a substitution.

74. The recombinant protein system of claim 73, wherein the substitution is with a Q75. The recombinant protein system of any one of claims 71-74, wherein the mutation is a substitution at three or more positions corresponding to H8, K47, Y209, and K354 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).Leydig 775437Vyriad P-64-00447276. The recombinant protein system of claim 71 or 72, wherein the mutation is a deletion.

77. The recombinant protein sy stem of claim 76, wherein the mutation is a single deletion at the position corresponding to K47 on the Vesiculovirus Indiana glycoprotein (SEQ ID NO: 57).

78. The recombinant protein sy stem of any one of claims 18-77, wherein the rhabdoviral G glycoprotein of the first recombinant protein is inactivated to a lesser degree by serum, LDL, or vLDL compared to a rhabdoviral G glycoprotein not of the recombinant protein system.

79. The recombinant protein system of any one of claims 1-78, wherein the first recombinant protein is fused to the second recombinant protein, optionally wherein the first recombinant protein is N-terminal to the second recombinant protein.

80. The recombinant protein system of claim 79, wherein the first recombinant protein is N-terminal to the second recombinant protein, comprising a linker between the first recombinant protein and the second recombinant protein.

81. The recombinant protein system of claim 79, wherein the second recombinant protein is N-terminal to the first recombinant protein, comprising a linker between the second recombinant protein and the first recombinant protein.

82. The recombinant protein system of any one of claims 1-81, wherein the viral FMG of the first recombinant protein forms a bond with the binding domain of the receptor protein of the second recombinant protein.

83. The recombinant protein system of claim 82, wherein the bond is a covalent bond.

84. The recombinant protein system of claim 83, wherein the formation of the covalent bond is spontaneous.

85. The recombinant protein system of claim 82, wherein the bond is a non-covalent bond.Leydig 775437Vyriad P-64-00447386. The recombinant protein system of claim 85, wherein the formation of the non-covalent bond is spontaneous.

87. A dimer comprising two recombinant protein systems of any one of claims 2-86,wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other second recombinant protein,wherein the viral FMG of each first recombinant protein is bound to the viral FMG of the other first recombinant protein, andwherein the second recombinant proteins comprise (c)(1). and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

88. A trimer comprising three recombinant protein systems of any one of claims 2-86,wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other two second recombinant proteins,wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other two first recombinant proteins, andwherein the second recombinant proteins comprise (c)(1), and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

89. A tetramer comprising four recombinant protein systems of any one of claims 2-86,wherein the oligomerization domain of each second recombinant protein is bound to the oligomerization domain of the other three second recombinant proteins,wherein the viral FMG of each first recombinant protein is bound to the viral FMGs of the other three first recombinant proteins, andLeydig 775437Vyriad P-64-004474wherein the second recombinant proteins comprise (c)(1). and wherein the viral FMG of at least one first recombinant protein is bound to the binding domain of the receptor protein of at least one second recombinant protein.

90. The dimer of claim 87, the trimer of claim 88, or the tetramer of claim 89, comprising at least two different viral FMGs.

91. The dimer of claim 87 or 90, the trimer of claim 88 or 90, or the tetramer of claim 89 or 90. comprising at least two different binding domains of the receptor proteins.

92. The dimer of claim 87, 90, or 91, the trimer of claim 88, 90, or 91, or the tetramer of claim 89, 90, or 91 comprising at least two different targeting domains.

93. A membraned vesicle comprising the recombinant protein system of any one of claims 1-86.

94. The membraned vesicle of claim 93, wherein the membraned vesicle is a gesicle or an exosome.

95. A membraned vesicle comprising the dimer of claim 87, 90, 91, or 92, the trimer of claim 88, 90, 91, or 92. or the tetramer of claim 89, 90, 91, or 92.

96. An enveloped delivery vehicle comprising the recombinant protein system of any one of claims 1-86.

97. An enveloped delivery vehicle comprising the dimer of claim 87, 90, 91, or 92, the trimer of claim 88, 90, 91, or 92, or the tetramer of claim 89, 90, 91, or 92.

98. A recombinant viral vector comprising a nucleotide encapsulated by the membraned vesicle of any one of claims 93-95 or the enveloped viral particle of claim 96 or 97.

99. A composition comprising a pharmaceutically acceptable carrier and the membraned vesicle of any one of claims 93-95, the enveloped viral particle of claim 96 or 97, or the recombinant viral vector of claim 98.Leydig 775437Vyriad P-64-004475100. A method of delivering a payload to a target cell, the method comprising contacting the target cell with the membraned vesicle of any one of claims 93-95, the enveloped viral particle of claim 96 or 97, the recombinant viral vector of claim 98, or the composition of claim 99.

101. The method of claim 100, wherein the target cell is contacted in vitro or ex vivo.

102. The method of claim 100, wherein the target cell is contacted in vivo.

103. The method of any one of claims 100-102, wherein the payload is a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

104. The method of claim 103, wherein the CAR has antigenic specificity for CD19, CD20, CD22, DLL3, B7H3, or BCMA.

105. The method of claim 103 or 104, wherein the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28a or CD8a.

106. The method of any one of claims 103-105. wherein the transmembrane domain is the transmembrane domain of CD28 or CD8.

107. The method of any one of claims 103-106, wherein the intracellular signaling domain comprises a costimulatory domain and an activating domain.

108. The method of claim 107, wherein the costimulatory domain is 4-1 BB.

109. The method of claim 107 or 108. wherein the activating domain is CD3zeta.

110. The method of any one of claims 100-102, wherein the payload is a transgene or gene editing system.

111. A retroviral vector expression system comprising one or more nucleotide sequences encoding the recombinant protein system of any one of claims 1-86.Leydig 775437Vyriad P-64-004476112. The retroviral vector expression system of claim 111, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on separate plasmids.

113. The retroviral vector expression system of claim 111, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on the same plasmid.

114. The retroviral vector expression system of any one of claims 111-113, wherein the retroviral vector expression system comprises a vector construct and helper constructs that are each on separate plasmids.

115. The retroviral vector expression system of any one of claims 111-114, wherein the retroviral vector expression system is a lentiviral vector expression system or a Rous sarcoma virus (RSV) vector expression system.

116. The retroviral vector expression system of any one of claims 111-115, comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

117. The retroviral vector expression system of claim 116, wherein the CAR has antigenic specificity for CD19, CD20, CD22, DLL3, B7H3, or BCMA.

118. The retroviral vector expression system of claim 116 or 117, wherein the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28a or CD8a.

119. The retroviral vector expression system of any one of claims 116-118, wherein the transmembrane domain is the transmembrane domain of CD28 or CD8.

120. The retroviral vector expression system of any one of claims 111-119, wherein the intracellular signaling domain comprises a costimulatory domain and an activating domain.

121. The retroviral vector expression system of claim 120, wherein the costimulatory domain is 4-1BB.Leydig 775437Vyriad P-64-004477122. The retroviral vector expression system of claim 120 or 121, wherein the activating domain is CD3zeta.

123. The retroviral vector expression system of any one of claims 111-115, comprising one or more nucleotide sequences encoding a transgene or gene editing system.

124. A rhabdoviral vector expression system comprising one or more nucleotide sequences encoding the recombinant protein system of any one of claims 1-86.

125. The rhabdoviral vector expression system of claim 124, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on separate plasmids.

126. The rhabdoviral vector expression system of claim 124, wherein the nucleotide sequence encoding the first recombinant protein and the nucleotide sequence encoding the second recombinant protein are on the same plasmid.

127. The rhabdoviral vector expression system of any one of claims 124-126, wherein the rhabdoviral vector expression system comprises a vector construct and helper constructs that are each on separate plasmids.

128. The rhabdoviral vector expression system of any one of claims 124-127, wherein the rhabdoviral vector expression system is a vesiculovirus expression system.

129. A rhabdoviral vector expression system comprising one or more plasmids encoding:(a) a nucleoprotein (N), a phosphoprotein (P), a matrix protein (M), a glycoprotein (G). and a large polymerase protein (L), each of Vesiculovirus Indiana (VSIV); and(b) the recombinant protein system of any one of claims 1-86 and a transgene.

130. The rhabdoviral vector expression system of claim 129, wherein the rhabdoviral vector encodes in 5’ to 3’ order the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, the transgene, and the large polymerase protein.Leydig 775437Vyriad P-64-004478131. The rhabdoviral vector expression system of claim 129 or 130, wherein the rhabdoviral vector encodes the recombinant protein system between the nucleoprotein and the phosphoprotein, between the phosphoprotein and the matrix protein, between the matrix protein and the glycoprotein, or between the transgene and the large polymerase protein.

132. The rhabdoviral vector expression system of any one of claims 124-131, comprising one or more nucleotide sequences encoding a transgene or gene editing system, optionally wherein:(a) the rhabdoviral vector expression system is engineered to express human interferon β (IFNβ);(b) the rhabdoviral vector expression system is engineered to express a sodium iodide symporter (NIS);(c) the transgene comprises a nucleotide sequence encoding an IL-12 polypeptide, or a functional fragment or derivative thereof;(d) the transgene is a is a template for a positive sense transcript encoding the IL- 12 polypeptide, or a functional fragment or derivative thereof;(e) the IL- 12 polypeptide, or the functional fragment or derivative thereof, comprises an IL- 12 p40 subunit, or a functional fragment or derivative thereof; or(f) the IL- 12 polypeptide, or the functional fragment or derivative thereof, comprises an IL-12 p35 subunit, or a functional fragment or derivative thereof.

133. A method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising:(a) transfecting or transducing a packaging host cell with the retroviral vector expression system of any one of claims 111-123 or the rhabdoviral vector expression system of any one of claims 124-132; and(b) recovering the membraned vesicle, enveloped viral particle, or recombinant viral vector produced by the transfected or transduced packaging host cell.Leydig 775437Vyriad P-64-004479134. The method of claim 133, wherein the retroviral vector expression system or the rhabdoviral vector expression system comprises one or more nucleic acids encoding (i) a recombinant fusion protein, and (ii) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein.

135. The method of claim 134, wherein the ratio of (i) to (ii) is 1:3.

136. A method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with the retroviral vector expression system of any one of claims 111-123 or the rhabdoviral vector expression system of any one of claims 124-132, wherein the host cell is ex vivo.

137. A method of making a membraned vesicle, an enveloped viral particle, or a recombinant viral vector, the method comprising transducing a host cell with the retroviral vector expression system of any one of claims 111-123 or the rhabdoviral vector expression system of any one of claims 124-132, wherein the host cell is within a subject.

138. The method of claim 136 or 137, wherein the retroviral vector expression system or the rhabdoviral vector expression system comprises one or more nucleic acids encoding (a) a recombinant fusion protein, and (b) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein, wherein the ratio of (a) to (b) is 1:3.

139. A plasmid comprising one or more nucleotide sequences encoding the recombinant protein system of any one of claims 1-86.

140. A composition of claim 99, a retroviral vector expression system of any one of claims 111-123, or a rhabdoviral vector expression system of any one of claims 124-132 for use in treating a disease in a mammal.

141. The composition, retroviral vector expression system, or rhabdoviral vector expression system of claim 140, wherein the mammal is a human.

142. The composition, retroviral vector expression system, or rhabdoviral vector expression system of claim 140 or 141, wherein the disease is a genetic disease.Leydig 775437Vyriad P-64-004480143. The composition, retroviral vector expression system, or rhabdo viral vector expression system of claim 140 or 141, wherein the disease is a cancer.

144. The composition, retroviral vector expression system, or rhabdo viral vector expression system of any one of claims 140-143, wherein the administration is intravenous.

145. The composition, retroviral vector expression system, or rhabdo viral vector expression system of any one of claims 140-144, wherein the administration is intraperitoneal.

146. A method of making a viral FMG dimer, trimer, or tetramer, the method comprising:a. transfecting or transducing a packaging host cell with the retroviral vector expression system of any one of claims 111-123 or the rhabdoviral vector expression system of any one of claims 124-132; and b. recovering the viral FMG dimer, trimer, or tetramer.

147. A method of stabilizing a recombinant protein system of any one of claims 18 and 50-62, the method comprising maintaining the system at pH 7.4 with 0.1 to 2 mM of Ca2+.

148. The method of claim 147, wherein the buffer is HEPES (2-[4-(2-hydroxyethyl)piperazin-l-yl]ethanesulfonic acid) or Tris (Tris(hydroxymethyl)aminomethane).

149. The method of claim 147 or 148, wherein the method comprises maintaining the system with human serum albumin (HSA).

150. The method of claim 149, wherein the HSA is 1% HSA.